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Abstract 
Wnt/!-catenin signalling plays a central role in the regulation of multicelluar 
organism development and in the maintenance of tissue homeostasis in adults.  
Dysregulation of Wnt signalling resulting in aberrant pathway activation is a key 
initiating step in the development of a diverse range of cancers, including 
colorectal cancer, and as such is an important target for therapeutic intervention.  
A novel Wnt pathway inhibitor, ‘MSC’, has been identified as blocking activated 
Wnt signalling, specifically through inhibiting the ability of CDK8 and CDK19 to 
activate nuclear !-catenin/TCF-dependent transcription.  However, despite 
potently inhibiting Wnt-dependent transcription, the ability of MSC to reduce 
cellular viability was limited.  This study aimed to determine genes that whose 
loss operated with MSC to reduce cell survival. 
A whole-genome RNAi chemical sensitisation screen identified 3 genes whose 
depletion in combination with MSC treatment conditionally reduced the viability of 
HCT116 cells in vitro.  The outstanding hit of this screen was Histidyl Aminoacyl 
tRNA Synthetase (HARS).  The identification of this enzyme as an MSC 
‘interactor’ suggested links between Wnt signalling and the regulation of 
translation.  BRAF and MED11 RNAi also conferred conditional sensitivity to 
MSC.  Interestingly, MED11 is a component of the Mediator complex, a 
multiprotein transcription regulatory complex in which CDK8 functions to regulate 
!-catenin/TCF-dependent transcription, suggesting that mediator complex may 
be a key target of MSC action. 
A parallel overexpression screen was initiated to identify novel Wnt pathway 
activators, and subsequently used to map MSC resistance.  Expression of the 
transcription factors GBX1 and HMGB2, determined to be novel regulators of 
TCF-dependent transcription, blocked MSC-mediated disruption of Wnt signalling.  
Overexpression of either gene in a clinical context might therefore be regarded 
as a contra-indication for MSC-class therapies. 
These studies have highlighted potential avenues for broadening the scope of 
MSC activity through the determination of survival and resistance mechanisms, 
thus the rational design of MSC-combination therapies could be of huge clinical 
benefit for the treatment of colorectal cancer. 
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Chapter 1.  Introduction 
1.1 Signalling Pathways 
Cell fate during the development of multicellular organisms is widely regulated by 
cell-cell signalling events.  This signal transduction was first shown by Spemann 
and Mangold who demonstrated that transplantation of selected regions of newt 
embryonic tissue (termed ‘organisers’) into a host embryo resulted in the 
induction of secondary embryonic primordia, suggesting that cell-cell 
communication could be achieved by secreted signals (Spemann and Mangold, 
1924; 2001).  These secreted signals, or ligands, transduce signalling pathways 
that are pivotal in the organisation of embryonic development.  Interestingly, in 
animal systems this cell fate determination is controlled (in the most part) by 
seven key signalling pathways; wingless related (Wnt), hedgehog (Hh), janus 
kinase (JAK)/signal transducer and activator of transcription (STAT), 
transforming growth factor-" (TGF-"), receptor tyrosine kinase (RTK), Notch, and 
nuclear hormone pathways (Barolo and Posakony, 2002; Pires-daSilva and 
Sommer, 2003).  Despite their multiplicity of signal transduction mechanisms and 
the downstream components involved, these seven pathways elicit many of their 
effects through the transcriptional regulation of target genes via conditional (i.e. 
signal-dependent) transcription factors and are employed repeatedly during 
development (Barolo and Posakony, 2002; Pires-daSilva and Sommer, 2003).  
 
1.1.1 The Wnt signalling pathways 
The Wnt ligand family, which comprises 19 secreted Wnt glycoproteins in higher 
vertebrates (Papkoff et al., 1987), act through several extracellular receptors to 
activate discrete intracellular signalling cascades.  As well as having critical roles 
in the early development of an organism, Wnt signalling is also essential to adult 
tissue homeostasis, with its importance in stem-cell self renewal more recently 
identified (Angers and Moon, 2009; Barker et al., 2009; Clevers, 2006).  
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The ability of a subset of Wnt ligands to induce an increase in cytoplasmic beta-
catenin (!-catenin) levels initially lead to their division in to two subgroups: the 
‘canonical’ Wnt/!-catenin (or ‘Wnt-1’) signalling class, and the ‘non-canonical’ !-
catenin independent (or ‘Wnt-5a’) class (McMahon and Moon, 1989; Shimizu et 
al., 1997; Wong et al., 1994).  It has subsequently been determined that although 
several Wnt proteins preferentially activate either Wnt/!-catenin dependent or 
independent signalling, Wnt ligands themselves are not inherently canonical or 
non-canonical, rather that the diverse signalling cascades that these ligands 
trigger are defined by the ligand-receptor complex formed under a given cellular 
context (He et al., 1997; Liu et al., 2005; Tamai et al., 2004).  Frequently Wnt 
signalling is activated by multireceptor complexes including members of the Fz 
family of 7 transmembrane receptors. In total, there are greater than 15 Wnt 
receptors and co-receptors in vertebrates, including 12 Frizzled receptors (Fz) 
(van Amerongen et al., 2008), low-density lipoprotein receptor-related proteins 
5/6 co-receptors (LRP5/6) (He et al., 2004), receptor tyrosine kinase-like orphan 
receptors Ror1/2 (Paganoni et al., 2010) and the receptor tyrosine kinase Ryk 
(Lu et al., 2004). The number of possible combinations of ligand-receptor 
complexes provides an early indication of the intricacy of this signalling 
mechanism (Kikuchi et al., 2009).  Of the multiple Wnt-signalling cascades 
‘encoded’ by these combinations there are three that are most well understood 
(Figure 1): 
1. The canonical Wnt/!-catenin pathway 
This is the best-characterised pathway, and as the focus of this 
investigation it will be described in more detail later.  Briefly, under 
steady-state ‘Wnt-off’ conditions !-catenin is phosphorylated within a 
multi-protein destruction complex by glycogen synthase kinase 3 beta 
(GSK3!), targetting it for proteosomal degradation.  In the presence of 
Wnt, a Wnt-Fz-LRP5/6 receptor complex is formed which recruits and 
inhibits the destruction complex, stabilising !-catenin which 
translocates to the nucleus and activates the T-cell factor/lymphoid 
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enhancer factor (TCF/LEF)-dependent transcription of Wnt-target 
genes.  Physiologically, this pathway is involved in regulating cell fate 
determination and proliferation (Kühl and Kühl, 2012; Rudloff and 
Kemler, 2012). 
 - Figure 1b and Figure 2 
 
2. The planar cell polarity (PCP) pathway 
Wnt-5a and Wnt-11 have been shown to activate the Rac1 and RhoA 
GTPases downstream of dishevelled (mammalian homologues are 
termed Dvl1-3), which subsequently activate mediators Jun-N-terminal 
kinase (JNK) and Rho kinase (ROK) (Fanto and McNeill, 2004).  This 
pathway regulates the alignment of cells within the plane of a tissue 
and is evident in, for example, the uniform arrangement of hairs on the 
fly wing and the coordinated polarisation of hair cells in the 
mammalian ear.  This alignment is also exhibited in larger structures 
including mammalian epidermis hair follicle orientation (Devenport and 
Fuchs, 2008). 
 Significantly, the PCP and Wnt/!-catenin pathways are often 
antagonists of one another, which (in part) occurs through cross-talk at 
the Wnt-receptor level.  For example, the PCP-activating Wnt-5a 
ligand competes with Wnt-3a’s binding to Fz2, inhibiting the formation 
of a Fz/LRP5 ligand-receptor complex thus maintaining Wnt/!-catenin 
signalling in the off state (Sato et al., 2010). 
 - Figure 1a 
 
3. The Wnt/Ca2+ pathway 
Binding of selected Wnt ligands (including Wnt-4, Wnt-5a and Wnt-11) 
to Fz2, 3, 4, 5 and 6, and Ror1/2 receptors triggers the activation of 
heterotrimeric G-proteins, which activate phospholipase C (PLC) and 
leads to the release of intracellularly stored calcium (Blumenthal et al., 
2006; Kuhl et al., 2000; Nishita et al., 2010).  Calcium sensitive 
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enzymes such as Ca2+ and calmodulin-dependent kinase II (CAMKII) 
and protein kinase C (PKC) and the phosphatase calcineurin (Cn) are 
activated, and subsequently activate the transcription factor nuclear 
factor of activated T-cells (NFAT) (De, 2011; Saneyoshi et al., 2002).  
NFAT transcriptionally regulates genes involved in cell fate and cell 
migration (De, 2011).  
  Wnt/Ca2+ signalling is also capable of antagonising the Wnt/!-
catenin response through the phosphorylation of TCF transcription 
factors by Wnt/Ca2+ activated nemo-like kinase (NLK) (Ishitani et al., 
2003). 
 - Figure 1c 
 
However, it is currently unclear precisely how many non-canonical Wnt 
responses exist due to the limited molecular characterisation of !-catenin 
independent molecular endpoints.  Hence, our incomplete understanding of the 
multiple effects elicited by the multiple combinations of ligand-receptor 
complexes means that robust endpoint read-outs, such as TCF-reporter assays 
that are used to characterise the canonical pathway, are lacking (van Amerongen, 
2012).  
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Figure 1 placement. 
Figure 1.  Overview of multiple Wnt signalling pathways 
A. The Planar Cell Polarity Pathway. Signalling via the elements shown alters 
levels of c-Jun dependent transcription. However, non-transcriptional readouts 
including alterations to actin polymerisation drive many of the physiological 
effects. 
B. The ‘canonical’ Wnt "-catenin signalling pathway (see later for details)  
C. The Wnt-Ca2+ pathway. Signalling via the elements shown regulates NFAT 
dependent transcription, but other endpoints likely play a major role in 
physiological responses.  
D. Receptor combinations at the plasma membrane that (in the case of LRP5/6 
and Fz) simultaneously bind to different surfaces of a Wnt ligands leading to the 
formation of a multi-receptor complex. The exact combinations of receptors 
present in the complex are thought to specify the activation of distinct 
downstream pathways (adapted from (Niehrs, 2012)). 
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1.1.1.1  The canonical Wnt/!-catenin pathway  
The focus of this research is the Wnt/!-catenin cascade, and henceforth will 
simply be referred to as the Wnt signalling pathway.  The pathway is comprised 
of proteins whose function in Wnt signalling is conserved across cell types and 
organisms, and form the basis of a ‘core’ minimal pathway required for the 
transcription of Wnt-target genes (Logan and Nusse, 2004).   
At its simplest, Wnt signalling via the interaction of these core components can 
be considered as having two states: ‘Off’ (in the absence of Wnt ligand) and ‘On’ 
(in the presence of Wnt ligand; Figure 2).  In the ‘Off’ state, the TCF-
transcriptional co-activator !-catenin is recruited to a multiprotein ‘destruction’ 
complex by the multidomain scaffold proteins Axin and Adenomatous Polyposis 
Coli (APC).  This facilitates the sequential phosphorylation of essential 
serine/threonine residues by two further destruction complex constituents, 
Casein Kinase 1# (CK1#) and Glycogen Synthase Kinase 3! (GSK3!), targetting 
the phosphorylated !-catenin for degradation by the proteasome (Liu et al., 2002; 
Orford et al., 1997). 
In the ‘On’ state, signalling is initiated by the binding of Wnt ligand to the 
transmembrane receptors LRP5/6 (single-pass receptor) and Fz (seven-
transmembrane receptor).  Dishevelled (Dvl) and Axin bind to the intracellular 
domains of these receptors, preventing the formation of the destruction complex 
and allowing for the accumulation of !-catenin.  !-catenin subsequently 
translocates to the nucleus and binds the transcription factor TCF/LEF to activate 
the transcription of Wnt-target genes (reviewed in (Cadigan and Waterman, 
2012)). 
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Placement for Figure 2. 
Figure 2.   The canonical Wnt/!-catenin Signalling Pathway    
OFF:  In the absence of Wnt ligand, Axin forms a scaffold, binding Adenomatous 
Polyposis Coli (APC) protein, Casein Kinase I# (CK1#), Glycogen Synthase 
Kinase 3! (GSK3"), and !-catenin.  !-catenin is phosphorylated by CK1# and 
GSK3" at the N-terminus, ubiquitinated by "-TrCP (an E3 ubiquitin ligase) and 
targeted for degradation by the proteosome, suppressing transcription.     
ON:  In the presence of Wnt ligand, Frizzled (Fz) and LDL-like receptor protein 
(LRP)5/6  form a co-receptor complex.  LRP5/6 is phosphorylated by CK1$.  
Subsequent phosphorylation of LRP5/6 by GSK3! is mediated through the 
recruitment of Dishevelled (Dvl) to the plasma membrane by Fz, which also 
recruits Axin to LRP5/6. The destruction complex is inactivated, !-catenin 
stabilises and translocates to the nucleus.  Through the displacement of Groucho 
from Lymphoid Enhancer Factor (LEF)/T-cell factor (TCF), a transcriptionally 
active complex is formed and target genes (e.g. Myc and Axin2) are transcribed 
(reproduced with kind permission from (Ewan and Dale, 2008)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  The canonical Wnt/β-catenin signalling pathway   
OFF:  In the absence of Wnt ligand, Axin forms a scaffold, binding Adenomatous Polyposis Coli (APC) 
protein, Casein Kinase Iα (CKIα), Glycogen Synthase Kinase 3β (GSK3β), and β-catenin.  β-catenin 
is phosphorylated by CKIα and GSK3β at the N-terminus, ubiquitinated by β-TrCP (an E3 ubiquitin 
ligase) and targeted for degradation by the proteosome, suppressing transcription.    
ON:  In the presence of Wnt ligand, Frizzled (Fz) and LDL-like receptor protein (LRP)5/6  form a co-
receptor complex.  LRP5/6 is phosphorylated by CKIγ.  Subsequent phosphorylation of LRP5/6 by 
GSK3β is mediated through the recruitment of Dishevelled (Dvl) to the plasma membrane by Fz, which 
also recruits Axin to LRP5/6. The destruction complex is inactivated, β-catenin stabilises and 
translocates to the nucleus.  Through the displacement of Groucho from Lymphoid Enhancer Factor 
(LEF)/T-cell factor (TCF), a transcriptionally active complex is formed and target genes (e.g. Myc and 
Axin2) are transcribed (reproduced with kind permission from (Ewan and Dale, 2008)).
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This simple overview provides a framework that allows the pathway to be 
considered in four stages: 
i. Extracellular Wnt-receptor interactions 
ii. Intracellular receptor signal transduction 
iii.  The !-catenin destruction complex 
iv.   TCF/LEF-mediated transcription 
 
1.1.1.1.1 Extracellular Wnt-receptor interactions 
A defining feature of canonical Wnt signalling is the requirement for the presence 
of both Fz and LRP5/6 receptors (or ‘co-receptors’) in order for TCF-dependent 
transcription to occur.  In vitro it has been demonstrated that a trimeric Wnt-Fz-
LRP5/6 complex forms in the presence of both Wnt-1 and Wnt-3a (using the 
extracellular domains of Fz8 and LRP6 (Bourhis et al., 2011; Tamai et al., 2000)).  
This indicates that Wnt ligands bind to both receptors simultaneously in order to 
form the complex.  In an important advance, Janda et al. (Janda et al., 2012), 
recently determined the structure of XWnt8 in complex with the Wnt binding 
domain (CRD) of Fz.  Interestingly it has also been shown in vitro that LRP6 is 
able to bind two different Wnt proteins concurrently, suggesting that multiple 
combinations within a trimeric or possibly multimeric complex may occur in vivo 
(Chen et al., 2011; Ettenberg et al., 2010; Gong et al., 2010).  
In vivo, levels of Wnt-Fz-LRP5/6 complexes are enhanced by the concentration 
of Wnt ligand at the cell surface by proteoglycans such as Syndecan 1 and Dally 
(Lin and Perrimon, 1999; Perrimon and Bernfield, 2000).  The ligand then binds 
to the cysteine-rich domain (CRD) of Fz and to one of two PE domains of LRP6 
(Ettenberg et al., 2010; Gong et al., 2010; Mao et al., 2001b).  Levels of Fz 
receptor have recently been shown to be regulated by the Lgr5 receptor in 
complex with the ligand R-spondin, thereby altering the level of Wnt pathway 
activation in response to the same level of Wnt ligand (Macdonald and He, 2012). 
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As well as being modulated by activators, Wnt signalling is further regulated by 
evolutionarily conserved inhibitors.  Antagonism at the extracellular receptor level 
is a common feature, with small protein inhibitors often preventing ligand-
receptor interaction. Secreted antagonists include Wnt-inhibitory factor 1 (WIF 1), 
secreted Frizzled-related proteins (sFRPs) and Dickkopf (Dkk) proteins.  WIF 1 
has been shown to bind both canonical and non-canonical Wnts via a ‘WIF 
domain’ (Hsieh et al., 1999), however although this is believed to sequester the 
signal, the precise mechanism of WIF 1-Wnt regulation is not entirely understood 
(Cruciat and Niehrs, 2012).  Similarly, sFRPs prevent binding of Wnt – receptor 
interaction, for which two mechanisms have been proposed.  sFRPs contain a 
CRD which has been suggested to recruit Wnts away from the co-receptors (Lin 
et al., 1997).  A second domain, Netrin-related domain (NTR), was shown to be 
required for optimal Wnt inhibition (using a Wnt reporter assay; (Bhat et al., 
2007)), whilst it has since been shown that the NTR domain alone is capable of 
binding Wnt8 and inhibiting signalling (Lopez-Rios et al., 2008).  A further model 
of sFRP-mediated inhibition via direct binding to Fz should also be considered.  
sFRPs and Fz proteins are able to dimerise through the CRD, hence have the 
potential to inhibit signalling through the formation of non-functional complexes 
(Bafico et al., 1999; Dann et al., 2001; Rodriguez et al., 2005).  Dkks specifically 
inhibit canonical Wnt signalling through high-affinity binding to LRP5/6, forming a 
tertiary complex with a second receptor Kremen1/2 (Mao et al., 2002; 2001a).  
These interactions are mediated through the colipase fold of Dkk, with the 
inhibitory effect imparted by the DKK_N domain (Brott and Sokol, 2002).  
Interestingly, and in contrast to Dkk1 which solely inhibits Wnt signalling, Dkk2 
can act as either an inhibitor or activator of signalling (Brott and Sokol, 2002; 
Mao and Niehrs, 2003). This cellular-context dependent dual-activity may be 
determined by the presence or absence of the Kremen2 receptor; in its absence 
Dkk2 activates signalling (Mao and Niehrs, 2003).  Together, these demonstrate 
that the tight regulation of the Wnt/!-catenin cascade is first evident at the 
extracellular level. 
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1.1.1.1.2  Intracellular receptor signal transduction 
Extracellular cues are translated intracellularly by means of receptor 
phosphorylation events and subsequently the engagement of cytoplasmic 
components, of which Dvl and Axin have key roles in controlling downstream 
signal transduction.  
Present within the cytoplasmic region of LRP5/6 are five conserved PPPSPxS 
motifs.  These motifs are dually phosphorylated by GSK3! in the presence of 
Wnt, providing the docking site for Axin (Tamai et al., 2004; Zeng et al., 2005).  
Significantly it has been demonstrated that only a single motif is sufficient for 
signal transduction, and mutation of the S residue in all motifs results in total 
signal ablation (Swiatek et al., 2006; Tamai et al., 2004).   
The LRP5/6 PPPSP motif is initially phosphorylated by GSK3!, priming the xS 
residue for phosphorylation by membrane-associated CK1$ (Davidson et al., 
2005; Zeng et al., 2005).  Phosphorylation by GSK3 is dependent on Fz-LRP5/6 
interaction, and conditionally occurs following Wnt-induced Dvl recruitment to the 
membrane by Fz.  Dvl binds to the cytoplasmic portion of Fz via its PDZ 
(Postsynaptic density 95, discs large, zona occludens-1 domain (Wong et al., 
2003)), with recent evidence suggesting that this is further facilitated by the 
binding of the DEP (Dishevelled, Egl-10, Pleckstrin) domain to both Fz and 
potentially phospholipids within the plasma membrane (Simons et al., 2009; 
Tauriello et al., 2012).  It has been postulated that this in turn directly recruits 
Axin to the membrane (through the oligomerisation of Dvl-Axin at their DIX/DAX 
domains), initiating the phosphorylation of LRP5/6 by the Axin-tethered GSK3 
(Zeng et al., 2008).   
Three models have been proposed regarding the mechanism of signal 
transduction from this point.  The first is the ‘Initiation-Amplification model’, 
whereby the priming of LRP5/6 for Axin binding in this way may create a ‘feed-
forward loop’ that promotes and enhances further Axin recruitment (MacDonald 
et al., 2008; Zeng et al., 2008).  Evidence that LRP5/6 minimally requires four 
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phosphorylated PPPSPxS motifs to produce a semi-transduction competent 
receptor suggests that the phosphorylation of these motifs is dependent on 
having functional neighbour motifs, and that this phosphorylation is essential for 
achieving maximal Axin recruitment (MacDonald et al., 2008; Zeng et al., 2008).  
A second hypothesis generated from similar evidence is that ‘LRP5/6 
Signalosomes’ form.  Based on the observation that Wnt ligands induce LRP6 
aggregation and that Dvl DIX-DIX polymerisation is required for adequate 
phosphorylation of these large aggregates, this large complex could then recruit 
high levels of Axin (leading the inactivation of "-catenin turnover) through DIX-
DAX interaction, hence potentiating the Wnt signal (Bilic et al., 2007; Schwarz-
Romond et al., 2007).  The third model proposes that ‘Endosomal Signalling’ 
vesicles are formed as a consequence of Wnt-driven caveolin recruitment to 
LRP6 (Yamamoto et al., 2006).  Caveolin-LRP6 binding enables phosphorylated 
LRP6 to recruit Axin, and subsequently ‘signalosomes’ are formed by caveolin-
mediated endocytosis.  Regardless of which of these models is determined to be 
correct, the ultimate outcome is that Axin membrane-recruitment occurs and that 
"-catenin turnover activity is suppressed and/or "-catenin turnover complex 
components are targeted for degradation (Macdonald and He, 2012; Mao et al., 
2001a; Tolwinski et al., 2003).  This prevents destruction complex formation and 
allows for the accumulation of !-catenin. 
 
1.1.1.1.3  The !-catenin destruction complex 
In order to understand Wnt-initiated !-catenin accumulation in the cytoplasm, it is 
important to first consider how !-catenin is regulated in the absence of Wnt 
ligand.  When Wnt stimulation is lacking cytoplasmic !-catenin is phosphorylated 
and subsequently targetted for degradation by a large multi-protein complex; the 
‘!-catenin destruction complex’.  This complex consists of several core 
components (in addition to !-catenin); scaffold proteins Axin and APC, 
serine/threonine kinases GSK3! and CK1#, and upon !-catenin phosphorylation 
the F-box containing E3-ubiquitin ligase !-TrCP is recruited.  The complex is 
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likely to involve additional proteins that are dynamically recruited/engaged, 
however complete understanding of the intricacy of the machinery remains 
elusive (Stamos and Weis, 2013). 
In the absence of Wnt signalling, free Axin is able to act as a central scaffold for 
the assembly of the destruction complex components.  CK1#, GSK3! and !-
catenin bind to sites in the centre of Axin, such that the kinases are in close 
proximity to their !-catenin substrate.  The stability provided by this scaffold 
greatly enhances CK1# phosphorylation of !-catenin at Serine45 (Amit, 2002; 
Dajani et al., 2003; Liu et al., 2002), priming it for further phosphorylation by 
GSK3! at conserved N-terminal Ser33 and Ser37 residues (Hagen et al., 2002; 
Liu et al., 2002).  This creates the conserved !-TrCP binding site, which in a 
complex with Skp1/Cullin forms the SCF that ubiquitinates and targets !-catenin 
to the proteosome, triggering its proteolytic degradation (Hart et al., 1999; Orford 
et al., 1997). Additionally, the scaffold APC binds to Axin’s RGS (regulator of G-
protein signalling homology) domain where it is phosphorylated by CK1# and 
GSK3! at seven 20-mer repeats, resulting in a ~1500 fold increase in its affinity 
for !-catenin (Ha et al., 2004; Liu et al., 2006).  Not only does this act to further 
stabilise the complex, it is also postulated to shield !-catenin from 
dephosphorylation by Protein Phosphatase 2A (PP2A), ensuring that Wnt/!-
catenin signalling remains sequestered (Su et al., 2008). 
What is also not entirely clear is how Wnt-dependent LRP6 phosphorylation 
prevents !-catenin phosphorylation.  As briefly discussed in the previous section, 
it is thought that Dvl recruits Axin away from the destruction complex.  It was 
originally proposed that this resulted in dissociation of !-catenin and GSK3! from 
Axin, causing Axin hypophosphorylation and hence removing the !-catenin 
binding sites (Kimelman and Xu, 2006).  Axin inactivation (or degradation) may 
also be enhanced by the Wnt-induced dissociation of APC from the destruction 
complex causing subsequent inhibition of GSK3! activity (Valvezan et al., 2012).  
However, the decrease in Axin activity and/or levels has been shown to lag 
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behind that of !-catenin accumulation, hence other mechanisms of destruction 
complex disruption must also be required for this process (Willert et al., 1999; 
Yamamoto, 1999).  More recently it has been discovered that LRP6 
phosphorylation (at the PPPSPxS motifs) results in the direct binding to and 
inhibition of GSK3! catalytic activity. This suggests that that Axin recruitment to 
the plasma membrane via Dvl leads to the phosphor-dependent PPPSP-
inactivation of GSK3! activity and therefore "-catenin degradation (Cselenyi et 
al., 2008; Wu et al., 2009; Zeng et al., 2005).    
Despite the uncertainty surrounding the mechanism of destruction complex 
disruption, it is evident that Wnt-receptor complex formation inhibits !-catenin 
phosphorylation, allowing it to accumulate. The raised levels of "-catenin 
associate with binding partners throughout the cell and accumulate in the 
nucleus in a process that is thought to be primarily driven by the concentration of 
binding partners in the nucleus (Lloyd-Lewis, 2011).  
 
1.1.1.1.4  TCF/LEF-mediated transcription 
Following translocation to the nucleus, !-catenin associates with the TCF/LEF 
transcription factor family, activating transcription of Wnt-target genes.  Target 
genes contain a binding sequence called the Wnt Response Element (WRE) 
which is recognised and bound by the High Mobility Group (HMG) domain of 
TCF/LEF (van Beest et al., 2000; van de Wetering and Clevers, 1992).   
In the absence of !-catenin, TCF/LEFs repress gene transcription by forming a 
complex with co-repressors including hydrogen peroxide-inducible clone (HIC5; 
(Ghogomu et al., 2006)) and myeloid translocation gene families (MTG; (Moore 
et al., 2008)), however the most well characterised is the Groucho/Transducin-
like enhancer of split (Gro/TLE) family (Cavallo et al., 1998; Roose et al., 1998).  
Gro/TLE binds to the central region of TCF/LEF (Groucho binding sequence; 
GBS) and co-represses target genes in part by regulating histone modifications 
through the binding of histone deacetylases (HDACs; (Chen et al., 1999)).   
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!-catenin-TCF/LEF transcription activation is thought to occur in two ways.  The 
simplest model is that following stabilisation and nuclear translocation of !-
catenin, it displaces the Grouch/TLE co-repressor and recruits other proteins to 
form a transcriptionally active complex (Daniels and Weis, 2005).  Alternatively, a 
‘transcriptional switch’ may mediate transcriptional activation.  In vertebrates four 
TCF/LEF isoforms exist: TCF1, LEF1, TCF3, TCF4.  In the absence of Wnt 
signals it has been shown that TCF3 acts as a repressor (in most cases), which 
can be phosphorylated following Wnt signalling (e.g. by homeodomain-interacting 
protein kinase 2; HIPK2), causing TCF3 to dissociate from the WRE (Cole et al., 
2008; Kim et al., 2000; Merrill et al., 2004).  TCF3 is then replaced by one of the 
alternative TCF/LEF isoforms (bound to !-catenin), hence a switch occurs from 
an inactive to active complex.  Interestingly it has been demonstrated that LEF1 
most commonly activates genes upon recruitment (Kratochwil et al., 2002; Reya 
et al., 2000), whereas TCF1 and TCF4 can apparently serves as both co-
activators and co-inhibitors dependent on the cellular context in which they are 
involved (Galceran et al., 1999; Korinek et al., 1998; Roose et al., 1999; Tang et 
al., 2008). 
In either case, !-catenin’s N-terminal transactivation domain binds Bcl9, which in 
turn recruits Pygopus (Pygo1/2, (Kramps et al., 2002)).  The plant homeodomain 
(PHD) of Pygo binds methylated Histone 3, bridging the Wnt target gene’s WRE 
with the proximal promoter (Fiedler et al., 2008).  Interestingly, Pygo has also 
been demonstrated to interact with RNA polymerase II transcriptional regulatory 
complexes including Mediator via the Med12/13 and the TFIID subunit TAF4, 
again linking the !-catenin-TCF/LEF complex directly to transcriptional activation 
(Carrera et al., 2008; Wright and Tjian, 2009).    
It is clear that Wnt/!-catenin signalling actually extends far beyond the simplicity 
of the ‘core’ signalling pathway components.  In fact, Wnt-transcriptional 
regulation is dependent on many proteins interacting in a vast range of 
complexes, with these interactions varying in their nature depending on the 
cellular/system context.  In many ways, the pathway may best be regarded as a 
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network; a concept that has important implication for the design of therapeutic 
inhibitors (see later; (Kestler and Kuhl, 2008)). 
 
1.1.1.2 Wnt signalling in development, homeostasis and tumourigenesis 
Over the last 30 years Wnt signalling has been highlighted as a key pathway 
across all animal species studied, with its activity ranging from the regulation of 
cell fate and the establishment of tissue polarity in embryonic development, to 
the maintenance of stem cell populations and the control of cell proliferation in 
adult tissues (Clevers, 2006; van Amerongen and Nusse, 2009). 
Dissection of the Wnt pathway in ‘model organisms’ has provided much of our 
understanding of its activity.  In Drosophila melanogaster Wnt/Wg (Wingless; the 
Drosophila Wnt equivalent) signalling is required for the patterning of the 
embryonic wing epidermis (Bejsovec and Arias, 1991), whilst in the wing imaginal 
disc it functions as a morphogen, determining cell fate in a concentration-
dependent manner (Neumann and Cohen, 1996; Zecca et al., 1996).  Its role in 
vertebrate axis specification was first identified in Xenopus laevis (McMahon and 
Moon, 1989), and genetically engineered murine systems continue to provide a 
wealth of knowledge spanning  mammalian embryogenesis, development and 
adult tissue homeostasis (Wang et al., 2012).      
Having such vast developmental and homeostatic implications means that hyper- 
or hypo-activation of Wnt signalling can have detrimental effects.  Increased Wnt 
signalling is implicated in the progression of multiple cancers (Figure 3), whilst 
decreased signalling has been linked to Alzheimer’s Disease (AD) and bone 
formation disorders (De Ferrari and Moon, 2006; Hoeppner et al., 2009).  In the 
case of cancer, activation of Wnt signalling in the absence of ligand is the 
principal mechanism of that drives disease progression.  In the early stages of 
Wnt research it was discovered that the Apc gene harbours an inactivating 
mutation in ~85% of colorectal cancers, constitutively activating Wnt-target gene 
transcription (Kinzler et al., 1991; Nishisho et al., 1991; Su et al., 1993).   
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Although dysregulation frequently occurs when a ‘core’ member of the pathway is 
mutated and causes constitutive activation of the pathway (as with Apc), 
epigenetic silencing of genes encoding Wnt inhibitors also potentiates cancer 
progression, for example Dkk1 and sFRP1 have both been shown to be 
inactivated in colorectal cancer (Aguilera et al., 2006; Caldwell et al., 2004).  The 
tumourigenic effect of this aberrant signalling has been a driving force behind 
much of the research conducted on the Wnt cascade, with a significant focus on 
the identification of pathway-targeted therapeutics for the treatment of cancer.  
As this project principally focuses on the effects of Wnt inhibitors on colorectal 
cancers, the role of Wnt signalling in the intestine will now be discussed. 
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Figure 3 placement 
Figure 3. Wnt signalling is dysregulated in multiple cancers 
The incidence of the 20 most common cancers diagnosed in 2010 (UK only; 
excluding non-melanoma skin cancer).  * indicates cancers with known links to 
Wnt signalling (adapted from (CRUK)). 
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1.1.1.2.1  Wnt signalling in the intestine 
1.1.1.2.1.1  Intestinal homeostasis 
The mammalian intestinal wall comprises three layers; an outer layer of smooth 
muscle cells, a middle layer of connective tissue containing lymphatic 
vasculature, and an inner lining of a single-cell thick epithelium.  The small 
intestine is responsible for nutrient absorption, and hence the epithelium is 
arranged into two functionally distinct structures in order to maximise its 
absorbance efficiency; the absorbing villus and proliferative crypt.  The finger-like 
luminal villi protrusions are composed of multiple differentiated cells (enterocytes, 
goblet, enteroendocrine and tuft cells (Gerbe et al., 2011; Pinto and Clevers, 
2005a)), whilst the glandular crypt invaginations contain undifferentiated stem 
and progenitor cell populations (Pinto and Clevers, 2005a).  The large intestine 
(or colon) also contains sub-mucosal crypts, however as this predominantly 
functions to absorb water it has a flat luminal epithelium as opposed to villi 
(Schepers and Clevers, 2012).   
Intestinal epithelium undergoes rapid renewal, with proliferative cells in the crypt 
driving differentiated cell turnover in the villus.  Multipotent intestinal stem cells 
anchored at the base of the crypt divide approximately once per day, which 
generates a population of transit-amplifying (TA) cells (Barker et al., 2007).  The 
TA cells divide rapidly (every 12-16 hours), and the non-proliferative daughter 
cells migrate up the villus where they differentiate into the functional cell 
subtypes and continue their migration towards the villus’ apex (Figure 4).  These 
cells themselves are eventually lost, undergoing apoptosis before being shed into 
the lumen (Pinto and Clevers, 2005a).  Interestingly, within this daughter 
population in the small intestine a subset of cells differentiate into Paneth cells 
(Pinto and Clevers, 2005b).  Paneth cells migrate towards the bottom of the crypt 
where they actively secrete Wnt ligands that help to maintain neighbouring 
intestinal stem cells. They are also thought to moderate microbial ecology 
through the secretion of lysozyme and antimicrobial peptides (Bjerknes and 
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Cheng, 1981a; 1981b; Pinto and Clevers, 2005b).  Less is known about the 
source of Wnt ligands in the colon crypt. 
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Figure 4 Placement 
Figure 4a&b.  Wnt signalling in the intestinal crypt/villus 
Intestinal epithelial stem cells (pink) are located at the bottom of the crypt and are 
maintained in part by Wnt signalling from neighbouring Paneth cells (orange). 
Once the progeny of the stem cells migrate beyond the high concentration of Wnt 
ligand at the base of the crypt, they continue to proliferate as transit amplifying 
cells (TA cells; blue), before differentiating to cell types including absorbative 
enterocytes and secretory goblet cells (yellow).  Adapted from (Radtke and 
Clevers, 2005). 
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Wnt signalling is critical for the maintenance of this homeostasis within the self-
renewing crypt.  This was first discovered in TCF4 knockout mice where there 
was an absence of inter-villi crypts in the small intestine, identifying a key role for 
Wnt signalling in the maintenance of the crypt progenitor regions (Korinek et al., 
1998).  However it is evident that cell-fate determination is also Wnt signal-
dependent.  The TCF4-/- mice lacked enterendocrine cells, whilst the villi of mice 
with inactivated APC became repopulated by crypt-like cells that were unable to 
migrate or differentiate (Korinek et al., 1998; Sansom et al., 2004).  Significantly, 
nuclear !-catenin levels were highest in cells at the bottom of the crypt, with a 
gradient in signalling (inferred though the gradual decrease in expression of Wnt 
target genes) towards the lumen (Batlle et al., 2002; Kongkanuntn et al., 1999; 
Kosinski et al., 2007; van de Wetering et al., 2002).  More recent studies have 
suggested that high levels of Wnt signalling in the intestine specify a stem cell 
fate, as identified by a well characterised panel of stem cell markers and a 
relatively low rate of proliferation.  By contrast, lower levels of Wnt signalling 
were shown to drive the proliferation of transit amplifying cells (TA cells); cells 
that express c-Myc and cycle rapidly (Hirata et al., 2013).  These findings 
highlight the essential role of Wnt/!-catenin signalling for the maintenance of 
cells in an undifferentiated and proliferative state in intestinal homeostasis.   
 
1.1.1.2.1.2  Colorectal cancer 
One of the earliest links between Wnt signalling and colorectal cancer was 
identified in patients with familial adenomatous polyposis (FAP) who harbour 
hereditary loss-of-function mutations in one Apc allele, with polyps developing by 
loss of heterozygosity (LOH) (Groden et al., 1991; Joslyn et al., 1991; Kinzler et 
al., 1991; Nishisho et al., 1991).  It was subsequently shown that APC bound to 
"-catenin and regulated "-catenin degradation (Rubinfeld et al., 1993).  FAP 
patient colon polyps are benign however progression into adenocarcinoma 
occurs with the accumulation of further mutations such as activation of Ras or 
inactivation of the tumour suppressors PTEN and p53 (Fodde et al., 2001; 
 22 
Janssen et al., 2006; Marsh et al., 2008).  It has since been identified that the 
majority of sporadic colorectal cancers carry somatic mutations in Apc with the 
remainder of tumours often carrying activating mutations in !-catenin or Axin2 
(Kinzler and Vogelstein, 1996; Liu et al., 2000; Morin et al., 1997), though it is 
evident that the neoplastic transformation of tissue induced by this overactive 
signalling event is insufficient to drive tumour progression. 
Colorectal cancer has been studied in several mouse models, with the first 
created and now most widely used being the ApcMin (Multiple intestinal neoplasia) 
mouse (Moser et al., 1990).  Generated using random mutagenesis, the ApcMin 
mice harbour a nonsense mutation in an allele of Apc.  Similarly to patients with 
FAP the mice develop multiple polyps which become tumourigenic following LOH, 
although conversely to the colon polyps and tumours of FAP patients these 
predominantly arise in the small intestine.  Other models have since been 
generated using gene targetting, with the aim of phenotypically recapitulating 
colorectal cancers more closely.  Of particular interest are the adult systems in 
which conditional bi-allelic truncation or deletion of Apc can be induced in 
colorectal epithelium (Sansom et al., 2004; Shibata et al., 1997).  Within days all 
cells of the epithelium acquire a progenitor-like phenotype.  Interestingly c-Myc (a 
Wnt target gene (He et al., 1998)) must be intact for tumourigenesis to occur, and 
its knockdown is able to rescue the targeted Apc phenotype (Sansom et al., 
2007).  Together these results suggest that not only is Wnt signalling critical for 
the regulation of intestinal homeostasis, it’s dysregulation and resulting 
constitutive activation drives polyp formation, ultimately prolonging the 
transcription of Wnt target genes that in turn drive polyp transformation into 
adenomas.    
 
1.1.1.3  Colorectal cancer therapeutics 
Over the past few years Wnt signalling has become a major focus for drug 
discovery as mechanisms leading to its dysregulation have been uncovered.  
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Although aberrant Wnt signalling in colorectal cancer would appear to be an ideal 
target for therapeutic intervention, the complexity of the pathway (e.g. numerous 
ligand-receptor combinations), its normal function in tissue homeostasis, and the 
lack of easily ‘druggable’ targets (i.e. a suitable Wnt-specific enzyme), means 
that the development of Wnt-inhibiting therapeutics has proved difficult.  This 
picture is further complicated by the fact that ‘core’ Wnt components often have 
other roles outside Wnt signalling (e.g. !-catenin is involved in cell-cell adhesion 
junctions) and that dysregulation of the pathway (both up and down regulation) is 
also involved in the progression of a panel of diseases.  Together these 
limitations mean that it is difficult to predict potential side-effects of Wnt inhibitors. 
Despite this, novel information regarding the mechanistic details of Wnt signalling 
is driving the development of new targetted therapeutic agents (Lian et al., 2012; 
Merrill, 2012).  The role of some of these inhibitors under development for the 
treatment of colorectal cancer will now be discussed (see Appendix 1 for 
comprehensive list of canonical Wnt pathway inhibitors).  
   
1.1.1.3.1  Wnt-targetting colorectal cancer therapeutics 
A key point to emphasise before discussing the details of anti-colorectal cancer 
therapeutics is that inhibitors that block Wnt signalling upstream of mutated APC 
or "-catenin can be considered as potential anti-colorectal cancer therapeutics 
since the pathway does not behave as a digital switch in which the pathway is 
either ON or OFF (despite the simple version illustrated in Figure 2).  In reality, 
the activated levels of "-catenin/TCF-dependent transcription can be modulated 
by the expression of multiple other components.  For example, the extracellular 
Wnt inhibitor Dkk1 is one of the most commonly inactivated molecules linked to 
Wnt signalling (Aguilera et al., 2006), but functions at the level of Wnt ligand 
binding.  For ease of discussion, therapeutics are considered below as if they 
target distinct ‘levels’ of the pathway (where this has been demonstrated).  A 
unified consideration of how therapeutics can be used to ‘target a Wnt network’ 
follows. 
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1.1.1.3.1.1  Extracellular-targetted therapies 
The most upstream approach to the inhibition of Wnt signalling has been the 
prevention of Wnt ligand secretion and receptor binding.  Anti-Wnt antibodies and 
Wnt binding proteins titrate Wnt ligands and have been used as biological 
therapeutics (Cruciat and Niehrs, 2012).  One of the most advanced ‘Wnt-titration’ 
therapeutics is a soluble Fz8 CRD fused to a humanized immunoglobulin Fc 
domain (F8CRDhFc). This reagent was initially shown to be effective against 
teratocarcinomas and MMTV-Wnt-1 driven breast cancer (DeAlmeida et al., 
2007; Liu et al., 2012) and has now been developed (as OMP-54F28) for phase 
1 clinical trials against a range of solid tumours.  
A number of biological agents have been developed that inhibit Wnts binding to 
Frizzled and LRP5/6 receptors. One of the furthest developed is an antibody 
(OMP-18R5) that binds 5/10 Fz receptors (Fz-1,2,5,7,8) and is active as a single 
agent against a subset of colon, breast, pancreatic and lung cancers (Gurney et 
al., 2012).  This antibody, now known as Vantictumab, entered phase 1 clinical 
trials in 2011.  
There is huge potential for the further development of extracellular biological Wnt 
pathway modulators that could be guided by the recent structural 
characterisation of Wnt, LRP and Frizzled interactions. Definition of the ligand 
binding specificity of further Wnt receptors (e.g. LRP5, Ror, Ryk) and inhibitor 
binding domains (e.g. sFRP, WIF and Dkk) should offer additional opportunities 
to target distinct Wnt subsets and explain some currently unpredictable effects of 
reagents, such as the enhancement of Wnt signalling by Dkk2 and sFRP2 in a 
subset of cellular contexts (Cruciat and Niehrs, 2012; Marschall and Fisher, 
2010).  
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1.1.1.3.1.2  Cytoplasm-targetted therapies 
The antihelmitic compound niclosamide was identified as a Wnt signalling 
inhibitor in a cell imaging-based assay for Fz1 endocytosis (Chen et al., 2009), 
and was shown to reduce Fz and LRP6 levels together with TCF-dependent 
transcription (Lu et al., 2011).  Niclosamide inhibited the growth of colorectal and 
ovarian tumours in both preventative and therapeutic settings in vivo (Osada et 
al., 2011; Yo et al., 2012).  
By binding !%catenin, CK1# and GSK3!, Axin acts as a scaffold that enhances 
!%catenin phosphorylation and ubiquitin-dependent degradation (Clevers and 
Nusse, 2012).  An inhibitor of tankyrase, XAV939, was identified in a cell-based 
screen for repressors of TCF-dependent transcription (Huang et al., 2009b).  
TNKS1 and TNKS2 ADP-ribosylate Axin, marking it for ubiquitylation by the 
RNF146 E3 ubiquitin-ligase.  The increased Axin levels resulting from tankyrase 
inhibition enhance !%catenin degradation (Riffell et al., 2012).  XAV939 reduced 
colorectal (and breast cancer) cell growth under conditions of low serum, and 
reduced rates of adenoma formation in the mouse intestine following APC 
deletion (Casas-Selves et al., 2012).  
In a biochemical screen for regulators of !%catenin stability another antihelmitic 
compound, pyrvinium, was identified as a pan-CK1 binding molecule that showed 
selective allosteric activation of purified CK1# (Thorne et al., 2010).  However, 
recent biochemical studies have suggested that pyrvinium may not function by 
binding CK1, but instead functions through an AKT-dependent mechanism 
leading to GSK3 activation (Venerando et al., 2013).  In addition to promoting 
!%catenin turnover, pyrvinium promoted Axin stability and the degradation of 
Pygo.  Significantly it has been shown that pyrvinium inhibits the growth of colon 
cancer cells in vitro, demonstrating its potential as a colorectal cancer therapeutic 
(Saraswati et al., 2010). 
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1.1.1.3.1.3  Nuclear-targetted therapies 
One of the most direct approaches to interfere with !%catenin/TCF-dependent 
transcription is to block the interaction between !%catenin and TCF-transcription 
factors.  Lepourcelet et al., identified natural products that blocked !%catenin’s 
binding to TCF in biochemical assays and colon cancer cell proliferation in vitro 
(Lepourcelet et al., 2004).  In silico virtual screening for compounds that bound 
the TCF-binding surface of "$catenin identified two small molecules, NU-74654 
and BC21 (Tian et al., 2012; Trosset et al., 2006).  BC21 prevented TCF binding, 
TCF-dependent transcription and colorectal cancer growth in cell culture. 
Structure-based modeling was also central to the design of ‘stapled’ alpha helical 
peptides that blocked !%catenin’s interactions with TCF4 or Bcl9, a 
transcriptional co-activator (Grossmann et al., 2012; Kawamoto et al., 2012).  In 
this technically challenging approach, cross-linking ‘staples’ were used to 
stabilize and increase the "$catenin affinity of short alpha-helical peptides 
derived from Axin (fStAx-35) and Bcl9.  fStAx-35 blocked TCF-dependent 
transcription without altering levels of !%catenin and inhibited proliferation of 
colorectal cancer cells at 10-20µM concentrations.  
Cell-based screening for inhibitors of TCF-dependent transcription (induced by 
siRNA mediated depletion of Axin) identified a series of oxazole ligands (iCRT3, 
5,14) that bound !%catenin, blocking its interaction with TCF4.  These 
compounds increased colorectal cancer cell cycle arrest in the G1/S phase 
(Gonsalves et al., 2011).  The natural product carnosic acid was identified in a 
biochemical screen for inhibitors of the !%catenin/Bcl9 interaction and was shown 
to inhibit Wnt-target gene expression in colorectal cancer cells (la Roche et al., 
2012).  
Once !%catenin has formed a complex with DNA-bound TCF factors, it activates 
transcription through the recruitment of a range of co-activating factors (reviewed 
in (Cadigan and Waterman, 2012)).  The C-terminal transactivation domain of 
!%catenin interacts with the histone acetyl-transferase CBP, contributing to 
changes in histone H3 and H4 modification and chromatin structure.  In a cell 
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based screen, Emami et al. identified ICG-001 as an inhibitor of !%catenin/TCF-
dependent transcription and showed it bound CBP and blocked the 
!%catenin:CBP interaction (Emami et al., 2004).  Two related inhibitors (PRI-724 
and CWP232291) have entered phase I clinical studies for the treatment of 
advanced solid tumours and AML (Garber, 2009).  In addition to inhibiting the 
growth of intestinal tumours in APC-mutant min mice, ICG-001 reduced 
idiopathic pulmonary fibrosis (Henderson et al., 2010).  
One of the key links between the !%catenin/TCF/DNA complex and 
transcriptional initiation/extension by RNA polymerase II is the multiprotein 
mediator complex (Xu and Ji, 2011).  !%catenin binds to Med12 within the 
mediator ‘kinase module’ that comprises CDK8, cyclin C, Med12 and Med13.  
!%catenin is also linked to the kinase module via the !%catenin co-activators, 
Bcl9 and Pygo which in turn bind Med12 and Med13 (Carrera et al., 2008).  
CDK8 is amplified in a subset of colorectal, ovarian and breast and has been 
shown to be required for colorectal tumour growth in vivo and for the 
maintenance of an undifferentiated state (Adler et al., 2012; Firestein et al., 2008).  
CDK8 phosphorylates a number of nuclear targets including the C-terminus of 
RNA polymerase II.  CDK8 also activates TCF-dependent transcription through 
the inhibitory phosphorylation of E2F1, interfering with E2F1’s ability to repress 
!%catenin/TCF-dependent transcription (Morris et al., 2008; Zhao et al., 2012).  
Compounds that target CDK8 are under development by Selvita (Sel-120) and 
were identified indirectly in a cell-based screen for inhibitors of p21-induced 
transcription (Senexin A; (Porter et al., 2012)).   Senexin A blocked 
!%catenin/TCF-dependent transcription in colon cancer cells and co-operated 
with the chemotherapeutic doxorubicin in preventing lung cancer growth. 
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1.1.1.3.1.4  Multi-level / undefined mechanisms 
Cell-based screening for small molecule regulators of !%catenin/TCF-dependent 
transcription identified a number of additional pathway regulators without 
characterizing their molecular targets.  Two groups identified inhibitors, 
CCT031374 and KY02111, which reduced levels of !%catenin and TCF-
dependent transcription, even in the presence of inhibitors of GSK3 (Ewan et al., 
2010; Minami et al., 2012).  The therapeutic potential of targetting alternative !-
catenin degradation pathways was further supported by the finding that 
Hexachlorophene promoted !-catenin degradation through a Siah1/APC 
dependent, but GSK3–independent pathway (Park et al., 2006).  A series of 
diaminoquinazolines inhibited transcription at an undefined level in colon cancer 
cells (Mao et al., 2012).  Furthermore, both the diterpenoid NC043 and the Fe2+ 
binding compound HQBA blocked signalling downstream of !%catenin 
accumulation and inhibited tumour growth in vivo (Coombs et al., 2011; Wang et 
al., 2011).  Interestingly, reducing luminal iron levels in the gut was also shown to 
lower rates of tumourigenesis in an APC mutant mouse model (Radulescu et al., 
2012).  
Many small molecule inhibitors of non-Wnt pathway components have been 
shown to interfere with !-catenin/TCF-dependent transcription in specific cellular 
contexts (e.g. Src, PKA, PI3K; reviewed in (Voronkov and Krauss, 2012)).  On a 
conceptual level, this raises a question as to what should be considered a ‘Wnt-
inhibitor’; particularly as some responses may be secondary to cellular 
transcription changes induced by primary alterations to the function of ‘non-Wnt’ 
pathways.  Nonetheless, mechanistic details support direct action on the Wnt 
pathway for some compound classes. 
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1.1.1.3.1.4.1  Non-steroidal anti-inflammatory drugs (NSAIDS)  
NSAIDS including sulindac, aspirin and celecoxib have been used in the clinic to 
prevent colon cancer and are thought to act in part by inhibiting cyclooxygenase 
enzymes (COX) leading to a reduction in the levels of the bioactive lipid 
prostaglandin E2 (PGE2; (Elder and Paraskeva, 1998; Smalley and DuBois, 
1997)).  Raised levels of PGE2 in cancer bind the G-protein coupled receptor 
(GPCR) EP2 and activate !%catenin/TCF-dependent transcription (Castellone et 
al., 2005), while celecoxib lowers PGE2 levels and blocks !%catenin/TCF-
dependent transcription (Takahashi-Yanaga et al., 2008).  However, celecoxib 
also acts through COX-independent pathways (Grosch et al., 2001).  Some 
NSAIDs including indomethacin bind to peroxisome proliferator activated 
receptor gamma (PPAR$) nuclear receptors and, by acting as partial agonists, 
block the action of strong agonists (Bishop-Bailey and Warner, 2003).  As PPAR$ 
forms a ligand-dependent complex with !%catenin/TCF this offers an alternative 
route for NSAID action against Wnt signalling.  Interestingly, the PPAR$/PPAR& 
antagonist FH535 was isolated in a screen for inhibitors of !%catenin/TCF-
dependent transcription and was shown to interfere with the PPAR$:!%catenin 
interaction (Handeli and Simon, 2008).  Surprisingly, the NSAID sulindac bound 
the Dvl PDZ domain with a Ki of 10µM and inhibited !-catenin/TCF-dependent 
target gene expression in Xenopus embryos (Lee et al., 2009).  Although 
NSAIDS have clear effects in vivo and have been linked to multiple mechanisms, 
careful studies will be required to link effect to mechanism since many NSAIDS 
don’t achieve the concentrations and exposures in vivo that are frequently 
studied in vitro (Ettarh et al., 2010). 
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1.1.1.3.1.4.2  Flavonoids  
Flavonoids are a broad family of polyphenolic plant compounds that target a 
range of cellular pathways and processes (reviewed in (Havsteen, 2002)).  
Several flavonoids are active against Wnt signalling, including; genistein, 
quercetin, isoquercitrin and curcumin (reviewed in (Amado et al., 2011)).  With 
the exception of flavone activity against tankyrase (Yashiroda et al., 2010), little 
evidence has so far identified a direct Wnt molecular target that could account for 
the array of biochemical changes observed, including reductions in !%catenin 
and Dvl protein levels and the prevention of DNA binding by !%catenin:TCF 
protein complexes.  Part of the difficulty in identifying a direct mechanism may be 
due to the effects many flavonoids have on pathways including PI3K, MAPK and 
Notch that may indirectly modulate the Wnt pathway activity. 
 
1.1.1.3.2  Drugging a Wnt network 
The conventional, linear view of Wnt signalling underemphasizes key aspects of 
the pathway.  Firstly, signalling is not either ‘on’ or ‘off’; key outputs such as the 
level of !%catenin/TCF-dependent transcription can be modulated over 4 orders 
of magnitude and the level of activity determines biological outcomes (Buchert et 
al., 2010; Luis et al., 2011).  Secondly hundreds of context-specific ‘Wnt pathway 
regulators’ have been identified, particularly in the last few years with the onset of 
high-throughput RNAi and proteomic screens (Major et al., 2008; Tang et al., 
2008).  Thirdly, the absolute level of pathway activity likely reflects the integrated 
output of multiple regulators in patterns that are not simply additive.  For example, 
R-spondin, which binds to the Lgr5 receptor, does not itself signal but alters the 
output from a fixed level of Wnt ligand by altering Fz receptor degradation 
(Macdonald and He, 2012).  Lastly, non-Wnt signals such as EGF can directly 
modulate the activity of !%catenin/TCF-dependent transcription independent of 
upstream Wnt pathway components (Yang et al., 2011).  The range of potential 
functional interactions, when fully described, may best be represented as a graph 
network (Kestler and Kuhl, 2008).  The network view can be used to highlight 
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aspects of therapeutic targetting including compound dosing, dynamics and the 
use of compound combinations that target a distinct pathways a subset of which 
are alluded to in the ‘theoretical pathway’ structure diagram in Figure 5.  The 
network view is also a useful tool with which to discuss the approach and results 
in this thesis, thus is considered in more detail below in relation to the use of 
therapeutics targetting the pathway. 
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Figure 5.  A schematic representation of the Wnt network 
Network nodes represent functional units (proteins or protein complexes; see 
inset) and vertices represent functional interactions (+ve or –ve).  While the total 
network is complex, individual cell contexts express a simpler subset of nodes, 
each of which would contribute toward total pathway activity. Targetting highly 
connected core components of pathways that are expressed in all cell types 
(coloured nodes; e.g. Wnt, MAPK, Notch etc.) would be most effective at 
blocking the corresponding pathway, but would be predicted to maximise toxicity.  
Targetting non-core nodes or individual vertices (e.g. a signal-transducing 
protein-protein interaction) might lack single-agent efficacy due to a partial effect 
on Wnt pathway activity but would minimise toxicity.  By contrast, inhibiting 
molecules such as CBP (e.g. ICG-001) or CK1# (e.g. pyrvinium) that can be 
represented as highly connected nodes or as components of multiple nodes 
would enhance the probability of single agent efficacy, but would increase the 
probability of toxicity via action at unintended nodes. Combinations of single 
node-specific inhibitors should maximise the cell context specificity.   Drug 
resistance to single agent inhibitors may develop through mutation to target 
nodes or by expression of nodes from outside the cell context.  
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1.1.1.3.2.1  The Wnt signalling network, drug doses and dynamics 
‘Just right’ levels of Wnt signalling are required for homeostasis within normal 
and, at altered levels, diseased tissue.  For example, liver and melanoma 
oncogenesis is associated with lower levels of !%catenin/TCF-dependent 
transcription than intestinal tumourigenesis (Buchert et al., 2010; Lucero et al., 
2010).  Therapeutic molecules that partially alter signalling levels may therefore 
reach an efficacy threshold in one tissue but may be ineffective in another, even 
if the molecular target is equally expressed.  Partial efficacy may result from the 
partial inhibition of a strong pathway regulator (e.g. a well-connected network 
node in Figure 5) or full inhibition of a molecule that contributes a smaller effect 
on total pathway activity (e.g. a peripheral node in Figure 5).  For example, the 
partial inhibition of GSK3! (a well connected node) by lithium may be needed to 
generate a ‘just right’ level of !%catenin/TCF-dependent transcription for the 
treatment of bipolar patients (Klein, 2012).  Surprisingly, a therapeutic level of 
Wnt signalling may be either lower or higher than that that characterizes the 
disease state, even in cancer.  An example of this was identified in the case of 
riluzole, an FDA-approved drug that was originally approved for treating 
amyotrophic lateral sclerosis, which was subsequently found to be an effective 
melanoma-specific therapeutic (possibly) functioning by super-activating the 
pathway above a ‘just right’ level (Biechele et al., 2010) 
Different levels of pathway activity distinguish stem and ‘transit amplifying’ cells 
within one tissue.  As discussed earlier, in the intestinal epithelium high levels of 
mutant !%catenin induced supernumerary stem cell formation and was 
accompanied by low levels of proliferation, while a lower levels led to fewer stem 
cells, but increased progenitor cell proliferation (Hirata et al., 2013).  Within 
individual tumours, heterogeneous levels of nuclear !%catenin and TCF-
dependent transcription are driven by microenvironmental factors that in turn 
couple to distinct cell phenotypes including stem cell, migratory and proliferative 
(de Sousa et al., 2011).  Each tumour cell subpopulation (e.g. stem or progenitor) 
will likely have cellular networks that respond differentially to therapeutics.  
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Inhibitors such as the anti-Fz antibody OMP18-R5 have been shown to be active 
against tumour-initiating/cancer stem cells (Gurney et al., 2012), but it is not 
currently clear whether they are directly active against the Wnt-driven 
proliferative compartment. These hidden details of therapeutic mechanism may 
make the use of biomarkers of drug response difficult using techniques such as 
western blotting, if the target cell subpopulation is not first purified. 
On a longer timescale, immediate-early responses to Wnt inhibitors will feed 
through to changes in target gene expression, including alterations to cell 
differentiation.  Analysis of the timing of ‘Wnt-off’ responses in an intestinal 
hyperplasia model showed that responses (changes in apoptosis/differentiation) 
were complete within only 48 hours (Jarde et al., 2013).  By contrast, tumour-
regression frequently took 2-4 weeks for therapeutics described earlier.  Although 
this time difference may be explained by the details of the therapeutic, its access 
to the tumour or a unique feature of a particular tumour model, it is interesting to 
speculate that initial treatments induce a rapid response from tumour 
subpopulations with a sensitive Wnt network and that unresponsive cells later 
convert into responsive cells as their microenvironment changes during therapy.  
This interpretation would predict that short pulses of Wnt pathway inhibitor 
combinations that target distinct cell(s) with a discrete network structure would 
induce very rapid responses and could minimize long-exposure associated 
toxicity.  Interestingly, short-period pulses of Wnt signalling have been suggested 
to be optimal during tissue regeneration (Zimmerman et al., 2012), and for the 
efficient differentiation of human pluripotent stem cells into cardiomyocytes in 
vitro (Lian et al., 2012; Minami et al., 2012). 
 
1.1.1.3.2.2  The Wnt signalling network and cellular toxicity 
One common concern for the use Wnt pathway therapeutics is the potential for 
acute toxicity in adult tissues that are maintained by stem cells, based on the 
central role for Wnts in stem cell biology (Wend et al., 2010).  Additional side 
effects may include metabolic changes, based for example, on the role of Wnt 
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signalling in the maintenance of liver zonation; and the potential for neurological 
effects, based on the action of Wnts on synapse formation in the CNS and PNS 
(Benhamouche et al., 2006; Harrison-Uy and Pleasure, 2012; Klein, 2012; Koles 
and Budnik, 2012; Liu et al., 2011; Wend et al., 2010; Zarnescu and Zinsmaier, 
2009).  Toxicity may also be associated with off-target effects of inhibitors.  For 
example, pyrvinium has been suggested to have alkylating activity in addition to 
its effects on CK1# (Saraswati et al., 2010).  Longer-term treatment with Wnt-
inhibitor therapeutics might be expected to promote the onset of diseases for 
which Wnt activators are being developed and vice-versa.  This could include 
ageing-related diseases (Naito et al., 2012).  Nonetheless an understanding of 
the ‘Wnt network’ in diseased tissue may be able to maximize on-target 
specificity by exploiting unique dependencies/network structures that are not 
likely to be present within other adult tissues. 
 
1.1.1.3.2.3  The Wnt network and combinatorial therapies 
Standard of Care (SoC) chemotherapy in cancer   
Combinatorial therapy can be divided into two types: combinations in which 
compounds target distinct tumour cell types and combinations that target distinct 
processes within one cell.  Targetting Fz receptors in solid tumours with OMP-
18R5 synergized with chemotherapeutic agents including taxol, irinotecan and 
gemcitabine, at least in part by reducing the slow-growing, tumour-
initiating/cancer stem cell compartment, whilst SoC chemotherapeutics agents 
‘debulked’ tumours by targetting rapidly proliferating cells (Curtin and Lorenzi, 
2010; de Sousa et al., 2011; Gurney et al., 2012; Malanchi et al., 2011).  
Providing further evidence for this hypothesis, the CK1# inhibitor pyrvinium and 
sFRP7 potentiated the activity of doxorubicin against prostate and HCC tumours 
respectively (Wang et al., 2011; Yu et al., 2008).  Additionally, salinomycin and 
gemcitabine combined to repress pancreatic tumour growth (Zhang et al., 2011).  
In vitro, PKF115-584, quercetin and an anti-Wnt-1 antibody increased the 
chemosensitivity of colon and melanoma cells towards 5FU, temozolomide, 
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cisplatin, doxorubicin and docetaxel respectively (He et al., 2005; Sinnberg et al., 
2011; Wang et al., 2011; Xavier et al., 2011; Yu et al., 2008), while GDK100017 
enhanced lung cancer radiosensitivity (Lee et al., 2013).  By contrast, the 
tankyrase inhibitor XAV-939 failed to synergise with 5FU or oxaliplatin in the 
killing of primary colorectal cancer spheroid cultures (Tenbaum et al., 2012).  In 
vivo, Wnt inhibitors may also work indirectly by reducing a side effect of standard 
chemotherapy – the ability to promote tumour relapse.  The CDK8 inhibitor 
Senexin A and pyrvinium were shown to prevent doxorubicin-induced stromal 
phenotypes that supported tumour progression, while pyrvinium also enhanced 
SoC efficacy by reducing the Wnt ligand-dependent expression of the drug 
export protein, mdr-1 (Basu et al., 2012; Porter et al., 2012).  The tankyrase 
inhibitor, XAV939 reduced paracrine stromal Wnt signalling to tumour cells and 
synergized with araC to increase survival in acute lymphoblastic leukemia (Yang 
et al., 2013).  Similarly, DNA-damage induced Wnt-16 expression in fibroblasts 
promoted prostate cancer resistance to chemotherapeutics through a pathway 
that was inhibited by XAV939 (Sun et al., 2012).   
Far less explored are the mechanisms by which chemotherapeutic agents 
synergise with Wnt inhibitors within a single cell type.  Studies in embryonic stem 
cells showed that the DNA damaging agent cisplatin induced !-catenin/TCF-
dependent transcription, which in turn blocked apoptosis, suggesting that the 
inhibition of Wnt signalling may enhance the cell-killing efficacy of DNA-
damaging SoC agents (Carreras Puigvert et al., 2013). 
Wnt:non-Wnt inhibitor combinations 
In the context of a network, the definition of which components are ‘Wnt-specific’ 
is somewhat unclear.  Components of pathways such as PI3K, Ras/MAPK and 
Notch interact to affect the levels of !%catenin/TCF-dependent transcription as 
well affecting well-studied non-Wnt outcomes (reviewed in (Bertrand et al., 2012; 
Hu and Li, 2010; Itasaki and Hoppler, 2009; Voronkov and Krauss, 2012)).  For 
example, activation of Ras or PI3K signalling increased !%catenin nuclear 
accumulation, tumour initiation and progression in the intestine (He et al., 2007; 
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Marsh et al., 2008; Phelps et al., 2009; Sansom et al., 2006).  Unexpectedly 
however, reduction of PI3K signalling through treatment of colorectal cancers 
with PI3K inhibitors did not revert cancers to a less advanced tumour phenotype 
as might have been predicted, but instead led to the activation of a metastatic 
phenotype that was dependent on high levels of nuclear !%catenin (Tenbaum et 
al., 2012).  Encouragingly though, treatment of primary colorectal cancers 
expressing high levels of nuclear !%catenin in spheroid culture with the tankyrase 
inhibitor XAV-939 reduced !%catenin levels, redirecting cell the cellular program 
such that PI3K-inhibition induced apoptosis rather than promoting metastasis 
(Tenbaum et al., 2012).  More in line with expectation, combinations of the Wnt 
inhibitors pyrvinium and PKF115-584 with a Ras inhibitor (FTS) were found to 
synergise in the in vitro killing of colorectal cancer cell lines with mutant KRAS 
and APC or !%catenin (Mologni et al., 2012).  The Wnt inhibitors XAV939 and 
pyrvinium also synergistically inhibited non small cell lung cancer cell line growth 
in combination with the EGFR receptor inhibitor gefitinib (Casas-Selves et al., 
2012). 
 Wnt:Wnt inhibitor combinations  
Although combinations involving different Wnt inhibitors have not yet been 
described, they should offer therapeutic advantages. Firstly, they should allow 
greater control over the absolute level of pathway activity than single agents.  
Secondly, they should allow the tailoring of inhibitor combinations (and therefore 
maximal effect) to Wnt pathway branches that are selectively active in the 
disease setting, thereby reducing toxicity.  Finally, in the cancer context, they 
should reduce the chances of resistance developing through the activation of 
alternative branches of the network (Figure 5).  A useful initial combination would 
likely involve both extracellular and intracellular Wnt pathway inhibitors in 
colorectal cancer since APC/!%catenin mutations are frequently accompanied by 
reduced expression of extracellular Wnt repressors such as Dkk1 (Ying and Tao, 
2009).  In addition, combinations should allow a greater range of disease-
associated phenotypes to be targeted since activation at the Wnt ligand level can 
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induce a greater range of cancer hallmark changes than downstream changes 
induced by, for example, mutant "-catenin alone (Collu et al., 2009).  
A major future task will be the identification of efficacious therapeutic 
combinations and corresponding susceptible patient populations from the huge 
numbers of potential drug combinations and genotypes.  One approach to this 
would require the systematic mapping of functional dependencies amongst ‘Wnt 
pathway regulators’ combined with mutation and expression analyses of 
diseased tissues to allow the definition of ‘patient-stratified functional networks’ 
that would represent each cell type within the diseased tissue (Figure 5).  A 
second more empirical approach would be to identify efficacious combinations 
through direct experiment using patient tissues (Tenbaum et al., 2012).  Here, 
the recent identification of R-spondin dependent organoid growth conditions for 
normal and diseased tissues has been a major advance (Schuijers and Clevers, 
2012), since this may in future allow inhibitor combinations to be directly tested in 
vitro on tumour material, prior to the use of efficacious agent combinations in the 
patients from which the tumours were isolated.  However, high-throughput 
implementation of in vitro organoid growth and treatment technologies would be 
needed to maximize their potential in drug combination studies.  A third empirical 
approach is to use ‘synthetic lethal’ genome-scale screens to identify disease-
specific, druggable molecular targets that synergise with single-agent 
therapeutics to induce cell killing.  This approach was taken as part of the work in 
this thesis.  A key starting point for these studies would be the identification of 
cell systems/single agent therapeutic combinations that have a low background 
of cell killing, against which alterations in gene expression during the screen 
would be predicted to result in robust conditional changes in cell viability.   
Suitable combinations for a screen that could be suggested based on the existing 
literature would include the combination of a tankyrase inhibitor and breast 
cancer cells since tankyrase inhibition was able to reduce !%catenin/TCF-
dependent transcription but was unable to induce cell death under normal cell 
growth conditions (Bao et al., 2012). 
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1.2  Contextualisation of the cDNA studies conducted 
The foundation for the cDNA screen undertaken in this research was established 
in the Dale laboratory.  Experimental support for the ‘network’ nature of Wnt 
signalling resulted from studies within the Dale laboratory that are described in 
Jamie Freeman’s thesis (Freeman, 2008).  In this work, a cell-based cDNA over-
expression screen of 9000 Xenopus tropicalis cDNAs was carried out for novel 
regulators of the TCF-dependent transcription.  This led to the identification of 
~50 novel pathway activators through the co-expression of cDNAs a mutant Wnt 
co-receptor, "NLRP (shown to induce a ‘mid-level’ of Wnt pathway activity, 
Figure 6 (Brennan et al., 2004)).  Surprisingly, it was subsequently found that 
47/50 ‘activating’ cDNAs did not activate TCF-dependent transcription when 
expressed alone in the HEK293-based 7df3 reporter cell line, suggesting that 
their function was dependent on the activity of "NLRP.  
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Figure 6 placement 
Figure 6.  Schematic representation of the dynamic range of Wnt/TCF-
dependent transcription 
Constitutive activation of basal Wnt signalling by "NLRP is anticipated to provide 
a platform for the identification of ‘super-activators’ and ‘inhibitors’ of TCF-
dependent transcription (adapted from (DasGupta et al., 2005)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Schematic representation of the dynamic range of Wnt/TCF-
dependent transcription
Constitutive activation of basal Wnt signalling by ΔNLRP is anticipated to provide 
a platform for the identification of ‘super-activators’ and ‘inhibitors’ of TCF-
dependent transcription (adapted from (DasGupta et al., 2005)).
40
 41 
A key observation in this work was that when each of the 50 activating cDNAs 
was expressed in the presence of each other (50 x 50), a unique pattern of 
functional co-operativity was observed.  Many cDNA pairs would only functionally 
co-operate to induce transcription in combination with a selected subset of other 
cDNAs.  A network of functional co-operation was constructed that usefully 
informed other studies of the pathway.  Firstly, it was observed that functional co-
operativity was more often observed between components of different protein 
complexes (as highlighted by the overlap with protein interaction networks). 
Secondly, it was determined that ‘core’ Wnt pathway components appeared to be 
highly connected nodes in the functional connectome.  Thirdly, it was noted that 
cDNA pairs showed distinct patterns of sensitivity to small molecule inhibitors of 
TCF-dependent transcription, suggesting that the functional connectome could 
be used to ‘place’ the action of drugs with unknown molecular targets in a 
functional context. 
 
1.3  Background to the ‘MSC’ compound used in this 
report 
The Dale laboratory previously published the results of a cell-based screen for 
inhibitors of the Wnt signalling pathway (Ewan et al., 2010).  In the Ewan study, a 
HEK293 based cell line (7df3) containing an integrated, Dvl-ER fusion protein 
and a TCF-luciferase reporter was used to screen for small molecule inhibitors of 
TCF-dependent transcription (see Methods; Figure 7).  The Wnt pathway was 
induced in the cell line by addition of estradiol, leading to the refolding of the Dvl-
ER fusion partner and the activation of TCF-dependent transcription.  The Ewan 
study (Ewan et al., 2010) described the screen of a 63,000 compound library that 
was added (1 well per compound) simultaneously with estradiol, and levels of 
TCF-dependent transcription were assessed 24 hours later (Figure 7).  The 306 
‘hit’ compounds that reproducibly reduced TCF-dependent transcription were 
processed through a series of ‘deconvolution’ assays that were designed to:  
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1. Remove non-specific ‘toxic’ compounds.  7df3 cells could be cultured in 
the absence of estradiol and had very low levels of background TCF-
dependent transcription, suggesting that any compounds that simply killed 
7df3 cells and reduced TCF-dependent transcription, were doing so 
through non-Wnt ‘toxic’ pathways. 
2. Identify compounds that had activity against tumour cell lines in 2D growth 
including HCT116, SW480 and HT29 cells.  This step was based on the 
observation that growth in these lines could be suppressed through the 
reduction of TCF-dependent transcription as engineered through siRNA 
depletion of Wnt regulators such as "-catenin or through the re-expression 
of Wnt pathway inhibitors such as APC or transcriptionally-inactive forms 
of TCF factors. 
3. Remove compounds that blocked ‘non-specific’ TK-luciferase (i.e. non-
Wnt) promoter activity. The aim here was to remove ‘off-target’ inhibitors 
of transcription. 
4. Deconvolve the ‘level’ at which the compound worked within the pathway 
by testing whether the pathway could be blocked when it was activated at 
multiple levels through the expression of various Wnt pathway activators 
(e.g. %NLRP, Dvl-2, Axin-GSK3 binding domain, "N-"-catenin, VP16-
TCF).  
 
Based on these criteria and following an assessment of their chemical tractability 
(e.g. size, reactivity, stability, patent position etc.), a subset of 10 compounds 
were selected for additional studies.  Nine of the ten compounds were described 
by Ewan et al. and were not subsequently developed as therapeutic candidates 
based on a further assessment of their chemical tractability and the robustness of 
their biological responses (Ewan et al., 2010).  One of the compounds not 
described in the paper (CCT071459) had an IC50 of 1µM in the 7df3 TCF-
luciferase reporter assay and was selected for further development in a major 
collaboration between Cardiff University, The Institute of Cancer Research (ICR) 
and Merck Serono. 
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Continued development of the CCT071459 compound series took place during 
the course of the work described in this thesis, and subsequently the activity of 
the more developed ‘daughter compound’ termed MSC was assessed in these 
studies.  Reference to unpublished studies carried out by other individuals within 
the Cardiff / ICR / Merck Serono collaboration will be made at appropriate places 
throughout this work where the data affected the direction of the work undertaken. 
1.3.1  The molecular target of MSC 
Following extensive collaboration-wide target identification studies (including 
cellular reporter assays, stable isotope labelling by amino acids in cell culture 
followed by mass spectrometry and enzyme activity confirmation assays), the 
molecular targets of MSC were determined as being CDK8 and CDK19.  CDK8 
and CDK19 are members of the cyclin-dependent family of serine/threonine 
kinases, whose function is regulated by the conditional presence of a cyclin 
subunit.  The CDK family is crucial in controlling cellular proliferation in 
mammalian systems through the regulation of the cell cycle (Malumbres and 
Barbacid, 2005).  The cell cycle is a tightly controlled series of events essential 
for the precise, error-free replication of eukaryotic cells. The transition from one 
cell cycle phase to the next is controlled, in part, by specific CDK-cyclin 
complexes.  The expression of cyclin D (CycD) is triggered by mitogenic signals.  
CycD preferentially binds and activates CDK4 and CDK6, which then 
phosphorylate ‘pocket proteins’ including retinoblastoma protein (RB) and 
partially inhibit its anti-proliferative effect, allowing expression of the E-type 
cyclins and thus priming the cells to initiate DNA synthesis.  Late in the G1 phase 
and immediately prior to the DNA replication S phase, CDK2 interacts with CycE 
which drives G1/S phase transition through additional phosphorylation of pocket 
proteins (resulting in their complete inhibition and maximising CycE availability).  
Subsequently a CDK2-CycA complex is formed which pushes the cell cycle from 
S phase to the G2 phase.  During the G2 phase CDK1 is bound to CycA which 
facilitates the onset of mitosis, with cells driven through the final mitosis (M) 
phase by the binding to and activation of CDK1 by CycB, forming the ‘M phase 
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promoting factor’ (Malumbres and Barbacid, 2009; Pitts et al., 2013).  The 
formation of the correct CDK-cyclin complexes is achieved through the synthesis 
at degradation of each cyclin at defined points during the cell cycle, providing an 
additional level of control over its progression (Malumbres and Barbacid, 2009). 
As briefly described, RB and p53 play crucial roles in the regulation of the cell 
cycle by preventing aberrant cellular proliferation and genome mutation 
respectively (Cox and Lane, 1995; Hernando et al., 2004).  Loss of function of 
these proteins reduces cell cycle regulation, thus uncontrolled cellular 
proliferation and/or loss of genome stability occurs.  For this reason they are 
described as tumour suppressors, with their corresponding RB1 and TP53 genes 
classified as tumour suppressor genes.  
It is evident that not all of the >20 CDKs presently identified are key players in 
cell cycle regulation; many possess diverse roles outside of cell cycle control 
(reviewed in (Lim and Kaldis, 2013)).  The targets of MSC, CDK8 and CDK19, 
are two examples of such ‘non-cell cycle associated’ CDKs.  CDK8 is a 
ubiquitously expressed nuclear protein whose best characterised function is as a 
regulator of transcription as part of the Mediator complex, and is hence described 
as a ‘transcriptional CDK’ (Galbraith et al., 2010).  In complex with CycC (also 
ubiquitously expressed) and the mediator proteins Med12 and Med13, the 
CDK8:CycC kinase core forms the regulatory module of the multi-protein 
Mediator complex which plays a central role in the control of both basal and 
regulated transcription (Firestein and Hahn, 2009; Malik and Roeder, 2010).  
Interestingly it has also been identified that CDK8 is an essential regulator of 
nuclear !-catenin activity, which in turn provides a link between the basal 
transcription components and the enhancement of !-catenin-TCF/LEF 
dependent transcription (Firestein and Hahn, 2009).   
CDK19 (also known as CDK11) is a paralogue of CDK8, with the human CDK19 
protein sharing 77% sequence homology with its CDK8 counterpart.  Less is 
known about the activity of CDK19, although it has been shown that CDK19 is 
able to interact with the same Mediator complex kinase module components as 
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CDK8 (Conaway et al., 2005; Knuesel et al., 2009), suggesting that these 
kinases are functionally redundant (to an as yet unknown degree).  This is 
supported by in-house studies that have shown that a reduction in HCT116 
colorectal cancer cell number is dependent on the dual knockdown of CDK8 and 
CDK19 genes (with no effect on cell number observed when each gene was 
knocked-down independently; data not shown).  
Significantly, CDK8 has been determined to be a colorectal cancer oncogene 
(Firestein and Hahn, 2009).  The observation that CDK8 is amplified in a range of 
colon cancers combined with its role in the regulation of both transcription and !-
catenin nuclear activity indicates that CDK8 may super-activate !-catenin, and 
serve to potentiate malignancies driven by aberrant Wnt/!-catenin signalling 
(Firestein et al., 2008; Firestein and Hahn, 2009).  Therapeutic reduction of this 
activity is therefore a desirable target for the treatment of colorectal cancers.  
 
 
 
 
 
 
 
 
 
 
 
 
 46 
1.4  Aims and objectives 
The work described in this thesis can be divided into two parts.  In the first, a 
cDNA screen for novel regulators of Wnt signalling was undertaken.  The 
rationale for this study was an extension of the deconvolution studies (point 4 on 
page 42).  Data from the drug discovery collaboration determined that MSC 
acted at the level of the TCF-complex, in that it blocked transcription driven by a 
VP16-TCF fusion protein – a strong activator that drives ligand- and "-catenin-
independent TCF-dependent transcription.  Following a whole genome cDNA 
screen for the identification of Wnt signalling regulators (using a cDNA library 
provided by Dr. Gary Davidson from Karlsuhe Institute of Technology), the 
objective was to determine whether transcription induced by any novel pathway 
regulators identified would be sensitive or resistant to inhibition by MSC.  The 
underlying hypothesis was that a large-scale ‘map’ of inhibitor sensitivity in 
relation to novel and existing cDNA regulators would help identify the probable 
molecular target of MSC and would identify genes whose function might alter 
MSC compound resistance and sensitivity in a clinical context.   
The second major part of the work described in this thesis was initiated after the 
Cardiff / ICR / Merck Serono collaboration identified the molecular target of the 
MSC compound as the CDK8 and CDK19 serine/threonine kinases.  It is 
important to note that CDK8 has been shown to play a central role in the coupling 
of "-catenin/TCF to RNA polymerase II at Wnt target genes (in addition to other 
roles; see discussion).  By this stage in the drug development programme, work 
including my studies had shown that the more advanced CCT071459 daughter 
compound MSC had nanomolar activity against TCF-dependent transcription, yet 
had little efficacy against colorectal cancer cell growth in 2D culture (unlike the 
CCT071459 parent compound).  
In the second major part of the work here described, a synthetic lethality screen 
using an esiRNA library was carried out to identify genes whose function was 
conditionally required for cell growth in 2D culture in the presence of the 
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CDK8/19 inhibitor, MSC.  The rationale for the synthetic lethality screen was 
based on the analogous observation that siRNA depletion of Parp1 in BRCA1 
mutant cells uncovered a synthetic dependence of Parp1 function conditionally in 
cells lacking BRCA1 function, and that Parp1 small molecule inhibitors could be 
used to selectively kill BRCA1 deficient cells (Farmer et al., 2005).  The 
underlying hypothesis for the synthetic lethality study was that novel gene 
functions functionally co-operate with CDK8/19 to drive growth in 2D cell culture.  
This hypothesis was based (at least in part) on the observation that HCT116 
colorectal cancer cells in which Wnt/"-catenin driven transcription was reduced 
(by loss of "-catenin and reduction in Wnt ligand levels), did show reduced levels 
of in vivo cell proliferation (HCT116 cell xenografts; (Bafico et al., 2004)), 
suggesting that loss of TCF-dependent transcription may not be sufficient for 
growth inhibition in 2D culture. 
 
In summary, the cDNA overexpression study identified a number of novel Wnt 
pathway regulators, two of which were resistant to MSC inhibition.  Furthermore, 
the esiRNA synthetic lethality screen identified a small number of genes whose 
loss led to MSC-dependent inhibition of 2D colorectal cancer cell growth. 
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Chapter 2.  Materials and Methods 
 
2.1 Routine cell culture and cell line details 
Unless otherwise stated, cells were passaged when they approached 70% 
confluence and were routinely tested (monthly) for mycoplasma contamination by 
PCR analysis.  Details of the mutation status of colorectal cell lines used can be 
found in Appendix 2. 
2.1.1 The 7df3 TCF-Luciferase (TLIG) reporter cell line  
The Wnt-pathway reporter cell line was generated by Dr. Helen Wildish, as 
described by Ewan et al. (Ewan et al., 2010).  Briefly, HEK293T cells expressing 
a haemagglutanin tagged-dishevelled 2-oestrogen receptor fusion protein (HA-
Dvl2-ER) that allowed for oestrogen-dependent Wnt signalling induction were co-
transfected with a Wnt-responsive bicistonic luciferase/green fluorescent protein 
(GFP) reporter plasmid (‘TLIG’ vector; Figure 7a).  The integrated TLIG reporter 
construct comprises a Wnt responsive element (WRE) from the Xenopus Xnr3 
promoter upstream of four repeats of a short TCF binding sequence and the 
basal TK-promoter TATA box and transcriptional initiation site.  Clone ‘7df3’ 
(stably expressing the reporter construct under 3&g/ml blasticidin and 200&g/ml 
hygromycin selection (Life Technologies and Roche respectively)) was chosen 
based on its high signal:noise luminescence ratio following lithium induction 
(Figure 7bi&ii).  
7df3 cells were cultured in Dulbecco’s Modified Essential Medium (DMEM; Life 
Technologies) supplemented with 10% foetal bovine serum (FBS; Life 
Technologies), 2mM L-glutamine (Life Technologies) and 50units/ml penicillin, 
50&g/ml streptomycin (Life Technologies) at 37°C and 5% CO2.  The cells were 
maintained under 3&g/ml blasticidin and 200&g/ml hygromycin selection. 
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Figure 7 placement 
Figure 7.  Schematic representation of the TCF-luciferase reporter cell line 
a.  The TLIG reporter construct was generated to contain four multimerised TCF 
binding sites downstream from the Xnr3 promoter, driving the transcription of 
luciferase and GFP reporter genes in the presence of Wnt pathway stimulation 
(taken from (Ewan et al., 2010)).  
bi and ii.  HEK293 cells were stably transfected with a Dvl (labelled Dsh here) 
and the TLIG reporter construct.  The clones were induced with lithium and the 
most responsive clone (with highest induction:lowest background ratio) was 
selected (figure reproduced with the kind permission of Dr. Jamie Freeman 
(Freeman, 2008)). 
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2.1.2 Wild type and AT506.C2 reporter HCT116 colorectal cancer cells  
AT506.C2 is a HCT116 cell line stably transfected (using GeneJuice) with the 
super8-TOPflash luciferase TCF-reporter ((Veeman et al., 2003).  Cell line 
created by Dr. Christa Burger, Merck Serono).  AT506.C2 and HCT116 wild type 
cells were cultured in Minimal Essential Medium (MEM) Eagle (Sigma) 
supplemented with 10% FBS (PAA) and 2mM L-glutamine at 37°C and 5% CO2. 
2.1.3 SW480 colorectal cancer cells 
The cells were cultured in Lebovitz’s L-15 Medium (Life Technologies) 
supplemented with 10% FBS (Life Technologies) at 37°C and 5% CO2. 
2.1.4 SW620 colorectal cancer cells 
The cells were cultured in DMEM/F-12 (Life Technologies) supplemented with 
10% FBS (Life Technologies) and 2mM L-glutamine at 37°C and 5% CO2. 
2.1.5 Colo205 colorectal cancer cells 
The cells were cultured in DMEM supplemented with 10% FBS (Life 
Technologies) at 37°C and 5% CO2. 
2.1.6 Colo320 and DLD-1 colorectal cancer cells 
The cells were cultured in RPMI 1640 (Life Technologies) supplemented with 
10% FBS (Life Technologies), 2mM L-glutamine and 1mM sodium pyruvate at 
37°C and 5% CO2. 
2.1.7 Ls174T colorectal cancer cells 
The cells were cultured in Minimal Essential Medium (MEM) Eagle (Sigma) 
supplemented with 10% FBS (Life Technologies) at 37°C and 5% CO2. 
2.1.8 Cell banking 
A critical requirement for the high-throughput assays was the availability of large 
batches of identical cells. These were prepared and frozen prior to use. To 
ensure that assays were carried out using cells from the same passage, cells 
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were bulked up under normal culture conditions, trypsinised, counted and frozen 
in 70% appropriate antibiotic free culture media, 20% FBS and 10% DMSO. 
 
2.2 cDNA expression 
2.2.1 The cDNA library 
The Medaka (Oryzias latipes) cDNA library was kindly provided by Dr. Gary 
Davidson (Karlsruhe Institute of Technology, Karlsruhe; see Appendix 3 for 
Ensembl IDs).  In brief, the master library was prepared from full-length enriched 
and subtracted cDNA taken from 3 different developmental stages, including 
unfertilized eggs (each driven by a CMV promoter of their pCMV-Sport6 vector 
(Lickert et al., 2004)).  Sequencing was then performed and full-length, unique 
clones selected (18,000; originally from Jochen Wittbrodt, EMBL, 
Heidelberg).  The library contained 18,000 individual genes, but was provided as 
multiple pools of 24 cDNAs.  Each pool was supplied as 1µg plasmid DNA in a 
50µl volume (20µg/ml) in 8 x 96 well plates.  Representative pools from the 
library were quantified by absorbance to ensure that DNA was present prior to 
analysis.  
2.2.2 "NLRP, CMV-LacZ, pcDNA. 
"NLRP is a constitutively active form of the Wnt co-receptor LRP6 lacking the N-
terminal extracellular domain ((Brennan et al., 2004)).  A plasmid expressing a 
CMV-driven myc-tagged "NLRP6 was used to activate TCF-dependent 
transcription to a ‘mid’ level.  CMV-LacZ (cytomegalovirus-driven constitutively 
active LacZ expression plasmid; Life Technologies) was used as a transfection 
control. pcDNA3.1 (Life Technologies), a plasmid with a CMV-promoter, but no 
insert, was frequently used as a control or as ‘filler’ DNA to equalise levels of 
CMV-promoter-containing plasmid DNA in transfections.  
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2.2.3 Constitutive activator/control stock plasmid replenishment 
XL-1 Blue subcloning-grade competent cells (Stratagene) were transformed with 
desired plasmid according to the manufacturer’s manual, plated onto selective 
lysogeny broth (LB) agar plates (plasmid antibiotic selection marker dependent) 
and incubated overnight at 37°C.  Individual colonies were picked and grown in 
250ml LB broth (containing appropriate antibiotic) at 37°C overnight (with 
shaking).  Plasmids were purified using the QIAfilter Plasmid Maxi Kit (Qiagen) 
according to manufacturer’s protocol and DNA concentrations measured using 
the ND-1000 Spectrophotometer (NanoDrop Technologies). 
 
2.3 cDNA library screening 
2.3.1 The primary screen 
7df3 cells were transfected with a combination of 100ng of DNA comprising 70ng 
of each pooled cDNA (24 clones/pool) in a 96 well format together with 20ng 
constitutively active %NLRP6 plasmid to induce a mid-level of TCF-reporter 
activity, and 10ng/well CMV-LacZ transfection control plasmid as an internal 
control to allow results to be normalised to "-galactosidase expression as a 
marker of transfection efficacy.  Twenty-four hours prior to transfection, 7df3 cells 
were cultured to ~80% confluency and seeded into 96-well, black walled, clear 
bottom plates (Nunc) at a density of 3X105 cells/ml in 100µl antibiotic free DMEM.  
A total of 100ng DNA/well was prepared in Optimem (serum free media; Life 
Technologies) in a final volume of 25µl, followed by the addition of 0.3 µl/well of 
Transfectin (BioRad) diluted in 25µl Optimem.  Subsequent medium changes 
were completed according to the manufacturer’s guidelines.  Luciferase and !-
galactosidase reporter assays were carried out 48 hours after transfection (see 
2.4.1).  The screen was performed twice (with two repeats on each occasion) 
before selecting wells for deconvolution.  See ‘Results’ for details on hit selection. 
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To control for the ‘inducibility’ of the 7df3 cells (as compared to their 
‘transfectability’), a subset of wells in each experiment was treated with !-
estradiol to determine whether the TCF-luciferase reporter could be activated. 
For this, a final concentration of 4µM !-estradiol was added to untransfected cells 
for 24 hours prior to assay. This approach helped to monitor cell responsiveness 
from passage to passage.  
2.3.2 Deconvolution of cDNA ‘hit’ pools 
Hits identified in the primary screen as either activating or inhibiting the Wnt 
reporter were pools of multiple cDNAs containing 24 plasmids. To identify the 
activating/inhibiting cDNA(s) within each pool, each plasmid present within the 
pools that were identified as ‘hits’ were individually prepared.  Briefly, plasmids 
were grown from glycerol stock in 5ml of LB broth with 100µg/ml carbenicillin 
(37°C, overnight incubation).  Plasmids were then purified using the SV Wizard 
Plus Miniprep DNA Purification System (Promega).  DNA concentration was 
measured as detailed in 2.2.3. To assess the function of each member of each 
pool, cells prepared as with the primary screen were co-transfected with 70ng of 
each plasmid, 30ng "NLRP6 and 10ng LacZ, in individual wells on three 
replicate plates.  Three independent repeats were conducted.  Activation relative 
to 36 "NLRP controls was determined.  Putative hits were then reconfirmed both 
in the presence and absence of "NLRP6 co-activation and hit samples 
sequenced by Dundee Sequencing Service (using the SP6 and T7 primers 
provided).  Sequences were analysed using BLAST analysis to determine hit 
identity. 
2.3.3 cDNA MSC interference studies 
Cells transfected as described in the previous section (both in presence and 
absence of "NLRP6 co-activation) were treated with 125nM MSC (10 x 7df3 
IC50) in antibiotic and serum free media (or 0.1% DMSO for untreated controls) 
24 hours post-transfection.  TCF-luciferase reporter activity was measured (see 
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2.5.1) 72 hours post-MSC treatment.  Three independent repeats were 
conducted.  
 
2.4  esiRNA screening 
2.4.1 esiRNA production and sequences 
A genome-wide enzymatically-synthesized small interfering RNA library (esiRNA) 
representing 17,188 human genes was kindly donated by Professor Frank 
Buchholz (Max Planck Institute of Molecular Cell Biology and Genetics, Dresden 
(Buchholz et al., 2006; Kittler et al., 2004; Theis and Buchholz, 2011).  The 
library was supplied as 47 x 384-well plates containing individual esiRNAs. The 
library was used at a final concentration of 20ng per well in the primary and 
secondary screening experiments.  The library was sequentially diluted in TE 
buffer (Promega) and dispensed in to 384 well white test plates (Greiner Bio-
One) using the Biomek FX (Beckman Coulter) from a stock concentration of 
200ng/µl to a final concentration of 4ng/µl esiRNA/well aliquotted at 5µl/well (thus 
20ng esiRNA/well).  Appendix 4 and 5 provides information regarding well IDs 
and sequences of the primary library.  
A secondary, non-overlapping sub-library of 57 esiRNAs was selected from the 
primary screen for hit reconfirmation.  These non-overlapping esiRNAs were 
designed and synthesised by Eupheria Biotech (Sigma). Sequences for these 
non-overlapping esiRNAs can also be found in Appendix 6. 
Non-targetting siRNA negative controls; enhanced green fluorescent protein 
(eGFP) and renilla luciferase (R-Luc), and gene targetting positive controls; polo-
like kinase 1 (PLK1) and kinesin family member 11 (EG5) were purchased from 
Eupheria Biotech (Sigma) and plated into the 12 empty wells of each ‘master 
dilution’ plate at 20ng/well (4 repeats of each control/plate).  
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2.4.2 Assay optimisation 
Multiple different parameters were extensively assessed in order to establish the 
optimal final screening conditions.  These included determination of appropriate 
cell seeding density and frozen batch testing, HiPerFect transfection 
concentration, test compound concentration, assay time course, and assay 
miniaturisation.  Of the conditions that were systematically varied in the assay 
optimisation studies, the final conditions that were determined to be optimal were 
as follows:  plating of 2000 cells/well (1.3x105 cells/ml, 15µl/well), 5µl/ml 
HiPerFect (in final assay volume containing cells), with 10µM test compound (in 
final assay volume) or DMSO control, and assay read points at 72 hours and 120 
hours post-transfection.  
2.4.3 The primary screen protocol 
esiRNA and siRNA transfections were carried out in ‘reverse format’. For this, 
cells were plated onto esiRNA:HiPerFect complexes since this was found to 
reduce assay variability.  The esiRNA library and siRNA controls were pre-
dispensed at 20ng/well (5ul/well) in white 384 well assay plates and stored at -
80˚C.  Assay plates were defrosted overnight at 4˚C and centrifuged for 1 minute 
pre-assay.  The HiPerFect transfection mix was freshly prepared to give a final 
‘concentration’ of 5ul/ml in the presence of the cells.  Prior to cell addition, this 
equated to 7ul/well containing 0.14µl HiPerFect and 6.86µl of serum-free medium 
Thus the total volume prior to transfection, 15 minutes prior to use was 12µl.  
Fresh HCT116 cells (from the same batch on every occasion) were thawed and 
seeded 72 hours prior to use. On the day of transfection, they were trypsinised 
and seeded at 2000 cells/well in 384 well format plates in serum-containing MEM 
Eagle.  
48 hours post-transfection, compound was added to achieve a final concentration 
of 10µM, with the equivalent percentage of DMSO vehicle (0.1%) added where 
compound treatment was not required.  At either 72 hours or 120 hours post-
transfection cells were lysed (see 2.5.2) and frozen at -80˚C until all screening 
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had been completed.  Lysates were then defrosted at 4˚C overnight and 
equilibrated room temperature on the day of reading, and cell numbers (i.e. 
cellular viability) measured according to subsection 2.5.2.  Screening was 
performed in batches of 47 test plates, with 3 repeats of each condition 
conducted on different days. 
All liquid handling steps throughout the course of optimisation were performed 
manually, however these processes were semi-automated during the final screen 
using the Multidrop Combi (Thermo Scientific).  Furthermore, cells were manually 
counted using a haemocytometer during small-scale assays, whilst during screen 
bulk-cell preparation the Vi-CELL® (Beckman Coulter) was used to determine cell 
counts and viability.  A final measure to increase through-put was the switch from 
the Varioskan Flash Multimode Reader (Thermo Scientific) used during 
optimisation, to the LEADseeker Multimodality Imaging System (GE Healthcare).  
All parameters (including final reagent batches) were tested under screen assay 
conditions in a pilot experiment. 
Reverse transfection is a method of transfecting cells in suspension commonly 
used for high-throughput screens involving multiple multi-well plates (e.g. 384 
well plates in this instance).  Cells were cultured to ~80% confluency in 
preparation for transfection and diluted to the required cell number.  HiPerFect 
(Qiagen) diluted to the desired concentration in serum-free MEM Eagle was 
dispensed into pre-prepared 384well white assay plates containing test esiRNA 
(as described in 2.4.1).  After 20mins incubation cells were seeded on to the 
esiRNA:lipid complexes at the required density.   
Several different conditions were tested during optimisation assays, which are 
detailed in the figure legends of the corresponding data.  Final screening 
conditions are described in Results 3.2.1.  
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2.4.4 ‘Hit’ esiRNA reconfirmation in HCT116 cells  
93 selected hit esiRNAs (as identified using data analysis methods detailed in 
2.6.2.1) were narrowed to 45 hits were selected for bespoke generation of non-
overlapping esiRNAs; see Appendix 6 for sequences.   
2.4.5 ‘Hit’ Western blot assays 
‘Hit targets’ were assayed for the effects of esiRNA depletion of the expression of 
their cognate protein. This assay had a different transfection format because of 
the scale of the assay required to prepare sufficient cell extract for analysis.  
Where possible, transfection conditions were matched as closely as possible to 
those determined in the primary and secondary hit identification studies 
described above (using 24 well plate set-up to obtain enough protein; 19 times 
greater surface area than 384 well).  Briefly, HCT116 cells were reverse 
transfected (26,700 cells/well) with 380ng esiRNA in complex with HiPerFect 
transfection reagent (both original and non-overlapping samples were assessed).  
48, 72 and 120 hours post transfection, cells were harvested in RIPA buffer with 
a Complete Protease inhibitor (Roche), and proteins denatured at 95°C for 5 
minutes in Laemmli loading buffer (Life Technologies).  Following protein 
concentration determination using the Bradford assay, 3µg of each sample was 
run on 4% - 12% polyacrylamide and run at 100V.  Protein was then transferred 
to a nitrocellulose membrane using the Life Technologies iBlot system according 
to manufacturer’s protocol.  Membranes were washed in TBST before being 
blocked using 10% milk powder in TBST at room temperature for 1 hour.  The 
blot was simultaneously probed with the HARS (AbCam) and GAPDH (Merck 
Millipore) primary antibodies (in 5% milk-TBST) overnight at 4°C, and protein 
detected using the secondary horseradish peroxidase (HRP)-conjugated #-
mouse antibody (Sigma) for 1 hour at room temperature.  Pierce SuperSignal 
chemiluminscent substrate was used to determine HARS (and GAPDH) protein 
levels.  
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2.4.6 Compound combination assays 
HCT116 cells were seeded at 4500 cells/well in 96 well plates (using previously 
described culture conditions).  In the primary assay, cells were treated 24 hours 
post-seeding (with 10µM MSC + 1µM, 5µM or 25µM test compound, both 
individually and in combination, along side untreated DMSO controls), and 
viability measured using the ATPlite assay 24, 48 and 72 hours post-treatment 
(n=5).  Compounds deemed to be effective in a combination-dependent manner 
(determined by one-way ANOVA and Tukey test) were selected and further 
assessment by ‘chequerboard’ titration analysis.  HCT116 cells (seeded as 
previously described) were treated with a ‘chequerboard’ titration of ‘hit’ inhibitor 
concentrations (20nM – 25µM) in the presence and absence of MSC titration 
(40nM - 25µM; both individually and in combination, along side untreated DMSO 
controls).  Cell viability was measured as previously at 24, 48 and 72 hours (n = 
3).   
‘Hit’ combinations were tested in multiple cell lines according to the established 
HCT116 assay set-up.  Test compound was titrated (at a narrower range of 
200nM, 1µM and 5µM) was tested against 10µM MSC (both individually and in 
combination, along side untreated DMSO controls).  Cell viability was measured 
as previously at 24, 48 and 72 hours (n = 3).    
 
2.5 Luminescence assays 
2.5.1 Wnt reporter assay 
Luciferase reporter activity assays were performed using the Bright-Glo and Beta 
Glo assay systems (Promega).  48 hours post-transfection cells were lysed by 
the addition of Glo-lysis buffer (Promega) and shaken at room temperature for 
20mins.  Lysate was split for two assays: 30µl for firefly luciferase assay, and 
25µl for analysing !-galactosidase activity.  To assay luciferase activity, 30µl 
 59 
Bright-Glo reagent was added to the cell lysate, and assayed immediately for 
luminescence using the FLUOstar Optima plate reader (BMG Labtech).  To 
assess !-galactosidase control activity, 20µl Beta-Glo reagent was added to the 
cell lysate and shaken for a further 20mins at room temperature before the 
luminescence read-out was measured using the FLUOstar Optima. 
TCF-luciferase counts were normalised to !-galactosidase reporter activity to 
control for variations in transfection efficiency.  To allow for direct comparisons to 
be made between experiments, !-galactosidase-normalised luciferase values 
were subsequently normalised to the entire plate mean activity of %NLRP6. 
2.5.2 Viability assay 
Viability assays were performed using the ATPlite Luminescence Assay System 
(Perkin Elmer).  As ATP is present in all metabolically active cells it can be used 
as a marker of cell viability.  ATP levels cells rapidly decline under conditions that 
induce necrosis or apoptosis, hence the luminescence read-out is reduced.  This 
reduced signal (relative to untreated controls) is henceforth reported as a 
reduction in cellular viability. 
Cells were lysed at the required time-point by the addition of ATPlite lysis buffer 
and shaken at room temperature for 5 minutes.  Lysate was frozen at -80˚C until 
the completion of all time-points.  ATPlite substrate was added to all wells and 
shaken for 5 minutes according to the manufacturer’s protocol.  The luminometer 
used to measure cell viability in each case is detailed in 2.4.3. 
 
2.6 Data analysis and statistical methods 
2.6.1 cDNA screen data analysis 
Each of the wells were normalised to their corresponding !-galactosidase control 
activity to account for variations in transfection efficiency.  The normalised values 
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were then expressed as a fold of whole plate "NLRP induction (without controls).  
This ‘non-controls-based normalisation’, allowed for data to be normalised 
relative to the over-all distribution of values as opposed to being exclusively 
reliant on the performance of the controls.  Fold data from 4 independent repeats 
was combined into a single mean value and ranked in order of affect on %NLRP 
induction.  Each well was expressed as both a fold of the plate mean, and as the 
number of standard deviations away from the plate mean.  Results were cross-
checked against their raw data to eliminate false positive hit selection.  
Due to capacity of the deconvolution process (as each well contained 24 
individual cDNAs), only 20 of the top activating pools (and 16 of the most 
inhibitory pools – not deconvolved at this time) were selected for subsequent 
deconvolution.  Activating cDNAs were deconvolved (see 2.3.2) based on their 
ability to activate TCF-dependent transcription in the presence and absence of 
"NLRP co-activation.  Initial deconvolution of the putative activator from the pool 
of 24 cDNAs was conducted by expressing the mean luciferase value of the 
samples (n=3) relative to 36 "NLRP control wells.  A student’s two-tailed t-test 
was used to determine significance of activation.  The tentatively deconvolved 
activator from each pool was isolated and its activating ability reconfirmed, both 
in the presence and absence of "NLRP.  Where "NLRP stimulation was absent, 
cDNA activation was measured relative to the pcDNA3.1 control wells (n=6).   
2.6.2 esiRNA screen data analysis 
2.6.2.1 Screen optimisation 
Statistical analyses were conducted using Prism5 (GraphPad Software, Inc.).  
Targetting and non-targetting esiRNA controls were expressed as a percentage 
of untreated cell data. 
2.6.2.2 Primary screen quality control 
To determine whether a plate had passed or failed during screening, internal 
controls that had been placed on each plate (eGFP, R-Luc, PLK1 and EG5 
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esiRNAs) were assessed on a per-plate basis to determine whether any plates 
had failed based on the dynamic range of the controls.  The following selection 
criteria were employed: 
72 hours:  eGFP + R-Luc (‘non-targetting’) > 30,000 counts 
       PLK1 + EG5 (‘targetting’) < 15,000 counts 
                    120 hours: eGFP + R-Luc (‘non-targetting’) > 50,000 counts 
       PLK1 + EG5 (‘targetting’) < 25,000 counts 
Plates whose controls did not reach the cut-offs were flagged for further manual 
scrutiny, following which a subset of plates was selected for repetition. 
2.6.2.3 Global data analysis using cellHTS2 
All screen data sets were normalised using the cellHTS2 software package 
implemented in R (Boutros et al., 2006).  This publicly available software has 
been specifically developed by the Boutros Laboratory for the analysis of high-
throughput (384 well microtitre plate), cell-based RNAi screens. 
The data was normalised using a two-step procedure.  The assumption was 
made that the majority of samples would have no effect on viability and hence 
can act as their own controls (whether in combination with compound or not).  
This first step, termed ‘non-controls-based normalisation’, allowed for data to be 
normalised relative to the over-all distribution of values as opposed to being 
exclusively reliant on the performance of the controls (Birmingham et al., 2009).  
In this sense, the data sets were first normalised to the median value of each 
corresponding plate.  This often provides a more accurate representation of the 
true value of ‘inactive’ genes that define the measure of central tendency 
(especially due to the high number of values per plate in this instance), as 
opposed to the arithmetic mean which can be affected by outliers (Brideau et al., 
2003).  These median-normalised values were then further normalised using the 
B-score method (Brideau et al., 2003), which was used to explicitly correct for 
 62 
spatial effects caused by temperature and CO2 differences, for example (a well-
documented phenomenon known as plate edge effect; (Lundholt et al., 2003)).  
Although this analysis is similar to that achieved by Z scoring in that it is a “ratio 
of an adjusted raw value in the numerator to a measure of variability in the 
denominator” (Brideau et al., 2003), the complex algorithm used in this instance 
more extensively adjusts for variability in the numerator and allows for a greater 
measure of variability in the denominator.  Each individual replicate was assigned 
a B-score (a ‘variance’ score of each point in relation to its corresponding plate), 
which allowed for direct comparison of the strength of effect of all esiRNAs within 
a defined condition through rank ordering of these B-scores.   
2.6.2.4 Linear modelling 
As would be expected from a large-scale whole genome screen, many synthetic 
interactions were uncovered between individual esiRNAs and MSC treatment.  In 
order to robustly identify samples whose inhibition resulted in lethality only in the 
presence of MSC, a statistical model was used that could account for distinct 
classes of interaction.  A ‘Linear Model Interaction Test’ was developed by Dr. 
Eike Staub at Merck Serono for this purpose.   
In brief, with the linear model, the dependence of viability on presence of drug, 
esiRNA, or especially the combination of both, can be assessed by model 
coefficients and significance calls (p values for which the null hypothesis is that 
the coefficients are zero, i.e. there would be no effect).  Based on these 
parameters, a selection strategy was developed to filter out the hits using the 
screening approach. Finally, the siRNA hits were assessed for their absolute 
ability to reduce viability, i.e. how strongly they can reduce viability compared to 
the positive controls (e.g. PLK). 
The relationship of the dependent variable; synthetic lethality (‘y’), and the two 
independent variables; esiRNA knockdown – yes/no (a), and compound 
treatment – yes/no (b) were modeled as described below; firstly in a simplified 
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example to illustrate the principle and then using values that include scaling 
parameters that were used to process real data. 
- Example: 
 y = 20*a + 40*b - 1000*(a:b)  
– y(a=0;b=0) = 0  
– y(a=1;b=0) = 20  
– y(a=0;b=1) = 40  
– y(a=1;b=1) = -940  
In this scenario, 20, 40 and -1000 are hypothetical examples of model 
coefficients that would be derived from the B-scores resulting from the three 
‘treatment conditions’.  The model functions as follows: in the absence of both 
esiRNA (a = 0) and compound (b = 0) treatment there is no effect on cell viability, 
thus the synthetic lethality score (y), or ‘interaction score’ (as subsequently 
described), is 0.  When cells are subject to RNAi (a = 1) in the absence of 
compound (b = 0), the interaction score y = 20.  When the cells are treated with 
compound (b = 1) in the absence of RNAi (a = 0), the interaction score y = 40.  
However, when cells are subjected to both RNAi (a = 1) and compound treatment 
(b=1), interaction score y = -940, thus only when a and b are 1 is the synthetic 
lethality interaction effect evident.  The ‘Linear Model Interaction Test’ is an 
extension of this example model and is able to scale for the real world values 
observed in this screen (coefficients in this instance represent B-score values 
more likely to be seen), whereby: 
  
– y(a=0;b=0) = 30000  
– y(a=1;b=0) = 30000  
– y(a=0;b=1) = 30000  
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– y(a=1;b=1) =  5000  
 
Again, an interaction effect is only seen in the presence of both RNAi and 
compound treatment, however in this instance the advanced model has to 
account for the fact that 30,000 represents a zero value in actual terms, thus in 
the above example y = 5000 describes the literal value, rather than the true 
interaction value of -25,000.   
An ‘interaction value’ was determined for each sample that statistically 
summarised synergy (including the interaction significance) between compound 
and RNAi, whilst taking the effect of esiRNA knockdown alone on cellular viability 
into consideration.   
Different thresholds were set for prioritising and defining primary hits, which are 
described in the Results section. These included: 
• Interaction value < -1000  
• esiRNA p value > 0.1  
• Ratio (interaction p value / esiRNA p value) < 1x10-2  
 
2.6.2.4 esiRNA non-overlapping reconfirmation analysis 
This non-overlapping esiRNA assay was performed as with the primary screen. 
These hits were analysed ‘manually’ (as Dr. Staub was engaged with high-
priority analyses), with reduction in viability (the ‘equivalent’ in this instance of the 
‘interaction’ value previously described) calculated using the raw data (as whole-
plate normalisation was not appropriate since the hits had been specifically 
selected based on their ability to reduce viability) by determining the interaction 
based on the percentage reduction in viability compared to the ‘high’ control (R-
Luc; with EG5 used as the baseline) and significance of interaction determined 
using a two-way ANOVA, and a subset of genes reconfirmed that were deemed 
to have ‘synthetic lethal’ activity. 
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Chapter 3. Results 
3.1 cDNA screen 
Previous studies in the laboratory identified that overexpression of cDNAs (or 
cDNA pairs) that regulated Wnt pathway activity could be used to characterise 
the mechanism of action of novel small molecule pathway inhibitors whose 
targets were unknown (Ewan et al., 2010; Freeman, 2008).  However, these 
studies used a library of 9000 cDNAs, raising the possibility that additional 
regulators, and hence additional interactions that could facilitate the analysis of 
drug action, could be identified from a whole-genome scale screen.   
In order identify further cDNA regulators of TCF-dependent transcription, a 
whole genome Medaka cDNA library was screened in the 7df3 cell line according 
to the cascade shown in Figure 8.  The aim of the screen was to identify genes 
whose overexpression in the presence of %NLRP6 (a constitutively active form of 
LRP6; stimulating Wnt signalling at the top of the pathway) stimulation resulted in 
‘super-activation’ or inhibition of TCF-dependent transcription. Following the 
identification of novel signalling activators and the elucidation of the activator’s 
dependence on pathway co-stimulation by %NLRP, MSC-interference assays 
were conducted to determine the ability of the compound to disrupt this Wnt 
signalling (super-)activation.  In parallel with ‘conventional’ deconvolution assays 
being conducted in the laboratory, it was postulated that this would help to 
narrow the mechanism of action of the compound by mapping its activity onto a 
‘network’ of Wnt activator interactions.    
 An overview of the assay cascade is illustrated in Figure 8.  A Medaka 
library of 17,526 genes in pools of 24 cDNAs/well (in 96 well plate format) was 
kindly provided by Gary Davidson (KIT). In brief, 7df3 reporter cells were co-
transfected with the 70ng of each cDNA pool and 20ng of constitutively active 
%NLRP using forward transfection techniques previously established in-house.  
Cells were also transfected with 10ng of LacZ as a control for transfection 
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efficiency.  Luciferase and !-galactosidase reporter activities were measured    
48 hours after transfection. Following normalisation, pools were ranked according 
to their ability to activate or inhibit TCF-dependent transcription relative to 
%NLRP activation alone, and the top 20 activating and 16 inhibiting pools were 
selected for deconvolution. 
 
 
 
 
 
 
! !
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Figure 8. cDNA screening cascade 
Flow diagram indicating the overall approach taken to characterise Wnt-
regulatory genes within the Medaka cDNA library using the 7df3 reporter cell line. 
The screen was designed to identify super-activators and inhibitors of TCF-
dependent transcription that was driven by the activated Wnt co-receptor %NLRP, 
an activator that functions near the ‘top’ of the linear representation of the Wnt 
pathway. Due to assay prioritisation, the individual inhibitory cDNAs that had 
been prepared from the inhibitory pools were not further characterised. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Co-transfect 24 cDNA pools + 
ΔNLRP
Normalise to co-transfected LacZ
Rank pools by fold of mean and SD
Select 'super-activating' pools 
using combination of mean and 
SD rankings: 20
Select 'inhibitory' pools using 
combination of mean and SD 
rankings: 16
Miniprep 384 individual cDNAsMiniprep 480 individual cDNAs
Transfect individual cDNAs
Normalise to LacZ
14 'super-activator' hits
Figure 8.  cDNA screening cascade
Flow diagram indicating the overall approach taken to characterise Wnt-regulatory genes within 
the Medaka cDNA library using the 7df3 reporter cell line. The screen was designed to identify 
super-activators and inhibitors of TCF-dependent transcription that was driven by the activated 
Wnt co-receptor ΔNLRP, an activator that functions near the ʻtopʼ of the linear representation of 
the Wnt pathway. Due to assay prioritisation, the individual inhibitory cDNAs that had been 
prepared from the inhibitory pools were not further characterised.
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An overview of the primary screen data analysis can be seen in Figure 9.  Each 
of the 786 wells (8 plates x 96 well plate format) were normalised to their 
corresponding !-galactosidase control activity to account for variations in 
transfection efficiency.  The normalised values were then expressed as a fold of 
whole plate "NLRP induction (without controls), based on the assumption that 
the majority of pools would have no effect on basal "NLRP activity.  This 
normalisation allowed for cross-plate comparisons of the whole screen to be 
made, as it had previously been observed that plate to plate variation could lead 
to an inappropriate focus on hits from one plate if absolute luciferase expression 
values were used to select hit pools for further analyses.  Fold data from 4 
independent repeats (conducted on different days) was combined into a single 
mean value and ranked in order of affect on %NLRP induction.  Each well was 
expressed as both a fold of the plate mean, and as the number of standard 
deviations away from the plate mean.  To ensure that false positive hits were not 
selected as a consequence of the normalisation process, !-galactosidase control 
data was cross-checked (for each individual selected pool).  Final hit pools 
showed normal levels of !-galactosidase expression suggesting that the ‘effects’ 
of cDNA expression on TCF-luciferase expression were not due to effects on the 
expression of CMV-driven !-galactosidase.  Due to capacity of the deconvolution 
process, only 20 of the top activating pools and 16 of the most inhibitory pools 
were selected.  More hits were selected for the activating pools as these were 
thought to offer the greater opportunity in the analysis of MSC compound action. 
The selection scores were arbitrary as they were based on a maximum number 
of hits that could be processed, but equated to selection cut-offs of 2.52 and 
0.315 for reporter activity fold of plate mean, and 1.03 and -0.635 for reporter 
activity standard deviations away from plate mean (see Figures 10a&b). The 
primary data from the selected pools was also manually checked to ensure that 
the ‘Fold of "NLRP’ values were not inappropriately skewed by outlier values. 
!
!
 69 
"#$%&'!0!)*+,'-'./ 
Figure 9.  Data analysis protocol for cDNA pool selection 
Flow diagram indicating the overall approach taken to select cDNA pools with 
Wnt-regulatory activity within the Medaka cDNA library using the 7df3 reporter 
cell line.  Luciferase reporter activity was first normalised (on a well-by well basis) 
to "-galactosidase expression from the co-transfected control plasmid.  Each of 
the 4 repeat cDNA pool values were expressed as fold of corresponding plate 
"NLRP mean and the number of standard deviations from dataset mean, and the 
highest ranking (and most overlapping) hit pools selected.  Following the cross-
check of !-galactosidase activity to minimise false hit selection, 20 ‘super-
activating’ and 16 ‘inhibitory’ pools were selected and their individual cDNA 
components prepared by DNA miniprep.  864 individual cDNAs were prepared in 
total.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normalise raw TCF-reporter  
luminescence units to 
corresponding LacZ control raw 
luminescence units
Express each value as fold of 
corresponding plate ΔNLRP mean
Rank cDNA pools by fold of 
plate mean 
Integrate fold of mean 
and standard 
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identify 'top hit' pools
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individual cDNA 
components of each 
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hits' against raw data 
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Rank cDNA pools by standard 
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864 individual cDNAs
Figure 9.  Data analysis protocol for cDNA pool selection
Flow diagram indicating the overall approach taken to select cDNA pools with Wnt-regulatory 
activity within the Medaka cDNA library using the 7df3 reporter cell line.  Luciferase reporter activity 
was first normalised (on a well-by well basis) to β-galactosidase expression from the co-transfected 
control plasmid.  Each of the 4 repeat cDNA pool values were expressed as fold of corresponding 
plate ΔNLRP mean and the number of standard deviations from dataset mean, and the highest 
ranking (and most overlapping) hit pools selected.  Following the cross-check of β-galactosidase 
activity to minimise false hit selection, 20 ‘super-activating’ and 16 ‘inhibitory’ pools were selected 
and their individual cDNA components prepared by DNA miniprep.  864 individual cDNAs were 
prepared in total. 
20 'activating' 
pools
16 'inhibiting'
pools
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Figure 10a&b.  Primary cDNA screen hit distribution 
Luciferase reporter activity was first normalised (on a well-by well basis) to "-
galactosidase expression from the co-transfected control plasmid. Each cDNA 
pool was assayed 4 times.  Each of the 96-well plates are individually coloured 
above.  Any point greater than 5 fold of plate mean or 5 standard deviations 
above the mean was represented as 5 to allow the spread of the majority of the 
data to be visualised. 
a. Normalised luciferase reporter activity was expressed as a fold of the plate 
mean for each of the 8 x 96 well plates (as coloured; each point = 1 well) that 
were assayed. Lines indicating cut-offs of 2.52 and 0.315 the plate mean are 
illustrated as used for hit selection.!
b. Normalised luciferase reporter activity for wells in each plate (as coloured; 
each point = 1 well) were expressed as the number of standard deviations away 
from the dataset mean. Selection cut-offs indicate 1.03 and -0.635 standard 
deviations from plate mean. 
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As the principal aim of the study was to identify genes whose overexpression 
resulted in upregulation of TCF-dependent transcription and to subsequently 
‘map’ the ability of MSC to disrupt this interaction, the activator pools were 
prioritised for deconvolution.  Each of the 24 cDNAs comprising the pool was 
prepared individually and co-transfected into 7df3 cells in accordance with the 
primary screen format (see Figure 11 for a hit pool deconvolution flowchart).  
Following three independent repeats the activating cDNA from each pool was 
determined.  As previously, TCF-dependent luciferase units were normalised to 
their corresponding "-galactosidase transfection control.  Because the cDNAs 
had been specifically selected based on their ability to induce TCF-dependent 
transcription, each of the three repeats was expressed as a fold of %NLRP 
control wells (n=12; on the same plate) and the mean activity of the three repeats 
tested for significance against the %NLRP controls (n=36; from all three repeats) 
using a student’s two-tailed t-test.  
!
!
!
!
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Figure 11. Activator cDNA pool deconvolution approach 
Flow diagram demonstrating the approach taken to deconvolve Wnt-regulatory 
genes from the 20 most activating cDNA pools selected from the primary screen 
of the Medaka cDNA library using the 7df3 reporter cell line. Following co-
expression of the activators with the activated Wnt co-receptor %NLRP, data was 
normalised to the "-galactosidase control to account for variations in transfection 
efficiency.  The mean of three repeats was calculated and the significance of any 
activation (relative to 36 %NLRP control wells) was determined, with 17 activators 
putatively determined.  Following further reconfirmation 14 activating cDNAs 
were fully validated and taken forward for further investigation.  
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Co-transfection of individual cDNAs from 
'super-activating' hit pools into TCF-
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TCF-dependent 
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Figure 11. Activator cDNA pool deconvolution approach
Flow diagram demonstrating the approach taken to deconvolve Wnt-regulatory genes from the 20 most 
activating cDNA pools selected from the primary screen of the Medaka cDNA library using the 7df3 
reporter cell line. Following co-expression of the activators with the activated Wnt co-receptor ΔNLRP, 
data was normalised to the β-galactosidase control to account for variations in transfection efficiency.  
The mean of three repeats was calculated and the significance of any activation (relative to 36 ΔNLRP 
control wells) was determined, with 17 activators putatively determined.  Following further reconfirmation 
14 activating cDNAs were fully validated and taken forward for further investigation. 
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Fourteen out of the 480 cDNAs isolated from the 20 pools were fully validated as 
being ‘super-activators’ based on activation >1.5X ‘basal’ "NLRP TCF-
dependent transcription and a t-test p value <0.01.  The putative Wnt pathway 
activators are listed in Table 1. 
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Library Ensembl ID Proposed Gene ID 
BlastX Description      
[Homo sapiens] Accession Number 
BLAST 
Expect (E) 
value  
ENSORLG00000011147 SEZ6L2 Seizure 6-like protein 2 isoform 5 precursor NP_001230261.1 1.00E-56 
ENSORLG00000003634 !-catenin Catenin beta-1 NP_001895.1 0 
ENSORLG00000017521 GBX1 Homeobox protein GBX-1 NP_001092304.1 3.00E-114 
ENSORLG00000020562 IKZF1 DNA-binding protein Ikaros isoform 1 NP_006051.1 1.00E-141 
No ENSEMBL IDi - B-cell lymphoma 6 protein isoform 2 NP_001128210.1 1.00E-108 
No ENSEMBL IDii - High mobility group protein B2  NP_002120.1 4.00E-61 
ENSORLG00000007641 WNT-1 Proto-oncogene Wnt-1 precursor  NP_005421.1 2.00E-170 
ENSORLG00000015359 HMGXB4 HMG domain-containing protein 4 NP_001003681.1 4.00E-87 
ENSORLG00000011432 KRAS GTPase KRas isoform b precursor NP_004976.2 7.00E-106 
ENSORLG00000000858 PITX1 Doublesex- and mab-3-related transcription factor A2  NP_115486.1 2.00E-56 
ENSORLG00000018912 HRAS GTPase HRas isoform 1  NP_005334.1 3.00E-116 
ENSORLG00000006877 RTN2 High mobility group protein B2 NP_002120.1 2.00E-70 
ENSORLG00000000668 OCLN Occludin isoform a NP_002529.1 9.00E-63 
ENSORLG00000010346 TGIF1 Homeobox protein TGIF1 isoform b NP_775299.1 5.00E-57 
 
Table 1.  Validated cDNA activator hit list 
The identity of the 14 reconfirmed super-activators of TCF-dependent 
transcription.  ‘Library Ensembl ID’ and ‘Proposed Gene ID’ columns indicate the 
preliminary identity of the gene according its well location (as determined by 
deconvolution) as detailed in the parent gene-by-gene cDNA library.  The cDNA 
hits were sequenced and the translated nucleotide sequences analysed using 
BLAST against the Homo sapiens genome to confirm this identity (both protein 
description and accession number are detailed).  BLAST E value indicates the 
significance of the match; the lower the E value the more significant the 
alignment.  cDNAs whose identity differs to the hypothesised gene ID are 
underlined. 
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The success of the screen was validated by the identification of known Wnt 
signalling activators in the presence of "NLRP; these included Wnt 1 and !-
catenin, whose identities were confirmed by sequence analysis (Figure 12a; 
Table 1).  In this context, it is clear that both Wnt 1 and !-catenin are able to 
super-stimulate TCF-dependent transcription driven by limiting levels of "NLRP. 
Although the 14 hits had been allocated a proposed gene ID using the available 
library Ensembl IDs, each hit was re-sequenced and its identify compared to the 
Homo sapiens homologue by protein BLAST analysis of their translated 
nucleotide sequences.  Ten of the activators were confirmed to be the same as 
their library annotation, whilst two hits without an associated Ensembl ID 
(annotated ‘No Ensembl IDi’ and ‘No Ensemble IDii’) were identified as being Bcl-
6 and HMGB2.  Finally, two genes originally annotated as PITX1 and RTN2 were 
subsequently identified as DMRTA2 and HMGB2 respectively (annotated as 
HMGB2* to prevent confusion).  Interestingly, HMGB2 from a different cDNA pool 
had been confirmed as matching its proposed identity, suggesting that 
contamination may have occurred during individual cDNA hit preparation.  
Further work is required to establish the cause of this and determine the true 
effect (if any) of RTN2.   Additional Wnt pathway regulators including KRAS, 
HRAS and HMGB2 were confirmed, with these hits overlapping with those 
identified in the precursor cDNA screen conducted by Jamie Freeman (Freeman, 
2008).  Interestingly for one of the pools, both IKZF1 and Bcl-6 were identified as 
significantly super-activating TCF-dependent transcription although at the lower 
end of activation. Further experiments will be required to determine whether 
there is synergistic activity between the these and "NLRP or whether their effect 
on TCF-dependent transcription was ‘additive’.  
For several of the original hit pools there was no single activator of TCF-
dependent transcription evident.  The simplest reason why these hits failed to 
reconfirm may be due to the identification of false positive hits. However one 
additional explanation for this observation is that more than one of the 24 cDNAs 
within the pool co-operated to drive TCF-dependent transcription. The hit 
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identification rate from the analogous screen of 9,000 Xenopus tropicalis cDNAs 
(in 3000 pools of 3 clones) 54 primary activating hits/139 pools suggested that 
there was a distinct possibility that pools of 24 clones may contain more than two 
clones with the ability to synergise with each other without requiring any 
functional interaction with "NLRP (Freeman, 2008). 
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Figure 12a&b.  Reconfirmation analysis of activator cDNAs 
Putatively active cDNAs identified from initial ‘whole pool deconvolutions’ were 
selected re-analysed for super-activation activation activity in the presence (a) 
and absence (b) of the constitutively active "NLRP in 7df3 cells.  Hits annotated 
according to sequence analysis where available, or their original library 
annotation where not.  The blue dashed line indicates the level of "NLRP control 
activation, and the red line indicates the level of pcDNA3.1 activation, to aid 
comparison. 
a. cDNA activation (n=3) in the presence of "NLRP expressed as fold of "NLRP 
activation control (n=12).  The standard deviation of each condition is shown.  
Significance of activation relative to "NLRP control wells was determined using 
students’ two tailed t-test; * = p value<0.01.  
b. cDNA activation (n=3) in the absence of "NLRP expressed as fold of 
pcDNA3.1 control (n=6).  The standard deviation of each condition is shown.  
Significance of activation relative to pcDNA3.1 control wells was determined 
using student’s two tailed t-test; * = p value<0.01. 
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The fourteen super-activating cDNAs were also tested for activity in the absence 
of "NLRP co-stimulation (Figure 12b).  Of the fourteen cDNAs assayed, eight 
significantly activated TCF-dependent transcription independently of pathway co-
activation.  Five of the hits were known Wnt signalling activators with three, the 
transcription factors DMRTA2, GBX1 and HMGB2 having little known association 
with Wnt signalling.  Interestingly, only !-catenin and Wnt 1 activated TCF-
dependent transcription to a greater level than the "NLRP control.   
Using the online resource GeneCodis (Carmona-Saez et al., 2007; Nogales-
Cadenas et al., 2009; Tabas-Madrid et al., 2012), the gene products were 
analysed for over-representation of annotations (relative to the whole genome) in 
several key areas.  Annotation of the genes with a Gene Ontology (GO) identifier 
meant that the hit genes could be compared for enrichment in the categories of 
biological process, molecular function and cellular component.  The genes were 
also compared to the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
collection of pathway maps to determine any enrichment of specific pathway 
features.  However, no significant enrichment was identified, likely due to the 
very small set of genes being analysed.  In future experiments, it is probable that 
this set of genes could be increased through the analysis of more pools or 
through the analysis of cDNAs on an individual basis, given the greater 
expression level of single cDNAs (if the expense can be justified). 
The super-activators were further investigated In order to determine whether their 
stimulation of TCF-dependent transcription could be disrupted by MSC.  Previous 
studies by J. Freeman (Freeman, 2008), showed that many cDNAs and cDNA 
pairs differed in their sensitivity to inhibition by putative Wnt pathway small 
molecule inhibitors.  Hence mapping compound sensitivity was predicted to 
provide insight into MSC’s mechanism of action. 
 
!
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Figure 13a&b. MSC-compound interference of ‘super-activator’-induced 
TCF-dependent transcription 
The ability of 10µM MSC to disrupt hit super-activation in 7df3 cells was 
determined.  
a.  The percentage effect of MSC treatment on the ability of the 14 ‘super-
activators’ to activate TCF-dependent in the presence of "NLRP was determined 
relative to their DMSO treated control (n=3).  The standard deviation of each 
condition is shown.  
b.  The percentage effect of MSC treatment on the ability of the 8 ‘super-
activators’ capable of activating TCF-dependent independently of "NLRP co-
activation was determined relative to DMSO treated comparisons (n=3).  The 
standard deviation of each condition is shown. 
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Ten micromolar MSC was added to 7df3 cells 24 hours after transfection and 24 
hours prior to analysis.  As can be seen in Figure 13a, the activity of all the 
cDNAs in combination with "NLRP was inhibited by MSC treatment in relation to 
DMSO control treatment.  It is unclear whether the level of inhibition was 
significantly different between each combination as this would need 
reconfirmation with additional experiments and a greater number of repeats.   
Interestingly in the absence of "NLRP co-stimulation (Figure 13b), GBX1 and 
HMGB2 maintained their activation phenotype following MSC treatment, but 
again this requires repetition to confirm the compound resistance seen.  
As MSC’s target had been determined as being the serine/threonine kinases 
CDK8 and CDK19 by this point in the study, it was unsurprising that MSC was 
able to interfere with those hits dependent on "NLRP co-expression in order to 
mediate their super-activating effects.  This was because CDK8 acts at the 
transcriptional level of the complex, playing a central role in the coupling of "-
catenin/TCF to RNA polymerase II at Wnt target genes, meaning any processes 
synergising with the upstream constitutively active "NLRP would be disrupted by 
MSC.  The more interesting hits for consideration at this point were those able to 
activate TCF-dependent transcription in the absence of "NLRP.  Again as 
expected MSC was able to reduce !-catenin, Wnt 1, KRAS and HRAS activated 
TCF-dependent transcription.  Interestingly however, MSC was unable to 
interfere with GBX1 and HMGB2 induced TCF-dependent transcription.  It is 
interesting to note that GBX1 and HMGB2 are transcription factors and it is 
possible that they mediate their effects at TCF-dependent promoters without a 
requirement for CDK8/Mediator complex activation (see discussion for further 
consideration of this point).  Further studies into this effect would be required 
since a difference in response was observed between HMGB2 and the 
alternative clone that was sequenced (HMGB2*).  This raises the possibility that 
as yet uncharacterised sequence differences may be present between the 2 
clones or that the HMGB2 MSC response is not highly reproducible.  However, 
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due to a change in project focus as a result of the identification of CDK8/CDK19 
as MSC’s molecular target, this issue was not pursued further. 
In summary, these studies have identified potential novel super-activators of Wnt 
signalling in a conditional setting, and were consistent with previous studies that 
suggested the activity of MSC was located at the transcriptional regulation level. 
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3.2 esiRNA screen 
This section describes a synthetic lethality screen for genes whose function in 
colorectal cancer cell 2D cell growth was required only in the presence of the 
MSC CDK8/19 inhibitor. 
Before discussing the details of the screen, it is important to describe a result that 
was surprising in the context of the literature that was known at the time (Figure 
14).  Bafico et al. (Bafico et al., 2004) showed that HCT116 cells, in which Wnt/"-
catenin driven transcription was reduced (by loss of "-catenin and reduction in 
Wnt ligand levels) had reduced levels of 3D cell proliferation (Bafico et al., 2004). 
This suggested that if MSC reduced TCF-dependent transcription, it should 
reduce 2D cell proliferation.  In addition, Firestein et al. (Firestein et al., 2008), 
showed that shRNA-depletion of CDK8 expression reduced HCT116 cell growth 
in 2D culture.  Based on these results reports, it was predicted that a highly 
active CDK8/19 inhibitor with 12.4nM activity against 7df3 TCF-dependent 
transcription would inhibit HCT116 cell proliferation.   
To test this prediction, HCT116 cells were treated with a titration of MSC (from 
4.5nM – 30µM) for 48 and 72 hours and cell proliferation was measured using an 
ATPlite assay.  Surprisingly, it can be seen in Figure 14a that there was no effect 
of compound on proliferation even at 2000 times the 7df3 TCF-reporter IC50 of 
MSC (12.5nM) at either 48 or 72 hours. This result further suggested that the 
growth-inhibitory activity that had previously been observed using the initial ‘hit’ 
compound from the same series (CCT071459) may have been due to ‘off target’ 
effects of the initial compound that were unrelated to its ability to inhibit TCF-
dependent transcription or to bind CDK8/19.  Interestingly, MSC was shown to 
have some anti-proliferative activity in 3D culture and in vivo anti-tumour studies 
(Figure 33 and data not shown; see Discussion). 
To examine whether the lack of a 2D growth response was due to the inactivity of 
the MSC compound in HCT116 cells against TCF-dependent transcription, a 
variant of the HCT116 line with a TCF-
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transfected with the TOPflash TCF-reporter construct) was tested (Figure 14b). 
MSC exhibited a dose-dependent inhibition of TCF-reporter activity in the AT506 
cells with the 48 hour IC50 (154nM) being 12 times that observed in the 7df3 cells. 
Inhibition of TCF-dependent transcription was also observed in other TCF-
reporter cell lines studied in the collaboration, including colorectal cancer cells 
(e.g. Ls174T cells).  However, a particular point of note from this study was the 
observation that TCF-reporter activity was only inhibited to ~45% of maximum; by 
contrast inhibition of TCF-reporter activity in 7df3 cells was >90% in most assays 
(data not shown).  Similar ‘partial efficacy’ responses to compound treatment 
were observed in other colorectal cancer cell lines with integrated TCF-reporters 
(e.g. ~40% in SW480 cells; Merck Serono data not shown).  
There are several reasons that could explain the lack of growth inhibition in the 
HCT116 cells following MSC compound treatment. These include one or more of: 
1. Partial efficacy.  It is possible that the final level of Wnt reporter activity 
remained sufficient to maintain cell proliferation. i.e. There is a minimum 
threshold level of Wnt reporter activity that is required for cell proliferation 
and the MSC compound failed to reduce activity below this level. 
2. 2D versus 3D (in vivo).  2D cell models don’t reveal a cell growth 
dependence on TCF-reporter levels.  In Merck Serono studies, it was 
observed that MSC partially inhibited tumour growth in vivo (data not 
shown), suggesting that in vivo studies may maintain this dependence. 
3.  MSC compound treatment is NOT equivalent to a simple reduction in "-
catenin levels or a reduction in TCF-reporter activity.  Since the time the 
project was started, the identity of the MSC target has been determined as 
the kinases CDK8 and CDK19.  Loss of function of these kinases affects 
TCF-reporter activity in ways that are not yet fully understood.  
 
Each of these possible explanations is consistent with the idea that MSC 
compound activity effects in 2D culture may be masked by contributions from 
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other pathways or gene products.  Many of these pathways may also function in 
vivo and could act to reduce the potential clinical activity of MSC. 
It is thus possible to view the lack of response to MSC compound as an 
opportunity to identify gene products whose activity co-operates with MSC’s 
target in maintaining tumour growth.  This stimulated the design of a whole-
genome ‘chemical sensitisation’ screen.            
The goal of the chemical sensitisation screen was to identify genes whose 
function was required for 2D cell proliferation in the presence of MSC.  It was 
predicted that genes whose inhibition had no affect on cell viability in the 
absence of compound but resulted in complete loss of viability in the presence of 
compound would be ideal starting points for the design of rational compound 
combination strategies for the treatment of Wnt/CDK8/19-dependent cancers. 
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Figure 14a&b. Effects of MSC on HCT116 cells 2D cell proliferation and 
TCF-dependent transcription.!
a. The viability dose response of HCT116 cells to MSC at 48 and 72 hours as a 
percentage of DMSO control.  Viability of the cells was measured using the 
ATPlite luminescence assay.  Mean values ±S.D. of 6 replicate wells per 
condition are displayed. 
b.  The TCF-luciferase reporter dose response of (HCT116)-AT506.C2 Wnt 
reporter cells to MSC at 48 and 72 hours as a percentage of DMSO control.  
TCF-luciferase was measured using the BrightGlo luminescence assay.  Mean 
values ±S.D. of 6 replicate wells per condition are displayed. 
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3.2.1 esiRNA assay development and optimisation 
Before a synthetic lethality screen could be carried out, a major series of 
optimisation experiments had to be performed since the scale of the final assay 
(total 216,576 individual data points) would be prohibitively expensive both in 
cost and time to repeat. Based on published and in house data on Wnt/"-
catenin/CDK8 dependence, HCT116 cells were chosen for the assays.  
Following the Dale group’s previous success with reverse siRNA transfection 
approaches (Freeman, 2008; Lloyd-Lewis, 2011), cells were set up to deplete 
gene products by transfection with esiRNA  for 48 hours followed by compound 
addition for a further 24 or 72 hours, resulting in total assay durations of 72 hours 
and 120 hours respectively.  The assay readout selected was a reduction in 2D 
cell viability as measured using a ‘simple’ ATPLite luminescence assay.  This 
assay is based on the principle that there is a decrease in ATP (and hence 
luminescence from exogenous supplied luciferase enzyme that is added to the 
lysed cell extracts) as cell viability or cell number decreases.  This provided a 
rapid, quantitative method for determining viability. 
The key reagent in this study was the 17,188 gene esiRNA library provided by 
Prof. Frank Buchholz.  Endoribonuclease synthesised small interfering RNAs 
(esiRNAs) comprise a set of overlapping siRNAs that are enzymatically 
generated by the digestion of longer dsRNA hybrids by the Dicer/RNAse III 
enzyme (Buchholz et al., 2006). The advantages of this reagent by comparison 
with chemically synthesised siRNAs are that they more efficiently target more 
genes (fewer false negatives) based on their greater sequence complexity, while 
having fewer false positives due to the lower concentration of any particular 
sequence siRNA. These advantages have been extensively documented 
(Buchholz et al., 2006; Echeverri et al., 2006; Kittler et al., 2004; Theis and 
Buchholz, 2011).  
The overall plan of the optimisation process is shown in Figure 15.  
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Figure 15. Overview of esiRNA screen optimisation processes 
Initial studies identified the optimal transfection reagent. Cells were seeded at 
3,000 and 6,000 cells per 384-well compared 3 different transfection reagents 
using a set of control esiRNAs. The best performing reagent was then used for a 
more extensive optimisation of cell numbers and transfection reagent 
concentrations. The volume of the assays was subsequently scaled down and 
fine-level assay optimisation was conducted under final screen conditions. This 
involved tests on batches of frozen or live cells and optimisation of plate reader 
parameters. The work culminated in a pilot screen that was based primarily on 
the use of control esiRNAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transfection reagent concentration 
optimisation
- good transfection efficiency with 
minimal toxicity
Transfection reagent selection
Cell seeding optimisation
Assay measurement optimisations
-plate reader parameter selection 
-dark vs. non-dark adapted plates
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Figure 15. Overview of esiRNA screen optimisation processes
Initial studies identified the optimal transfection reagent. Cells were seeded at 3,000 and 6,000 
cells per 384-well compared 3 different transfection reagents using a set of control esiRNAs. The 
best performing reagent was then used for a more extensive optimisation of cell numbers and 
transfection reagent concentrations. The volume of the assays was subsequently scaled down 
and fine-level assay optimisation was conducted under final screen conditions. This involved tests 
on batches of frozen or live cells and optimisation of plate reader parameters. The work 
culminated in a pilot screen that was based primarily on the use of control esiRNAs.
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Transfection reagent selection 
A key reagent for esiRNA transfection studies is the transfection reagent. Most 
optimised commercial reagents for esiRNA transfection are based on the 
formation of lipid-nucleic acid complexes however unfortunately the identity of the 
lipid/lipid mixes are normally proprietary information (hence undisclosed).  
Nonetheless, it has been established that key parameters for optimisation include 
cell number (the target being the lipids in the plasma membrane), the esiRNA 
and the lipid concentration (lipid delivery systems often mediate cytotoxic effects 
by compromising cell membranes), together with details of protocol that optimise 
the size and uniformity of siRNA-containing micelles. As a first step in this 
optimisation process, several transfection reagents were compared (Figure 16).  
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DharmaFECT
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Figure 16. Transfection reagent selection 
The transfection efficiency and cytotoxicity of three transfection reagents; 
DharmaFECT (a & b), HiPerFect (c & d) and INTERFERin (e & f) was 
determined at 5µl/ml and 15µl/ml transfection reagent.  Cell seeding densities of 
3000 cell and 6000 cells per well were reverse transfected with control esiRNA 
(‘non-targetting’ eGFP and R-Luciferase; ‘targetting’ PLK1 and EG5) in 384 well 
plates and viability assessed using the ATPlite luminescence assay at 48 and 72 
hours.  Mean values ±S.D. of 3 repeats are displayed as percentage of untreated 
control. 
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Three transfection reagents; a & b: DharmaFECT, c & d: HiPerFect; e & f: 
INTERFERin were compared for their ability to transduce esiRNAs against 
enhanced green fluorescent protein (eGFP), renilla luciferase (R-Luc), polo-like 
kinase 1 (PLK1) and kinesin-related motor protein 11 (EG5) esiRNAs at 48 and 
72 hours post-transfection (as shown in Figure 16).  PLK1 siRNA was used as an 
additional control.  Cells were assayed for ATP levels using the ATPlite 
luminescence assay, with reduction of cellular ATP level being equated as loss of 
cell viability since ATP rapidly declines when cells undergo necrosis or apoptosis. 
Optimal reagents were expected to show no (or minimal) viability reduction with 
eGFP and R-Luc reagents but to exhibit target-related reduction in cellular 
viability in response to depletion of PLK1 (mitotic progression regulator, 
knockdown of which results in mitotic arrest) and EG5 (required for the 
establishment of a bipolar spindle in mitotic cells).  PLK1 siRNA had previously 
been used at Merck Serono and was used as a ‘known control’ as targeted gene 
knockdown with this reagent was expected to result in >70% reduction in viability 
at 72 hours (data not shown). 
Each transfection reagent was tested using the afore mentioned controls, and 
cellular viability measured alongside untreated cells and cells treated with 
transfection reagent alone in order to determine transfection reagent toxicity.  
20ng esiRNA (or 5µl TE buffer for untreated/transfection media controls) was 
aliquotted into a 384 well plate and transfection reagent dispensed directly into 
the wells at 5µl/ml or 15µl/ml (final assay volume concentration).  Following 
micelle formation, cells were dispensed onto the esiRNA:lipid complexes at 3000 
or 6000 cells/well and viability measured at either 48 or 72 hours post-
transfection.  ATP-dependent luminescence was measured (as relative light 
units; RLU) using a luminometer, and the effect of each condition given as a 
percentage of the mean of the untreated control cells (Figure 16 a-f).  As can be 
seen in Figure 16c, 3000 cells transfected with 15µl/ml HiPerFect (at 72 hours) 
showed the closest response to that expected, with ~70% reduction in cell 
viability with EG5 esiRNA and PLK1 siRNA knockdown.  However, with ~25% 
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reduction in viability mediated by transfection reagent alone, and no apparent 
targetted-knockdown as expected with PLK1 esiRNA transfection, it was evident 
that further optimisation would be required from this starting point.  By 
comparison, the use of DharmaFECT (Figure 16a and b) resulted in both 
transfection reagent toxicity and off-target esiRNA toxicity (as seen by further 
reduction in cell viability even with transfection of the eGFP and R-Luc controls), 
and so it was not used any further.  INTERFERin (Figure 16 e and f) exhibited 
limited transfection efficiency and non-specific transfection reagent toxicity was 
evident at 3000 cells transfected with 15µl/ml (at both 48 and 72 hours), and so it 
was concluded that HiPerFect was the most promising reagent to take forward 
for assay optimisation.  
 
Cell seeding optimisation 
In order to determine ideal parameters for the high-throughput screen, cell 
numbers and the assay timecourse were further optimised using HiPerFect 
(Figure 17a-d). 
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Figure 17. Cell number and timecourse assessment 
Cell seeding of 2000, 3000, 4000, 5000 and 6000cells/well were reverse 
transfected with 15µl/ml HiPerFect and cell viability mediated by the panel of 
control esiRNAs measured at 72, 96, 120 and 144 hours post-transfection.  Cell 
seeding of 2000cells/well responded most effectively, with loss in viability 
sustained across all timepoints.  Mean values ±S.D. of 3 repeats are displayed 
as percentage of untreated control. 
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Using the reagents and assay format previously described (see previous 
‘Transfection reagent selection’ section), 2000, 3000, 4000, 5000 and 6000 
cells/well were transfected with the esiRNA panel of controls using 15µl/ml 
HiPerFect (Figure 17a-d).  Measurements were to be taken at 72 and 120 hours 
post transfection, as it was anticipated that this would have given sufficient time 
for the various esiRNA target mRNAs to be degraded and for their existing gene 
products to be degraded / diluted due to cell proliferation.  Measurements were 
also taken at 96 hours (in order to monitor assay performance between the final 
read parameters) and 144 hours post-transfection (to determine any cell over-
growth and its potential effect on assay window). 
Despite transfection reagent-mediated cytotoxicity at 72 and 96 hours, HCT116 
cells seeded at 2000 cells/well recovered well and achieved >90% reduction in 
viability (with the ‘targetting’ controls) at 120 and 144 hours (Figure17c and d).  
Significantly, it appeared that cells seeded at greater than 3000 cells/well elicited 
higher signals from the ‘targetting’ controls at the longest timepoints (120 and 
144 hours), suggesting that either the knockdown was unsustainable over an 
extended time or that cell overgrowth masked the RNAi effects Figure17a-d).  
Hence, seeding at 2000 cells/well was selected for further optimisation as 
sustained targetted reduction in viability was achieved across all time-points. 
 
Transfection reagent concentration optimisation 
In order to reduce the non-specific toxic effect of HiPerFect on cells seeded at 
2000 cells/well it was necessary to titrate the concentration of transfection 
reagent down from 15µl/ml.  It also became evident during the course of the 
optimisation assays that the primary screen plates would have to be stored as 
frozen samples prior to ATPlite luciferase measurements due to the number of 
plates involved (564 plates in total).  The expansion of the reagent in each well 
upon freezing increased the risk of well-to-well contamination (particularly at the 
defrosting stage), and as a consequence the total assay volume had to be 
reduced.   
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Figure 18. Transfection reagent titration 
Cells seeded at 2000cells/well were reverse transfected with 5, 10 and15µl/ml 
HiPerFect and cell viability mediated by the panel of control esiRNAs measured 
at a. 48, b. 72, c. 96, d. 120 and e. 144 hours post-transfection.  Mean values 
±S.D. of 3 repeats are displayed as percentage of untreated control. 
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Figure 18.  Transfection reagent titration
Cells seeded at 2000cells/well were reverse transfected with 5, 10 and15μl/ml HiPerFect 
and cell viability mediated by the panel of control esiRNAs measured at a. 48, b. 72, c. 96, 
d. 120 and e. 144 hours post-transfection.  Mean values ±S.D. of 3 repeats are displayed 
as percentage of untreated control.
99
 100 
Using the previously described transfection ‘control panel’, 2000 cells/well were 
transfected using 5µl/ml, 10µl/ml and 15µl/ml HiPerFect (Figure 18a-e).  The total 
assay volume was also reduced from 50µl to 30µl to prevent reagent overflow 
during the freeze-thaw process (by reducing both the cell seeding and 
transfection reagent mix volumes).  Viability measurements were taken (using 
the ATPlite assay) at 48, 72, 96, 120 and 144 hours post-transfection in order to 
determine the complete range of RNAi effects. 
As can be seen in Figure 18a-e, 2000 cells transfected with 5µl/ml HiPerFect 
resulted in consistent optimal non-targetted and targetted esiRNA effects (in 
particular from 72 hours onwards), with no non-specific transfection reagent 
cytotoxicity.  It was evident, however, that the reduction in assay volume resulted 
in the previously minimally toxic HiPerFect concentration of 15µl/ml becoming 
highly non-specifically cytotoxic.  This was likely due to the reduction in serum 
and nutrient-rich media concentrations, limiting the ability of the cells to recover 
from the transfection process.  Nevertheless, transfection using the lower 
concentration of 5µl/ml HiPerFect prevented this effect, and was determined to 
be the optimal transfection reagent assay parameter. 
 
Pre-assay cell culture conditions 
To limit cross-screen variation it was essential that the HCT116 cells used were 
from the same batch and cultured for the same duration.  Hence, cells could not 
maintained in continuous culture as they had been for the assay development 
process.  As cells transfected directly from frozen were likely to require further 
extensive optimisation due to their post-thaw fragility, frozen cells were cultured 
for 72 hours prior to transfection (using the protocol described in the previous 
section; Figure 19a-e), and RNAi response compared to the previous assay 
using continually cultured cells. 
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Figure 19. Optimisation of conditions using defined-passage cells 
HCT116 cells were thawed and cultured for 72 hours prior to assay seeding. 
Cells seeded at 2000cells/well were reverse transfected with 5, 10 and15µl/ml 
HiPerFect and cell viability mediated by the panel of control esiRNAs measured 
at a. 48, b. 72, c. 96, d. 120 and e. 144 hours post-transfection.  ‘Minimally-
cultured cells’ responded comparatively to long-term cultured cells, indicating that 
culturing cells in this method was suitable for HTS.  Mean values ±S.D. of 3 
repeats are displayed as percentage of untreated control. 
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Figure 19.  Optimisation of conditions using defined-passage cells
HCT116 cells were thawed and cultured for 72 hours prior to assay seeding. Cells seeded 
at 2000cells/well were reverse transfected with 5, 10 and15μl/ml HiPerFect and cell viability 
mediated by the panel of control esiRNAs measured at a. 48, b. 72, c. 96, d. 120 and e. 
144 hours post-transfection.  ‘Minimally-cultured cells’ responded comparatively to long-
term cultured cells, indicating that culturing cells in this method was suitable for HTS.  Mean 
values ±S.D. of 3 repeats are displayed as percentage of untreated control.
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The minimally-cultured cells responded in a similar manner to the continually-
cultured cells, however at 144 hours cells appeared to recover from targetted 
knockdown.  Although this timepoint was beyond that of the final screen scope, 
this observation was noted and the 120 hour screen timepoint closely monitored 
for signs of cell overgrowth (which would mask ‘true’ viability reduction as cells 
began to suffer the effects of nutrient depletion).   
 
Pilot screen 
The optimisation process was carried out on a small scale with reagents being 
dispensed a single well at a time and plate ATPlite measurement times taking >5 
minutes (per plate).  However, this was not conducive to a high-throughput 
screen set-up, and as such semi-automated equipment, spacious tissue culture 
facilities and a rapid-reading luminometer were required.  It was essential that the 
optimised assay was tested under the screen conditions to ensure that there 
were no alterations in assay performance upon transfer to the high-throughput 
setting.  
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Figure 20. Pilot assay 
Repetition of the final assay set-up (2000 cells/well, 5µl/ml HiPerFect) using high-
throughput conditions (72 hour timepoint measured only) demonstrated that the 
assay was directly transferable and suitable for the HTS setting.  Mean values 
±S.D. of 3 repeats are displayed as percentage of untreated control. 
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Cell response was assessed under the optimally established conditions (at the 
72 hour timepoint alone for simplicity; Figure 20).  In addition, PLK1 and EG5 
from the esiRNA library were isolated and tested alongside the controls in order 
to confirm the library’s viability (Figure 20; PLK1 test, EG5 test).  These test 
esiRNAs performed comparatively to the control PLK1 and EG5, thus the library 
esiRNA reagents were determined to be functional and suitable for the high 
throughput screen. 
A useful method for the determination screen of robustness (and the 
potential for false positive and negatives) is the calculation of the assay’s Z-factor 
(Zhang et al., 1999).  By comparing the ‘high’ (eGFP and R-Luc) and the ‘low’ 
(PLK1 and EG5) controls of the pilot test, the calculated Z-factor for the 
optimised assay was 0.55.  A Z-factor of >0.5 in a cell-based screen is deemed 
to be excellent for high-throughput screening, and so this assay format was 
deemed suitable for the full-scale high-throughput screen. 
Taken together the final conditions determined for the primary screen were:  
 
! 2000 cells/well (batch-controlled) 
! 5µl/ml HiPerFect 
! 72 and 120 hour timepoint measurements 
! LEADseeker luminometer; 3 second read 
 
 
 
 
 
 107 
3.2.2 Primary esiRNA screen 
The primary screen was conducted over a 35 day period and following cell lysis, 
plates were frozen down such that the ATPlite assays could be carried out in one 
session to enhance reproducibility.  A total of 216,576 data points were acquired 
comprising 3 repeats of esiRNA transfections for 72 and 120 hour timepoints, in 
the presence and absence of MSC. 
As a first step in the data analysis, internal controls that had been placed 
on each plate (eGFP, R-Luc, PLK1 and EG5 esiRNAs) were assessed on a per-
plate basis to determine whether any plates had failed based on the dynamic 
range of the controls.  As can be seen from the example in Figure 21, the 
controls on some plates failed and it was assumed that all data from the 
corresponding plate may have been compromised (using the criteria listed in 
Figure 21, a total of 62/564 plates were rejected from further analysis).  Repeat 
esiRNA transfections were carried out for plates for which more than one of the 
triplicates had failed (one complete set of 72 hours + compound, and 120 hours + 
compound repeats required re-assessment).  This ensured that at least 2 repeats 
existed for every plate, allowing a robust analysis to be carried out.  
 
!
!
!
!
!
!
!
!
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Figure 21.  Primary screen quality control 
a. Examples of plate controls from a plate that ‘passed’ (1) and ‘failed (2) quality 
control (from 72 hour timepoint). The 16 bars from each plate showing the 
relative luminescence units (RLU) are grouped into 4 repeats of 4 single well 
esiRNA control assays. From left to right, the sets are: eGFP (1-4), EG5 (5-8), R-
Luc (9-12), PLK1 (13-16)). As can be seen, plate 1 showed clear effects of the 
EG5 and PLK1 cytotoxic esiRNAs while plate 2 showed no effect. b. The cut-off 
values used to include or exclude plates in further data analysis. Typical values 
indicate the approximate RLUs most commonly observed. 
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Following the control assessment to ensure sufficient overall data quality, the 
primary data required pre-processing before statistical modelling and hit selection 
could be conducted.  The R-based software package cellHTS2 was used for this 
purpose (see Methods 2.6.2.3 for details), which enabled relatively rapid 
processing of the large-scale whole-screen dataset according to selected 
parameters.  Non-controls based normalisation of the screen dataset was 
conducted.  Each repeat was first normalised relative to the plate median (this is 
less prone to being skewed by extreme outliers than the mean value).  The 
nature of high-throughput screening means that it can be assumed that the 
majority of samples screened are ‘inactive’ providing an accurate representation 
of the plate’s true ‘central value’.  As such, normalised sample values 
represented deviation from the whole-plate sample median.  This method was 
used in preference to control-based normalisation, as although control-based 
normalisation scales data within a defined range (with the non-targetting and 
targetting controls acting as the upper and lower boundaries respectively in this 
instance) and account for plate-to-plate variations in assay window, the controls, 
due to their lower numbers are susceptible to greater error.  
Using cellHTS2, each normalised cellular viability value (derived from ATPlite 
luminescence) was assigned a B-score.  The B-score value was generated using 
an algorithm that incorporates parameters that help control for plate-based 
screening artefacts, for example the variation in temperature across a plate that 
can result in 384-well plate dependent edge effects ((Brideau et al., 2003); see 
Methods 2.6.2.3).  The B-score is a modified measure of the data point variance 
from the median.  At this point the B-score values were assigned to their 
corresponding gene identity (as detailed in the esiRNA library plate/well Ensembl 
ID file) and were stored as an excel file that is available on the attached data CD, 
Appendix 7.  These gene-associated cellular viability B-scores were 
subsequently used for esiRNA effect modelling. 
A statistical model was required that was capable of identifying hits that exhibited 
synergistic synthetic lethality when compound treatment was combined with gene 
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targetting, compared with RNA-mediated target knockdown (RNAi) or compound 
effects alone.  This ‘Linear Model Interaction Test’ was developed by Dr. Eike 
Staub of the department of Discovery Bioinformatics, Merck Serono (and 
implemented using the R statistics package version 2.9.1).  Details of the model 
are described in Methods. In brief, the relationship of the dependent variable 
(cellular viability B-score, resulting from previously described normalization 
procedures) and the two independent variables i.e. esiRNA knockdown (yes/no) 
and compound treatment (yes/no) were assessed using a linear model: 
Viability ~ esiRNA + MSC + esiRNA:MSC 
Thus, the model was developed to include the interaction between esiRNA and 
MSC combination treatment as the main target parameter, as we were interested 
primarily in effect on ATP levels that was exerted by treatment with both esiRNA 
and MSC in combination, but to a lesser extent by esiRNA or compound alone.  
Hence, an ‘interaction value’ was determined that statistically summarised 
synergy (including the interaction significance) between compound and RNAi, 
whilst taking the effect of esiRNA knockdown alone on cellular viability into 
consideration.    
Two interaction values were generated for each sample; a 72 hour and a 120 
hour timepoint interaction value. The interaction values for the 120 hour dataset 
were plotted in order to give a visual indication of whole-screen performance 
(Figure 22). 
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Figure 22a&b.  Visualisation of 120 hour primary screen interaction data 
Following esiRNA transfection of HCT116 cells and treatment with MSC, an 
‘interaction value’ of the effect of the combination was statistically determined.  
Negative interaction values indicate a reduction in ATP levels as a result of 
synthetic interactions in HCT116 cells (e.g. decreased cell proliferation, 
increased apoptosis or a reduction in ATP levels), whilst positive values indicate 
a synthetic increase in ‘viability’.  The combination interaction value for each 
sample is shown individually, and each of the plates is individually coloured.  Due 
to the size of the screen the data has been split into two panels; a - plates 1 to 24, 
b - plates 25 to 47. 
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Figure 22 illustrates the spread of the RNAi-MSC interaction values on a plate-
by-plate basis.  The majority of the 368 samples on each plate had little or no 
effect, and had interaction values centred between -10,000 - +10,000.  Synthetic-
interactions leading to a reduction of ATP levels in the presence of esiRNA and 
MSC are indicated by negative values, whilst positive values indicated RNAi-
MSC dependent increase in ATP levels.   Negative interactions can be 
interpreted as an alteration in cell numbers (e.g. ‘viability reduction’ through 
reduction in cellular proliferation or an increase in cell death) or as a reduction in 
the ATP level per cell.  For selected esiRNA:MSC combinations, it was clear that 
alterations to total cell numbers were responsible for synthetic interactions 
although this was not systematically examined.  Unless specifically stated, 
subsequent comments on ‘cell viability’ as characterised in the primary and 
reconfirmation screens will actually refer to a reduction in ATP levels as this is 
the most likely interpretation. 
Interestingly, some plates exhibit a greater number of hits at either end of the 
interaction scale than others.  A possible explanation for this was that although 
the genes were randomly distributed across the plates, the genes that were 
easiest to clone (and so generate esiRNA against) were located in the earlier 
plates, with genes of unknown function or pseudogenes located in the later 
plates.  Importantly, it was evident that the screening method and chosen data 
analysis were capable of identifying putative hits for further investigation, and 
these linear model interaction values were subsequently used for hit selection 
(discussed below).  
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3.2.3 Hit selection 
The objective of the screen was to determine a defined hit (or hits) whose 
silencing in combination with MSC resulted in loss of HCT116 viability.  However, 
there are in reality many different categories of potential interactions between an 
esiRNA and the MSC compound, which are important to consider prior to hit 
selection.  These are graphically illustrated in Figures 23a and b, together with an 
approximation of the number of hits that were observed in each category based 
on the relevant interaction score.  Conceptually simple synthetic interactions are 
shown in Figure 23a and more complex interactions in Figure 23b. Failure to 
discriminate these hits classes may have resulted in the selection of false 
positive interactions for further analysis.!
!
!
!
!
!
!
!
!
!
!
!
!
!
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Figure 23a.  Simple synthetic interactions 
Schematic representation of the four ‘simple’ RNAi-MSC interaction outcomes. 
Hypothesised decrease in HCT116 viability is shown by a negative interaction 
value, and increase in viability is shown by a positive interaction value.  MSC 
alone had no effect on viability across all conditions and so is only shown once 
for clarity.  
1. MSC alone = no effect 
esiRNA alone = no effect  
esiRNA+MSC = no effect 
2. esiRNA alone = no effect 
esiRNA+MSC = complete reduction in viability 
3. esiRNA alone = no effect 
esiRNA+MSC = moderate reduction in viability 
4. esiRNA alone = no effect 
esiRNA+MSC = increase in viability 
 
Approximate percentage of samples (in relation to the whole screen) falling into 
each category is shown. 
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Figure 23b.  Complex synthetic interactions 
Schematic representation of the hypothesised complex RNAi-MSC interaction 
outcomes.  Decrease in HCT116 viability is shown by a negative effect value, 
and increase in viability is shown by a positive effect value.  Scenario 1 from 
Figure 23a is shown for comparison.  
i. esiRNA alone = marginal to moderate reduction in viability  
esiRNA+MSC = moderate to large reduction in viability 
ii. esiRNA alone = moderate increase in viability 
esiRNA+MSC = no effect 
iii. esiRNA alone = moderate reduction in viability 
esiRNA+MSC = no effect 
 
Approximate percentage of samples (in relation to the whole screen) falling into 
each category is shown.   
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The interpretation of the different hit categories in Figure 23a is discussed in 
more detail:  
Figure 23a shows simple interactions, 4 types of which can be described: 
1. No interaction (blue).  The vast majority of esiRNAs had no effect on 
cell viability and did not co-operate to alter cell viability with MSC. 
2. Strongly decreased signal (dark green). These were the desired 
category of hits showing a strong synthetic interaction between MSC 
and esiRNA. 
3. Moderate synthetic effect (pale green). 
4. Positive effect on cell viability (yellow). The combination of MSC 
treatment and esiRNA knockdown had a positive effect on the ATPlite 
readout. The reason why ATP levels would increase following esiRNA 
and MSC treatment are unclear but could be because ATP synthesis 
or degradation rates are disturbed within target cells or because loss of 
the esiRNA targets increased cellular proliferation rates or decreased 
levels of cell death. 
 
More complex synergies are summarised in Figure 23b. These include 3 types: 
i. One where esiRNA inhibition alone moderately decreased cellular 
viability, while the addition of MSC further reducing it.  This was a 
potential ‘grey area’ of the screen, as hits located within this category 
may have been valuable ‘true hits’, however there was also the 
potential risk that these were ‘false leads’ resulting from off-target 
toxicity of MSC in that were already suffering from an esiRNA-
dependent reduction in integrity (Figure 23b, condition i).      
ii. One where gene silencing increased ‘viability’ which was then reduced 
to normal levels in the presence of MSC (Figure 23b, condition ii); 
resulting in a negative interaction value. 
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iii. One where the esiRNA:MSC combinations increased cell proliferation 
when esiRNA alone reduced cell viability (Figure 23b, condition iii), 
again resulting in a positive interaction value. 
 
The approximate percentage of samples within each category (in relation to the 
whole screen) is summarised in Figure 23.  These values were generated with 
reference to the output of the linear interaction statistical model (see Methods for 
details). For the simple category 2/3 hits described above, the selection criteria 
that were used were: 
• Interaction value < -1000  
• esiRNA p value > 0.1  
• Ratio (interaction p value / esiRNA p value) < 1x10-2  
Using appropriately adapted parameters (see Methods), the hits in the other hit 
categories were identified and counted as a proportion of the total esiRNAs as 
shown in Figure 23:1. 
Two examples of single esiRNA data outputs and the values generated by the 
linear interaction model analysis are illustrated in Figure 24.  Figure 24a shows 
the interaction of HARS (histidyl-tRNA synthetase; ‘PlusCmpd-sample’) with 
MSC, in relation to HARS alone (NoCmpd-sample) and the eGFP control in the 
absence and presence of MSC (NoCmpd-egfp and PlusCmpd-egfp respectively).  
This is an example of a clear synthetic lethal interaction (c.f. Figure 23a:3), with a 
large significant interaction value, and a minimal insignificant RNAi value.   A 
second example in the form of a ‘hit’ that would be selected based on its 
interaction value alone is demonstrated with CD79B (CD79b molecule, 
immunoglobulin-associated beta; Figure 24b).  However, this hit could prove to 
be a ‘false positive’ if selected as RNAi alone affects viability, thus resulting in a 
complex esiRNA:MSC interaction (c.f. Figure 23b:i). 
!
!
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Figure 24. Example hits from the primary esiRNA screen 
Box and whisker plots for a. HARS, b. CD79B are shown.  ‘Signals’ on the Y-axis 
denote the ‘interaction effect’ (y).  On the X-axis, the eGFP -/+ compound 
controls are shown alongside the sample +/- compound for cells treated for 120 
hours with esiRNA followed by 72 hours with compound.  Individual well readings 
are represented as green dots while the median of the readings is shown as a 
thick black bar.  The light box covers the interquartile range (25% and 75% 
quartiles) while the whiskers show the most extreme datapoints. 
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The aim of the screen was to focus on hit genes whose inhibition resulted in 
HCT116 lethality conditionally in the presence of MSC (Figure 23a:2+3, Figure 
24a), In order to identify significant hits (and reduce false positive hit selection), 
stringent criteria were implicated to select conditionally lethal genes based on the 
linear model statistical output. These were: 
• Interaction value < -1000  
• esiRNA p value > 0.1  
• Ratio (interaction p value / esiRNA p value) < 1x10-2  
 
These parameters defined hits that had significant interaction values less than     
-1000 (i.e. loss of viability), with no significant effect of esiRNA alone.  
Furthermore, selecting hits with an interaction:esiRNA p value ratio less than 
1x10-2 ensured that putative hit gene effects were genuine, and not simply on the 
borderline of significance.  This provided a more effective way of conclusively 
defining hits than simply ranking hits (by interaction values, for example) as it 
factored in false positive elimination strategies.  
Only hits that satisfied all selection criteria were chosen for reconfirmation.  In 
total, 83 genes that elicited RNAi-MSC dependent synthetic lethality fulfilled the 
necessary selection requirements.  Interestingly, no esiRNAs were found that 
induced complete cell killing in the presence of compound; the maximal effect 
recorded was ~45% killing.  Furthermore, only samples from the 120 hour assay 
timepoint passed the screen quality selection criteria.  The list of these primary 
hits (ranked according to their interaction p value) is shown in Table 2.  In 
addition to the principal means of selection, a further 10 hits that met some but 
not all of the selection criteria were chosen, as they were of potentially 
biologically relevant or interesting.  JAK3, for example, was selected due to the 
known ability of the activated JAK/STAT pathway to mediate cellular proliferation 
and tumour growth in cancer (Klampfer, 2008), and evidence that JAK/STAT 
signalling functions synergistically with Wnt signalling in cancer (Lin et al., 2011), 
and hence this was a biologically relevant hit.  Conversely, Dkk2, a Wnt 
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signalling antagonist, would hypothetically confer a degree compound resistance 
when inhibited.  However, a significant interaction effect of -12,700 was observed, 
thus this could serve to be a biologically interesting hit.  This subset of manually 
selected hits is listed under the primary hits in Table 2 (in alphabetical order).  
The gene list was analysed for over-representation of annotations in the GO 
categories of biological process, molecular function and cellular component (as 
described in Results 3.1).  The DAVID bioinformatics database (Huang et al., 
2009a) was searched in addition to GeneCodis.  The gene products were also 
compared to both the KEGG and Ingenuity (Ingenuity® Systems) collections for 
enrichment of specific pathway features.  However, no significant enrichment 
was identified.   
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Hit Rank 
Gene 
Name 
Ensembl ID 
Interaction   
p value 
Interaction 
Value 
1 HARS ENSG00000170445 !"#$%&'() &!*''')
2 MEN1 ENSG00000133895 +",-%&'-) &!#*'')
3 PTPN14 ENSG00000152104 ."+(%&'-) &!'!'')
4 FKBP10 ENSG00000141756 -"!,%&'-) &!+.'')
5 PLEKHG4B ENSG00000153404 ,"(#%&'-) &*.(')
6 LIMCH1 ENSG00000064042 !"''%&'.) &*-'')
7 HPD ENSG00000158104 '"'''!'+) &!+-'')
8 SERF1A ENSG00000172058 '"'''!-) &-$!')
9 IL4R ENSG00000077238 '"'''!(!) &!+#'')
10 DDX55 ENSG00000111364 '"'''+(,) &,.+')
11 KIF27 ENSG00000165115 '"'''..!) &-*+')
12 SKA1 ENSG00000154839 '"'''-+.) &!--'')
13 IL2RB ENSG00000100385 '"'''(!#) &,#+')
14 OR51E1 ENSG00000180785 '"'''(-#) &('.')
15 UGP2 ENSG00000169764 '"'''(*+) &*(-')
16 GEMIN6 ENSG00000152147 '"'''*'*) &!+!'')
17 NOP14 ENSG00000087269 '"''',(+) &,.'')
18 FOLR3 ENSG00000110203 '"'''$,#) &!!-'')
19 CELA3A ENSG00000142789 '"''!'$) &*+$')
20 TPT1 ENSG00000133112 '"''!'+) &!'!'')
21 MTAP ENSG00000099810 '"''!#) &-*.')
22 PRSS38 ENSG00000185888 '"''!+.) &,+*')
23 C2orf69 ENSG00000178074 '"''!.#) &!#''')
24 SLC12A6 ENSG00000140199 '"''!.+) &#.('')
25 CCDC30 ENSG00000186409 '"''!--) &+$*')
26 C2orf76 ENSG00000186132 '"''!*.) &$,,')
27 SLC25A39 ENSG00000013306 '"''!,-) &,$*')
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28 PLD6 ENSG00000179598 '"''!$) &!#,'')
29 U2AF2 ENSG00000063244 '"''!$) &$'$')
30 NHEJ1 ENSG00000187736 '"''#'-) &.!'')
31 TRIM28 ENSG00000130726 '"''##+) &,!!')
32 THAP6 ENSG00000174796 '"''#+.) &!+!'')
33 ULK1 ENSG00000177169 '"''#+.) &(#,')
34 CRHR2 ENSG00000106113 '"''#.*) &--!')
35 FOXG1 ENSG00000176165 '"''#$#) &!#-'')
36 FBF1 ENSG00000188878 '"''#$() &+..')
37 CCL4 ENSG00000129277 '"''++#) &**$')
38 LRP4 ENSG00000134569 '"''+*,) &!','')
39 FBXO5 ENSG00000112029 '"''+,$) &!#,'')
40 SLC29A1 ENSG00000112759 '"''+$) &*+.')
41 RNGTT ENSG00000111880 '"''.!() &-,#')
42 BRCA1 ENSG00000012048 '"''..!) &!#('')
43 NT5DC3 ENSG00000111696 '"''.-.) &,(#')
44 CYLD ENSG00000083799 '"''.-$) &!+#'')
45 SLC28A3 ENSG00000197506 '"''.**) &!##'')
46 DHRS2 ENSG00000100867 '"''-*.) &($(')
47 ENOX1 ENSG00000120658 '"''(.*) &!#''')
48 ZC3H13 ENSG00000123200 '"''*#+) &!+''')
49 SPP2 ENSG00000072080 '"''*..) &##''')
50 TNFRSF1A  ENSG00000067182 '"''*-$) &!'('')
51 TMEM61 ENSG00000143001 '"''*(() &(.'')
52 BRAF ENSG00000157764 '"''**() &!#('')
53 CTBP2 ENSG00000175029 '"''*,*) &!'$'')
54 SNRNP48 ENSG00000168566 '"'',##) &!'('')
55 CCDC33 ENSG00000140481 '"'',.() &!#,'')
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56 C6orf162 ENSG00000111850 '"'',-#) &$*,')
57 MATN2 ENSG00000132561 '"'',(-) &!'+'')
58 MSH3 ENSG00000113318 '"''$#.) &$((')
59 CDCA2 ENSG00000184661 '"''$.-) &-('')
60 C8orf42 ENSG00000180190 '"''$-.) &$!'')
61 PDE6B ENSG00000133256 '"''$,+) &-+$')
62 CCDC120 ENSG00000147144 '"''$,.) &!'.'')
63 SLC37A3 ENSG00000157800 '"'!'.) &.*'')
64 GPN2 ENSG00000142751 '"'!!() &*-'')
65 COG5 ENSG00000164597 '"'!!,) &!'.'')
66 ACTC1 ENSG00000159251 '"'!!$) &(*#')
67 BOLA2B ENSG00000169627 '"'!##) &,#-')
68 MMP20 ENSG00000137674 '"'!#-) &,'$')
69 MIER3 ENSG00000155545 '"'!#() &($!')
70 KCNB2 ENSG00000182674 '"'!+*) &!'*'')
71 TNPO3 ENSG00000064419 '"'!.*) &##!'')
72 WDR16 ENSG00000166596 '"'!-) &!,,'')
73 IER3 ENSG00000137331 '"'!-#) &$#.')
74 SART1 ENSG00000175467 '"'!-#) &-+!')
75 HS6ST1 ENSG00000136720 '"'!-#) &-*-')
76 JOSD2 ENSG00000161677 '"'!(#) &,**')
77 PRSS21 ENSG00000007038 '"'!(() &.*.')
78 MARCH8 ENSG00000165406 '"'!($) &!.#'')
79 SCYL1 ENSG00000142186 '"'!*!) &!#,'')
80 MED11 ENSG00000161920 '"'!*.) &,,*')
81 DFNA5 ENSG00000105928 '"'!*-) &!#,'')
82 NCAPG2 ENSG00000146918 '"'!*,) &!.('')
83 KCNIP2 ENSG00000120049 '"'!$!) &-.*')
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      )) ))
N/A ALS2 ENSG00000003393 '"''!-,) &!!('')
N/A DKK2 ENSG00000155011 -"!.%&'*) &!#*'')
N/A JAK3 ENSG00000105639 !"-*%&!#) &!!*'')
N/A KRTCAP2 ENSG00000163463 !"#(%&',) &!-*'')
N/A LIN54 ENSG00000189308 '"''!!$) &!#.'')
N/A PLSCR4 ENSG00000114698 +"-*%&'() &!.*'')
N/A PTP4A3 ENSG00000184489 ."'$%&'-) &,,$')
N/A ROGDI ENSG00000067836 ."!'%&'-) &!!#'')
N/A SRSF1 ENSG00000136450 #"'+%&'() &!!+'')
N/A THRA ENSG00000126351 ."'-%&'-) &!!#'')
 
Table 2. Primary hit selection 
The top 83 hit genes selected from the primary screen data (120 hour timepoint) 
are ranked according to their p value.  esiRNA:MSC linear interaction model 
values are given.  10 additional ‘biologically interesting’ hits are listed below the 
primary hits in alphabetical order.   
 
Although the focus of the study was to identify RNAi:MSC synthetic lethal 
combinations, hits at the ‘opposite end’ of the scale were determined, i.e. 
combinations that were able to increase cellular proliferation or increase ATP 
production (Table 3).  36 genes with significant interaction values > +5000 and 
significant esiRNA effects (-10,000 – 0) were identified (arbitrarily selected values 
used to putatively determine hits in this category).  The gene list was analysed 
for over-representation of annotations in the GO categories of biological process, 
molecular function and cellular component (as described in Results 3.1).  
Additionally the gene products were also compared to the KEGG collection for 
enrichment of specific pathway features.  However, no significant enrichment 
was identified, potentially due to the small set of genes analysed. 
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Gene 
Name) Ensembl ID)
Interaction  
p value Interaction value)
TMEM132B ENSG00000139364 0.000753 8090 
KLK6 ENSG00000167755 0.00384 9540 
TTC27 ENSG00000018699 0.00413 8860 
NDNF ENSG00000173376 0.00456 6950 
SPTY2D1 ENSG00000179119 0.00524 8190 
CCDC42 ENSG00000161973 0.00678 7190 
KDR ENSG00000128052 0.00714 10200 
C9orf139 ENSG00000180539 0.00862 13200 
ERP29 ENSG00000089248 0.00889 9010 
SRP72 ENSG00000174780 0.011 10300 
NA ENSG00000186841 0.0113 9570 
NEDD4 ENSG00000069869 0.0122 7110 
FAM47E ENSG00000189157 0.0136 8000 
TTC6 ENSG00000139865 0.0194 7180 
KLF1 ENSG00000105610 0.0233 8000 
PYCARD ENSG00000103490 0.0264 7200 
BMP5 ENSG00000112175 0.0277 8380 
FCHO2 ENSG00000157107 0.0281 15800 
C9orf43 ENSG00000157653 0.0288 9730 
GXYLT1 ENSG00000151233 0.0308 7230 
SCN4B ENSG00000177098 0.0318 9570 
PRLHR ENSG00000119973 0.0331 10500 
ENTPD5 ENSG00000187097 0.0339 13500 
CASP9 ENSG00000132906 0.0367 23000 
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IGSF6 ENSG00000140749 0.0372 12300 
TMEM150B ENSG00000180061 0.0381 11000 
INPP5E ENSG00000148384 0.0391 8460 
PPP6R1 ENSG00000105063 0.0418 7170 
GOT1 ENSG00000120053 0.0424 6850 
CCNG1 ENSG00000113328 0.0433 7020 
MTL5 ENSG00000132749 0.0438 9200 
NKAIN1 ENSG00000084628 0.0463 9560 
PASK ENSG00000115687 0.0472 8580 
LRRC39 ENSG00000122477 0.048 7150 
ZNF684 ENSG00000117010 0.0481 10200 
AMN1 ENSG00000151743 0.0495 11900 
 
Table 3.  esiRNA ‘activator’ ranking 
esiRNA:MSC combinations with positive interaction values (> +5000) and 
significant esiRNA effects (-10,000 – 0) were determined.  Genes were ranked 
according to their significance (p value) of interaction. 
 
Future detailed analysis of these hits could provide important information 
regarding drug resistance mechanisms, and may also identify novel Wnt pathway 
interactions and feedback mechanisms. However, further work in the project was 
restricted to genes showing synthetic lethality. 
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3.2.4 Reconfirmation assays 
Following the identification of RNAi:MSC interactions from the primary screen, 
selected gene hits were further characterised (see Figure 25 for the 
characterisation assay cascade).   
 
 
!
!
!
!
!
!
!
!
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Figure 25.  Hit characterisation  
Schematic representation of the hit characterisation process.  Hits identified from 
the primary screen were reconfirmed using two methods.  Non-overlapping 
esiRNAs against 45 of the primary hits were synthesised and RNA:MSC 
interactions re-verified.  Simultaneously, 12 commercially available inhibitors 
against the 9 of the primary hits were identified and obtained.  Small molecule 
inhibitor:MSC assays were conducted.  Hit protein knockdown was subsequently 
ascertained.  Further downstream assay plans are detailed.    
 
**ON OPPOSITE PAGE** 
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As hit reconfirmation assays were conducted in parallel, the left branch of the 
diagram (non-overlapping esiRNA reconfirmation) will first be discussed, followed 
by the small molecule inhibitor assays.  
 
3.2.4.1  Non-overlapping esiRNA reconfirmation 
Of the 93 hits identified in the primary hit list (Table 2), 45 genes were selected 
for the synthesis of a non-overlapping esiRNA.  Effects mediated in the presence 
of non-overlapping esiRNAs (designed to target a different region of the gene 
away from the original esiRNA) should validate synthetic RNAi:MSC interactions 
(i.e. that the conditional reduction in viability was not due to off-target effects).  
Due to resource limitation, 45 genes were selected for revalidation based on both 
their rank order in the primary screen and information on their background 
biology.  Biological insight was restricted to searches for known links to Wnt 
signalling or an involvement in oncogenesis.  Examples within this list include 
HARS (the top hit), LRP4 and Dkk2 (known Wnt signalling components and 
antagonists (Johnson et al., 2005; Wu et al., 2000)), TPT1 (translationally-
controlled tumour protein 1) and BRCA1 (breast cancer type 1 susceptibility 
protein (Hall et al., 1990; Miki et al., 1992)). 
Interaction of the non-overlapping esiRNAs with MSC was determined using the 
previously established assay conditions, with the raw data analysed for evidence 
of interaction by determining the percentage reduction in viability compared to 
the ‘high’ and ‘low’ controls, and the significance of the interaction determined 
using two-way ANOVA.  The reconfirmed genes can be seen in Table 4.   
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Gene Name Ensembl ID 
Percentage 
inhibition 
p value 
HARS ENSG00000170445 32 0.0038 
/%0!! ENSG00000161920 9 <0.0001 
BRAF ENSG00000157764 7 0.01 
FKBP10 ENSG00000141756 5 0.0057 
MEN1 ENSG00000133895 
Borderline – require further investigation U2AF2 ENSG00000063244 
1230# ENSG00000161677 
!
Table 4.  Non-overlapping hits  
The seven significant hit and borderline genes determined using non-overlapping 
esiRNA.  ‘Interaction’ was determined from the raw data by calculating the 
interaction based on the percentage reduction in viability compared to the ‘high’ 
control (R-Luc; with EG5 used as the baseline) and significance of interaction 
determined using a two-way ANOVA (n=3).  The percentage viability reduction 
and p values are given for the significant hits. 
 
Of the 45 genes tested, the interaction of 4 hits was significantly reconfirmed, 
with three additional hits indicating ‘borderline’ activity.  Further repetition may be 
needed to validate ‘borderline’ hits.  The reconfirmation rate of 4/45 (or 7/45 
using lower stringency criteria) was low by comparison with a rate of 
approximately 30-40% that was observed for screens for regulators of TCF-
dependent transcription and !-catenin levels and subcellular distribution 
(Freeman, 2008; Lloyd-Lewis, 2011).  Interestingly, the previous screen 
conducted by B. Lloyd-Lewis used the same esiRNA library and had identified 
many more primary hits using non-cell killing readouts (~250 primary hits per 
screen; 35-40% reconfirmation).  At present, we cannot be certain that the 
different primary and secondary hit reconfirmation rates are not related to the 
stringency of the hit selection in this screen.  However, it is more likely that the 
low reconfirmation rate reflects an intrinsic aspect of the biology of cell survival in 
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the presence of MSC compound since ‘true hits’ that had been selected in the 
primary screen would have been expected to reconfirm at similar rates. 
Interestingly, HARS, was again the top hit in the non-overlapping reconfirmation 
analysis.  Both the primary and secondary esiRNAs against HARS specifically 
resulted in a loss of HARS protein expression (Figure 26).  Importantly, in the 
larger-scale assays required for protein expression analysis, a significant 
reduction in cell number was observed only in HARS esiRNA: MSC combinations. 
Future studies could aim to determine whether this was driven by reductions in 
cell proliferation or increased apoptosis. 
Interestingly the second ranked hit was MED11; a component of the multiprotein 
Mediator complex (involved in the activation of RNA polymerase II transcription), 
situated in the ‘head’ module (Taatjes, 2010; Takagi et al., 2006).  The molecular 
target of MSC, CDK8, is central to the kinase module of this complex (Malik and 
Roeder, 2005), thus further disruption of the complex through interference of the 
head module may be required in order reduce cell viability.  
The serine threonine protein kinase BRAF is a third interesting hit.  With defects 
in BRAF linked found in a wide range of cancers (Davies et al., 2002), and 
notably a cause of metastasis in colorectal cancer (Tol et al., 2009), it was 
intriguing as to why inhibition of its functional isoform in combination with MSC 
should result in death of cultured colorectal cancer cells. 
!
!
!
!
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Figure 26.  HARS protein depletion 
Western blot analysis for HARS expression showing depletion of HARS protein 
(56kDa) with both the primary screen esiRNA and the secondary reconfirmation 
non-overlapping esiRNA at each time point analysed.  GAPDH levels are shown 
as controls for loading. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26.  HARS protein depletion
Western blot analysis for HARS expression showing depletion of HARS protein (56kDa) with 
both the primary screen esiRNA (48, 72 and 120 hour knockdown) and the secondary 
reconfirmation non-overlapping esiRNA (48 and 120 hour knockdown).  HiPerFect 
transfection media and R-Luciferase non-targetting controls are shown.  GAPDH (38kDa) 
levels are shown as controls for loading.  
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3.2.4.2  Small molecule inhibitor ‘reconfirmation’ 
In parallel with the non-overlapping esiRNA revalidation assays, attempts to 
replicate the conditional viability reduction with small molecule inhibitors 
(replacing esiRNAs) were made.  The rationale for this was two fold.  Firstly it 
was postulated that gene targetting by RNAi may not downregulate the hit targets 
completely (perhaps due to incomplete depletion of the gene).  In this case, 
residual gene product activity may have prevented a strong conditional response 
being observed – as was observed in the esiRNA screen where no genes 
showed 100% synthetic lethality.  Secondly, it would have been very time-
consuming and costly to correlate the level of each protein reduction with 
response for each putative esiRNA target. 
Compounds were identified that inhibited the corresponding esiRNA gene 
products with the rationale that they should synergise to inhibit cell growth.  In the 
longer-run, it was anticipated that the identification of any commercially available 
compounds (or compounds in the clinic) would improve the potential for clinical 
application of MSC in chemotherapeutic combination therapies. 
In order to identify commercially available compounds, an extensive in silico 
search was conducted for any inhibitors against the primary hit list (Table 2).  A 
secondary search of the ChEMBL and DrugBank databases ((Gaulton et al., 
2012; Knox et al., 2011)) was conducted by Dr. Oliver Karch (Dept. of Discovery 
Bioinformatics, Merck Serono).  In instances where multiple compounds were 
available against a single molecular target, only two were obtained (due to 
practical and resource limitations).  Apart from UGP2, all compound targets also 
had a corresponding non-overlapping esiRNA, thus results from the two 
reconfirmation assays could be used to corroborate one another.  In total, twelve 
compounds were accessible against nine of the primary hit targets (Table 5a). 
In addition, a panel of Wnt inhibitors (available ‘in-house’) were selected for 
combination testing with MSC (Table 5b; this included a second CDK8 inhibitor, 
Senexin A (Porter et al., 2012)).  It was postulated that the partial inhibition of 
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Wnt signalling by MSC may have been insufficient to reduce cellular viability in 
response to MSC in HCT116 cells (see Figure 14b).  Thus it was hypothesised 
that MSC might functionally synergise with other Wnt pathway inhibitors by 
targetting a separate ‘branch’ of the signalling network (see Figure 5); a 
suggestion that was supported by the identification of Wnt regulators in the 
primary esiRNA screen (Table 2).  
Together this approach should allow the identification of targets that synergise 
with MSC via reductions in Wnt signalling and through unrelated ‘interactor’ 
mechanisms that could not have been predicted at the outset.  
 
Table 5a.  Inhibitors against primary screen hit genes  
Inhibitors identified (and purchased) against genes from the primary hit list are 
detailed (in hit alphabetical order).  Where there are 2+ inhibitors for a target, 
only 2 have been selected.  Compound synonyms are listed, with the name in 
bold indicating the name used in all assays.  CAS (Chemical Abstracts Service) 
numerical identifiers are detailed. 
Hit Gene Name Ensembl ID Compound (with synonyms) CAS Number 
BRAF %435'''''!-**(.) BAY-43-9006, Nexavar, Sorafenib 284461-73-0 
BRAF %435'''''!-**(.) RAF265 (CHIR-265) 927880-90-8 
CRHR2 ENSG00000106113 K 41498 434938-41-7 
HPD ENSG00000158104 Nitisinone 104206-65-7 
JAK3 ENSG00000105639 BX-795 702675-74-9 
JAK3 ENSG00000105639 Tofacitinib citrate 540737-29-9 
PDE6B ENSG00000133256 Revatio, Sildenafil, UK-92480, Viagra 171599-83-0 
PTP4A3 ENSG00000184489 Emodin 518-82-1 
SLC29A1 ENSG00000112759 Lidoflazine 3416-26-0 
THRA ENSG00000126351 Tiratricol, TRIAC 51-24-1 
THRA ENSG00000126351 
Cytomel, Euthroid, Liothyronine, 
Rathyronine, Tertroxin, Thyrolar, 
Triostat 6893-02-3 
UGP2 ENSG00000169764 Iodoacetamide 144-48-9 
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Target Compound CAS Number 
PORCN LGK-974 (derivative) 1243244-14-5 
LRP6/Fz1 Niclosamide 50-65-7 
LRP6 Salinomycin 53003-10-4 
GSK3 BIO 667463-62-9 
TNKS1&2 XAV 939 284028-89-3 
PP2A IQ-1 331001-62-8 
TCF4 - !-catenin  PKF118-310 84-82-2 
CBP ICG-001 847591-62-2 
CDK8 Senexin A N/A 
Multiple Sulindac 38194-50-2 
 
Table 5b.  Inhibitors against Wnt signalling components 
Wnt inhibitors are listed according to their site of action in the pathway (from 
extracellular to nucleus).  CAS (Chemical Abstracts Service) numerical identifiers 
are detailed. 
 
To investigate the interaction between the compound test list in Table 5 and MSC, 
an initial simple combination viability assay was conducted to rapidly ascertain 
any compound-compound synergy.  HCT116 cells were treated (24 hours post 
96-well plate seeding) with 10µM MSC in combination with 1, 5 and 25µM test 
compound for 24, 48 and 72 hours.  The most significant effects were seen at 48 
and 72 hours treatment, with 1 and 5µM test compound (Figures 27 and 28).  
!
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Figure 27a&b.  esiRNA-directed inhibitor:MSC combination effect on 
HCT116 cell viability 
HCT116 cells seeded in a 96 well plate at 4500 cells/well for 24 hours were 
treated with either 1µM (blue bars) or 5µM (green bars) test compound in the 
presence (dark bars) and absence (light bars) of 10µM MSC.  Cell viability was 
measured at a. 48 and b. 72 hours post treatment using the ATPlite assay.  All 
controls are normalised to DMSO treated cells (grey bar).  10µM MSC treatment 
alone is shown in grey.  5FU was used as a control for viability reduction.  n = 5  
(* = P < 0,05; ** = P < 0,01; *** = P < 0,001; 1 Way ANOVA and Tukey Test).  N.B.  
This data was produced by Daniel Winter under my supervision during his visit to 
the laboratory. 
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Figure 28a&b.  Wnt-Wnt inhibitor combination effect on HCT116 cell           
viability 
HCT116 cells seeded in a 96 well plate at 4500 cells/well for 24 hours were 
treated with either 1µM (blue bars) or 5µM (green bars) test compound in the 
presence (dark bars) and absence (light bars) of 10µM MSC.  Cell viability was 
measured at a. 48 and b. 72 hours post treatment using the ATPlite assay.  All 
controls are normalised to DMSO treated cells (grey bar).  10µM MSC treatment 
alone is shown in grey.  n = 5  (* = P < 0,05; ** = P < 0,01; *** = P < 0,001; 1 Way 
ANOVA and Tukey Test).  N.B. This data was produced by Daniel Winter under my 
supervision during his visit to the laboratory. 
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This initial compound-compound combination assay was used to determine 
whether compounds (if any) were able to synergise with 10µM MSC (the same 
concentration used in the primary screen).  The plan was then to study 
compounds exhibiting synergy more extensively.   
At the 24 hour timepoint no compounds exhibited combinatorial reduction in 
viability (data not shown), however this was not surprising as this treatment time 
was equivalent to the 72 hour esiRNA primary screen timepoint which also 
revealed no significant interactions.  As can be seen in Figures 27 a and b (48 
hour and 72 hour timepoint respectively), several compounds induced weak 
combination-dependent loss in viability.  RAF265 (1µM) and BX-795 (1µM and 
5µM) both demonstrated significant reduction in viability in combination with MSC 
compared with test inhibitor treatment alone at both 48 and 72 hours treatment, 
with 5 µM Sorafenib significantly reducing viability at 48 hours alone.  
Interestingly, both RAF265 and Sorafenib are BRAF inhibitors, supporting the 
reconfirmation of BRAF with non-overlapping esiRNA.  By contrast, the 
interaction between the JAK3 inhibitor BX-795 and MSC was not replicated by 
the second JAK3 inhibitor tofacitinib citrate. Future studies with additional JAK 
pathway inhibitors may be able to help resolve whether the BX-795 interaction 
was based on an essential underlying role for the JAK pathway in the presence 
of MSC. 
Notably, only four Wnt pathway component inhibitors exhibited any significant 
activity in combination with MSC (salinomycin, BIO, ICG001 and Senexin A), with 
BIO (6-Bromoindirubin-3'-oxime) being the only compound to significantly reduce 
HCT116 viability across both timepoints (Figure 28a&b).  This was a somewhat 
surprising observation as BIO is a well-characterised inhibitor of GSK3 and 
powerfully activates TCF-dependent transcription in many systems.  
It was also somewhat surprising that this initial assay indicated Senexin A (a 
CDK8 inhibitor) was able to reduce cellular viability in combination with MSC as 
data from the drug discovery programme had shown that MSC was a selective 
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and potent CDK8 inhibitor.  Further investigations would be required to reconfirm 
this observation. 
Five compounds were selected for extended studies: BIO, RAF265, BX-795, 
salinomycin and Senexin A.  Test inhibitors were titrated (25nM to 25µM) in a 
‘chequerboard’ assay against MSC titrations (40nM to 25µM) in order to 
ascertain whether combinatorial activity was evident at defined compound 
concentration combinations (at 24, 48 and 72 hours).  Of the five compounds, 
only RAF265 and salinomycin demonstrated synergistic activity in these 
preliminary assays (see Appendix 8 for detailed BIO, BX-795 and Senexin A 
dose response curves).  Subsequent reconfirmation studies showed that there 
was in fact no synergy between salinomycin and MSC (Appendix 8, however the 
synergy between RAF265 and MSC, although weak, was highly reproducible 
both in studies presented here (Figure 29a and b) and in several (n=4 total) 
independent repeats (data not shown).  !
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Figure 29.  RAF265:MSC combination  
HCT116 cells seeded in a 96 well plate at 4500 cells/well for 24 hours were 
treated with a range of RAF265 inhibitor concentrations (20nM – 25µM) in the 
presence (green) and absence (red) of 2.5µM MSC.  Cell viability was measured 
at a. 48 hours and b. 72 hours post treatment using the ATPlite assay.  All 
controls are normalised to DMSO treated cells. n = 3. 
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Figure 29.  RAF265:MSC combination 
HCT116 cells seeded in a 96 well plate at 4500 cells/well for 24 hours were treated with a 
range of RAF265 inhibitor concentrations (20nM – 25μM) in the presence (green) and 
absence (red) of 2.5μM MSC.  Cell viability was measured at a. 48 hours and b. 72 hours post 
treatment using the ATPlite assay.  All controls are normalised to DMSO treated cells. n = 3.
a
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RAF265:MSC synergy was most evident in combination with 2.5µM MSC (Figure 
29) with the most significant difference in compound effect being observed at 48 
hours treatment (Figure 29a).  Note also that at high concentrations, RAF265 
alone showed significant toxicity that may have obscured its potential to interact 
with MSC.  At both 48 and 72 hours (Figure 29a&b), the most significant 
combinatorial inhibition was seen with 1µM RAF265:2.5µM MSC treatment.  
Importantly, 2.5µM MSC is 200 times the 7df3 IC50 for MSC. At these 
concentrations, it is not easy to exclude the possibility that MSC synergy might 
be functioning through action on off-target (non-CDK8/CDK19) targets including 
other protein kinases. 
To determine whether BRAF inhibition using alternative inhibitors would elicit the 
same result, Debrafenib (CAS 1195765-45-7) and SB590885 (CAS 405554-55-
4) were examined in combination with MSC.  The multi-kinase inhibitor, 
Sorafenib was also further assessed as it had shown activity in the preliminary 
compound assays (Figure 27a) but had not been tested in the chequerboard 
assays.  In addition, the activity of two MEK inhibitors (acting downstream of 
BRAF in the MAP kinase pathway) in combination with MSC were measured in 
order to determine whether MAP kinase pathway inhibition in combination with 
Wnt signalling inhibition synergised to reduce HCT116 viability.  However, neither 
the BRAF inhibitors nor MEK inhibitors showed any synergistic activity with MSC 
(data not shown), suggesting that that the RAF265 compound was the exception 
in its ability to synergise with MSC. 
Preliminary investigations were undertaken in alternative cancer cell lines to 
determine whether the RAF265:MSC dependent effect in HCT116 cells was 
more broadly observable.  At present a panel of seven CRC cell lines has been 
assessed (Colo205, Colo320, SW480, SW620, Ls174T and DLD1; see Methods 
2.1 for cell line details) using the assay design developed for HCT116 cells.  
Although these assays require further optimisation (as the HCT116-optimised 
format is not necessarily the most suitable for other lines), Ls174T cells showed 
RAF265:MSC conditional lethality at 48 hours treatment (Figure 30).   !
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Figure 30.  RAF265:MSC combination in Ls174T cells 
Ls174T cells seeded in a 96 well plate at 4500 cells/well for 24 hours were 
treated with a titration of 200nM, 1µM and 5µM in the presence (circles) and 
absence (triangles) of 10µM MSC.  Cell viability was measured 48 hours post 
treatment using the ATPlite assay.  All controls are normalised to DMSO treated 
cells. n = 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.  RAF265:MSC combination in Ls174T cells
Ls174T cells seeded in a 96 well plate at 4500 cells/well for 24 hours were treated with a 
titration of 200nM, 1μM and 5μM in the presence (circles) and absence (triangles) of 10μM 
MSC.  Cell viability was measured 48 hours post treatment using the ATPlite assay.  All 
controls are normalised to DMSO treated cells. n = 5.
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Taken together, the esiRNA screen identified a small number of genes, the loss 
of whose gene products co-operated with MSC to reduce cellular viability. The 
most significant of these effects was observed with HARS.  At present, no HARS-
specific compounds are available to explore this interaction further.  Of the other 
confirmed hits, BRAF appeared the most interesting since a number of small 
molecule inhibitors have been developed against both the wild-type and mutant 
protein.  One of these inhibitors, RAF265, synergised with MSC in multiple 
assays and in at least 2 cell lines (HCT116 and Ls174T).  However it is currently 
unclear whether the RAF265:MSC synergy operates via the Ras-MAP kinase 
pathway since other pathway inhibitors showed little effect. 
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Chapter 4. Discussion 
The Wnt/!-catenin signalling cascade is critically implicated in the development 
of many organisms, with its dysregulation linked to several disease processes.  
The original aim of this study was to identify novel modulators of TCF-dependent 
signalling by means of cDNA and esiRNA high-throughput cell-based screens.  
The identity of these novel hits and their biological activity were anticipated to 
provide tools with which to characterise the activity and targets of a number of 
small molecule inhibitors of TCF-dependent transcription that had been identified 
from cell-based compound library screens (Ewan et al., 2010).  In the early 
stages of this study it was not apparent which of several compound series under 
investigation, would ultimately be translated into a single clinical therapeutic 
candidate. 
During the project it became clear that a member of the CCT071459 small 
molecule chemical series was going to become the lead compound for further 
drug discovery efforts. The ‘daughter analogue’ of this series that was studied in 
the work described here is referred to throughout as MSC. In the course of the 
first two years of the project the molecular target of the CCT071459 series was 
determined to be the serine threonine kinases CDK8 and CDK19 through the use 
of bead-conjugated analogues, affinity purification and mass spectrometry.  At 
this point the esiRNA branch of the research changed direction to focus on the 
identification of genes whose function co-operated with MSC to maintain HCT116 
cancer cell growth in 2D culture. 
Both cDNA and esiRNA screens were successfully completed and identified 
fourteen cDNA regulators of TCF-dependent transcription and four genes whose 
function synergised with MSC to maintain HCT116 viability.  To provide a context 
for a discussion of the identity/function of the genes from each screen, it is 
necessary to consider the function of the MSC target, CDK8/CDK19. 
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CDK8 as the MSC molecular target 
CDK8 is a ubiquitously expressed cyclin-dependent serine-threonine kinase, 
functioning in the nucleus in a wide range of roles.  However, CDK8’s best 
characterised function is as a regulator of transcription as part of the Mediator 
complex (Galbraith et al., 2010).  In complex with Cyclin C (CycC) and the 
mediator proteins Med12 and Med13, this CDK8:CycC kinase core forms the 
regulatory module of the multi-protein Mediator complex (Figure 31), bridging 
RNA polymerase II (Pol II) and DNA-binding transcription initiation factors (Malik 
and Roeder, 2010).  Unlike cell-cycle CDKs, CDK8 is able to phosphorylate Ser2 
and Ser5 of the CTD of RNA Pol II, regulating its activity (Hengartner et al., 1998; 
Ramanathan et al., 2001).  Interestingly, a component of the core Mediator 
complex, MED11, was one of the four validated esiRNA hits that were identified 
in the whole esiRNA genome screen, suggesting that the absolute level of 
Mediator complex activity may be critical for cell survival in the presence of MSC.  
!
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Figure 31.  The Mediator complex 
Diagrammatic plan of Mediator complex components (taken from (Malik and 
Roeder, 2010)).  Distinct Mediator components interact and connect distinct 
classes of transcriptional regulators with the basal transcription apparatus 
including RNA polymerase II.  The kinase module CDK8/19, Cyclin C, Med12 
and Med13 acts as a switch to induce transcription of a subset of the ‘core 
Mediator complex’ target genes and repress others.  In particular, the kinase 
module activates Wnt target genes, while the Med12 component has been 
shown to directly interact with !-catenin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31.  The Mediator complex
Diagrammatic plan of Mediator complex components (taken from (Malik and Roeder, 
2010)).  Distinct Mediator components interact and connect distinct classes of 
transcriptional regulators with the basal transcription apparatus including RNA 
polymerase II.  The kinase module CDK8/19, Cyclin C, Med12 and Med13 acts as a 
switch to induce transcription of a subset of the ‘core Mediator complex’ target genes 
and repress others.  In particular, the kinase module activates Wnt target genes, 
while the Med12 component has been shown to directly interact with β-catenin.
149
 150 
A manual search of the esiRNA screen ‘interaction’ data set also identified 
Med12L and Cyclin C as reducing HCT116 viability (see Appendix 7 table), 
however they were not selected since they narrowly missed the hit selection 
cutoffs.  CDK8 itself (or CDK19) was not identified in the esiRNA screen, either in 
synergy with MSC or alone as being required for HCT116 viability.  This 
contrasted with the study by Firestein et al. (Firestein et al., 2008), which showed 
that 2D cultured HCT116 viability was reduced by ~70% following CDK8 short 
hairpin RNA (shRNA) lentiviral infection after 120 hours.  CDK8 function may be 
critical in many cell types since CDK8 null mice did not survive beyond 2.5-3.0 
days of early embryogenesis as it is required for pre-implantation (Westerling et 
al., 2007).  The contrast between the lack of response of esiRNA to CDK8 and 
the published studies suggests that the lack of response we observed in the 
screen may be due to a failure of the specific esiRNA reagent that was used.  
Further support for this observation has come from the demonstration that 
shRNAs targeted against CDK8 reduced proliferation of other colorectal cancer 
cell lines studied in the collaboration (data not shown).   
It is important to recognise that there are two major differences between the loss 
of CDK8 function and treatment with a highly selective CDK8 inhibitor.  Firstly, 
MSC inhibits the activity of both CDK8 and the closely related CDK19 paralogue 
(80% amino acid identity (Malumbres et al., 2009)), while siRNA-mediated loss of 
CDK8 does not reduce the activity of CDK19.  As yet, a detailed study of CDK8, 
CDK19 and CDK8/CDK19 loss has not been carried out in HCT116 cells.  
However initial data from the drug discovery programme suggests that shRNA 
dependent loss of both proteins synergises in the reduction of other colorectal 
cancer cell types in 2D culture (data not shown).  Despite this observation, it is 
unlikely that these kinases are completely functionally redundant, since 
knockdown of CDK8 alone in human cell cultures results in clear phenotypes 
(Donner et al., 2010; Firestein et al., 2008), and opposite roles of the kinases 
have been identified under certain conditions (Furumoto et al., 2007; Tsutsui et 
al., 2008).  Thus CDK8 loss alone may be predicted to induce fewer effects than 
MSC due to functional compensation by CDK19.   
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Secondly, and by contrast, MSC treatment might have been predicted to have 
had less of an effect than CDK8 siRNA depletion because it only blocks CDK8’s 
biochemical functions through ATP competition while the esiRNA removes both 
catalytic and structural functions.  Interestingly, previous studies involving 
transfection of human A375 and WM165-1 cells  (melanoma lines with high 
CDK8 protein levels) with kinase-dead mutants of CDK8 demonstrated that 
CDK8 structural/scaffolding functions can play a key role in cell survival (Kapoor 
et al., 2010; Knuesel et al., 2009). 
Given the lack of growth inhibition that was observed in HCT116 cells in 2D 
culture following MSC treatment (Figure 14a), it is unlikely that CDK8/CDK19 
catalytic activities are essential for HCT116 cell viability, although a net 
‘transcriptional’ output of the Mediator complex may be essential for viability 
when kinase activity is combined with the structural loss of other Mediator 
components. 
CDK8 and Wnt signalling 
The MSC CDK8/CDK19 inhibitor was developed from the CCT series of 
compounds that were originally identified as being potent inhibitors of TCF-
dependent transcription in the HEK293-based 7df3 reporter cell screen ((Ewan et 
al., 2010); unpublished data).   It has been established that the CDK8 kinase 
core is recruited to the regulation of Wnt/!-catenin signalling through the 
interaction of Med12 with !-catenin’s transactivation domain (Kim et al., 2006), 
enhancing !-catenin-TCF/LEF dependent transcription (Figure 32).  This 
enhancer effect has been linked with the observation that CDK8 is amplified in 
colorectal cancer, potentiating malignancies driven by aberrant Wnt/!-catenin 
signalling (Firestein et al., 2008; Firestein and Hahn, 2009).  CDK8 was also 
shown to indirectly induce TCF-dependent transcription by preventing the 
inhibitory action of E2F1 on !-catenin/TCF (Morris et al., 2008).  Thus, it is 
unsurprising that the primary ‘Wnt inhibitor’ screen identified a compound with 
CDK8 antagonistic activity. 
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Figure 32.  CDK8 and Wnt signalling 
Two pathways have been suggested to link CDK8 action to the regulation of 
TCF-dependent transcription.  In the first, CDK8 was suggested to directly 
regulate the coupling of the TCF/!-catenin complex to the core RNA polymerase 
II complex via its role in the Mediator complex.  In the second, CDK8 was shown 
to phosphorylate and inhibit the activity of E2F1, although it is unclear whether it 
does this in the context of the Mediator complex (adapted from (Galbraith et al., 
2010)).  
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Figure 32.  CDK8 and Wnt signalling
Two pathways have been suggested to link CDK8 action to the regulation of TCF-dependent 
transcription.  In the first, CDK8 was suggested to directly regulate the coupling of the TCF/β-
catenin complex to the core RNA polymerase II complex via its role in the Mediator complex.  In the 
second, CDK8 was shown to phosphorylate and inhibit the activity of E2F1, although it is unclear 
whether it does this in the context of the Mediator complex (adapted from (Galbraith et al., 2010)). 
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Despite its potency in the original cell-based screen, TCF-reporter activity in 
HCT116 cells was only partially inhibited (~45%) by MSC (Figure 14b), and there 
was no effect of MSC on HCT116 viability (Figure 14a).  Several inferences can 
be made from this result.  Firstly, it is possible that insufficient knockdown of TCF 
activity was achieved.  As is highlighted in Figure 5, TCF-dependent transcription 
can be modulated at many points along the classic ‘linear’ pathway, most 
significantly at highly connected core components.  However, further ‘branches’ 
of interactions exist that may comprise MSC-resistant pathways or may function 
to maintain ‘homeostatic’ levels of Wnt signalling through feedback mechanisms.  
More than one mechanism of pathway activation has previously been identified in 
HCT116 cells, where only the simultaneous removal of both the endogenous 
mutant !-catenin allele and the prevention of an autocrine Wnt ligand feedback 
loop inhibited cell growth (Bafico et al., 2004).  To explore the ‘network 
compensation hypothesis’ explanation for the lack of effect of MSC on HCT116 
viability, combinations of Wnt pathway inhibitors were tested together (Figure 28).  
Interestingly, no strong synergy was observed between any of the ten Wnt 
pathway component inhibitors and MSC in reducing cellular viability, suggesting 
that the absolute level of TCF-dependent transcription may not be critical for the 
proliferative response of HCT116 cells.  A demonstration that Wnt:Wnt inhibitors 
synergised to reduce TCF-dependent transcription levels in HCT116 reporter 
cells would be required to fully validate this suggestion. 
A second ‘stem cell’ hypothesis can explain the lack of MSC effect on HCT116 
viability in 2D culture (Clarke and Fuller, 2006).  Wnt signalling (and CDK8) has 
been extensively linked to stem cell function in multiple tissues, significantly 
including the intestine (Adler et al., 2012; Pinto and Clevers, 2005b).  The lack of 
a HCT116 ‘viability response’ to MSC and the low levels of response observed 
with even the most efficacious RNAi:MSC combinations may be because the 
reduction in stem cell targets (e.g. Wnt signalling targets) is only critical for a sub-
population of ‘stem cell’ like cells; although whether ‘stem cell’ like cells exist 
within 2D culture is a matter of debate.  Nonetheless, it has been shown that in 
many 2D systems, subpopulations of cells may respond to pharmacological 
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inhibition with different responses at the same compound concentration (Fallahi-
Sichani et al., 2013).  Interestingly, collaborators within the CCT series research 
programme determined that there was a response HCT116 cells cultured in 3D 
soft agar to MSC treatment (albeit at ~8µM MSC; Figure 33a), suggesting that 
under conditions that may require ‘stem cell’ function growth responses may be 
seen.  Furthermore, the more advanced daughter compound of MSC (MSCi; 
Figure 33b) showed a greater efficacy in 3D cultures, suggesting that larger 
interaction values may be achieved if this compound were to be assessed with 
the hits identified.  In addition, the observation that other cell lines showed MSC-
dependent 3D but not 2D efficacy responses at GI50s close to the 7df3 IC50 
(collaboration data, data not shown) means it remains possible that a repeat of 
the synthetic screen with an alternative cell line could identify targets with greater 
efficacy. 
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Figure 33.  HCT116 3D soft agar assay 
The HCT116 anchorage independent growth assay in soft agar was conducted 
over 14 days (Stefanie Gaus, Merck Serono).  The more advance 'daughter' 
compound (MSCi) that was developed during this study is also shown for 
comparison (b).  Cells were treated with compound every 2-3 days, and cell 
viability measured by AlamarBlue assay (n=4). 
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Figure 33.  HCT116 3D soft agar assay
The HCT116 anchorage independent growth assay in soft agar was conducted over 14 days 
(Stefanie Gaus, Merck Serono).  The more advance 'daughter' compound (MSCi) that was 
developed during this study is also shown for comparison (b).  Cells were treated with 
compound every 2-3 days, and cell viability measured by AlamarBlue assay (n=4). 
b
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Other CDK8 functions 
There are many additional roles for CDK8 (and CDK19) outside of their role in 
Wnt signalling (some of which are summarised in Figure 34).  Its function in 
processes such as embryonic stem cell pluripotency, the positive regulation of 
STAT transcription factors and the promotion of growth factor dependent 
transcription elongation has been determined (reviewed in (Galbraith et al., 
2010)).  In addition, there are potentially many roles for CDK8 outside of the 
Mediator complex.  Of note, up to 30% of this CDK8:CycC regulatory module can 
be purified without Mediator, suggesting that CDK8 function may extend beyond 
transcriptional regulation (Galbraith et al., 2010).  
Not only are there many alternate roles for CDK8 other than in Wnt signalling, 
there are many other potential biological responses that may be relevant for the 
biology of CDK8 inhibitors in tumour cells in 2D culture and in vivo.  Interestingly, 
Adler et al. suggested that the responses following inducible-shRNA-dependent 
CDK8 loss were particularly linked to the loss of a stem cell component ((Adler et 
al., 2012) and in house studies).   
It is important to consider that this is a large field of research that is in its relative 
infancy at present and as such CDK8 is a constantly moving target, with over 
2,200 studies published in the past five years (1,200 of which were published in 
the last two years alone) compared to 1,600 in the time prior to 2008.  The 
responses that were seen in the cDNA and esiRNA studies here cannot yet be 
definitively linked to any one CDK8 function and may be due to one or a 
combination of CDK8 effectors or due to processes that are only indirectly linked 
to CDK8 pathways and are required for the far-downstream contribution of CDK8 
to cell viability. 
 
 
 
 157 
Figure 34 Placement 
Figure 34.  Many roles for CDK8  
Schematic illustration of the known functions of CDK8. 
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In house assays have shown that CCT family compounds induce a reduction of 
HCT116 xenograft tumour proliferation in vivo (data not shown).  As tumours are 
subject to numerous paracrine signalling events between tumour cells and 
between tumour cells and stromal cells (fibroblasts, endothelial cells, immune 
cells), CCT-series compound action in vivo may be indirectly mediated by effects 
on CDK8 action in the stromal as well as the tumour component. Supporting this 
suggestion, it has recently been shown that HCT116 cells were able to protect an 
apoptosis-sensitive fibroblast population from apoptosis in co-culture in a CDK8-
dependent paracrine manner (Porter et al., 2012), suggesting that epithelial (with 
elevated CDK8)-stromal interactions in vivo are critical in mediating response to 
MSC.  Furthermore, the majority of the surface area of cells cultured in 2D is 
either in contact with the plastic culture surface or nutrient media, thus cell-cell 
interaction and communication is limited.  Therefore a reduction in cellular 
viability mediated by the compound in vivo (and 3D spheroid cultures) could 
appear more pronounced than in 2D assays.  Such a response may be occurring 
with RNAi:MSC dual inhibition in the 2D HCT116 cell assay, raising the 
possibility that the effects of hits identified under 2D conditions may be amplified 
when transferred into 3D and in vivo systems.  
In summary, the role of distinct CDK8 functions in HCT116 cellular responses is 
currently unclear.  What is also unclear is whether any gene products (identified 
here) that mediate HCT116 viability in the presence of MSC (in 2D culture) are 
linked to Wnt or immediate CDK8 targets.  Nonetheless, consideration of the 
biological function of two of the top esiRNA hits does raise possible mechanistic 
links.  These gene products are HARS and BRAF. 
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Histidyl Aminoacyl tRNA Synthetase  
The outstanding hit of the esiRNA chemical sensitisation screen was cytoplasmic 
Histidyl Aminoacyl tRNA Synthetase (HARS or HisRS; (Ibb, 2004)), whose 
endogenous expression in HCT116 cells conferred resistance to MSC.  HARS’s 
enzymatic activity is essential for protein translation, charging the cognate tRNA 
with histidine for its subsequent incorporation into proteins.  Identification of this 
enzyme as the strongest hit in the esiRNA screen was surprising and equally 
very interesting, as few direct links have previously been described connecting it 
to either Wnt or CDK8 function.  Interestingly, manual scrutiny of the interaction 
data also showed an RNAi:MSC combination-dependent with the inhibition of 
RARS (arginyl-tRNA synthetase), however this gene did not reach the stringent 
hit selection criteria.  
A link of potential significance between HARS and Wnt is the observation that the 
kinase TNIK (TRAF2 and NCK-interacting protein kinase) was able to bind to 
HARS in a yeast-2-hybrid protein-protein interaction assay (Camargo et al., 
2007).  Although TNIK was shown to be required for Wnt signalling in the 
intestine this link has only been made in one report (Mahmoudi et al., 2009), and 
evidence has yet to been presented to validate its suggested binding to HARS.  A 
second putative link may also exist between HARS and Wnt-driven hair biology.  
Despite its ubiquitous expression, a mutation in HARS causes its aminoacylation 
function to become defective resulting in Usher syndrome (Puffenberger et al., 
2012).  Patients with Usher syndrome experience progressive hearing loss 
(amongst other pathologies) resulting from mutations in HARS, which may be 
linked to damage or loss of cochlea hair cells (although the data is preliminary).  
More generally, an emerging literature suggests that there is great potential in 
combining translational inhibitors including rapamycin analogues and other 
chemotherapeutic agents. The results presented here hint at a possible future 
combinatorial link between an inhibitor of transcription (MSC:CDK8) and 
inhibitors of translation, perhaps via pathways including HARS.  
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Interestingly recent evidence suggests that amino-acyl tRNA synthetases may be 
‘repurposed’ for non-translational roles, as nuclear and extracellular roles have 
been uncovered; sites where translation does not occur.  Eukaryotic amino-acyl 
transferases have been shown to be organised into multi-synthetase complexes 
that have roles in regulation (Yang, 2013) and non-translational functions for 
amino-acyl transferases have been demonstrated in roles including angiogenesis, 
mTOR signalling, inflammatory responses and tumour growth (Bonfils et al., 
2012; Dorrell et al., 2007; Han et al., 2012; Park et al., 2012; Pierce et al., 2011; 
Xu et al., 2012).  Of particular interest is the observation that leucine tRNA 
synthetase (LARS) is a key component of a regulatory complex that controls the 
activity of the mTORC1 complex since the AKT/mTOR pathway is required 
downstream of APC loss for tumourigenesis and can be blocked by treatment 
with the mTOR inhibitor, rapamycin (Ashton et al., 2010; Fujishita et al., 2008).  
There are two key questions that must be addressed by further studies in order 
to determine the utility of HARS as a drug target: 
1. How general is the requirement for HARS? 
2. Is HARS enzymatic activity required for conditional lethality? 
A panel of colorectal cancer cell lines could be probed to assess the breadth of 
the necessity of HARS inhibition to confer MSC sensitivity.  This will help to 
ascertain HARS’s role as a broadly-relevant ‘druggable’ target.  Furthermore, 3D 
spheroid assays could identify whether the HARS RNAi:MSC combinatorial effect 
is amplified in 3D culture.  
It is currently unclear whether either the structural or enzymatic properties of 
HARS are critical for HCT116 survival when treated with MSC.  In order to 
understand the mechanism of synergy of MSC with the loss-of-function of HARS, 
HARS inducible shRNA knockout cell lines could be generated, and the ability of 
wild-type or mutant (e.g. kinase dead) HARS to rescue RNAi:MSC synthetic 
lethality elucidated.  If HARS enzymatic activity were to be shown to be critical in 
maintaining cells viability in the presence of MSC, the rational design of HARS 
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inhibitors could be conducted (based on the knowledge of HARS’s active site).  
Alternatively a high-throughput screen for HARS inhibitors could be carried out 
using compound libraries.  It is predicted that any HARS inhibitors 
created/identified would improve the potency of MSC when used in combination, 
and may potentially broaden the panel of patients that would benefit from 
treatment with MSC.  
Additionally, it would be useful to know what effects MSC has on HARS (if any), 
to determine how its function may be altered (and hence providing further 
information that may help understanding of the resulting biology, i.e. viability 
reduction).  For example, determination of MSC-dependent changes in HARS 
phosphorylation by mass spectrometry may provide insights into the viability 
reduction mechanism. 
 
Serine/threonine-protein kinase B-raf 
A further significant hit was the serine/threonine protein kinase, BRAF.  One of 
three Raf kinases, BRAF functions as part of the Ras/MAP (Mitogen-activated 
protein) kinase signalling pathway to phosphorylate MEK (MAP kinase kinase), 
thus it has a key role in the regulation of downstream Ras/MAPK target genes.  
RAF kinases are critical to cellular function, and defects in BRAF are found in a 
wide range of cancers, including colorectal cancer.  Despite the Ras/MAPK 
activation process being tightly regulated by multiple phosphatases and kinases, 
an activation mutation of BRAF (V600E) is commonly seen in many cancer 
subtypes (Davies et al., 2002). 
In the cDNA screen, the identification of Medaka HRAS and KRAS ability to 
super-activate TCF-dependent transcription complemented the previous 
identification of HRAS and KRAS in Jamie Freeman’s Xenopus tropicalis cDNA 
screen (Freeman, 2008).  The determination of synergistic interactions between 
Wnt and Ras/MAPK signalling was in line with studies showing that Ras/MAPK 
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signalling can modulate Wnt/!-catenin signalling, and may be essential for the 
expression of Wnt target genes and tumour progression in colorectal cancer (Kim 
et al., 2007; Phelps et al., 2009). 
Of the three Raf kinases only BRAF was determined to have synergistic 
interaction with MSC, although a manual search of the esiRNA:MSC interaction 
dataset showed that ARAF also exhibited MSC dependent interaction (but this 
was not significant enough to pass the selection criteria; see Appendix 7).  
Despite BRAF RNAi:MSC only reducing HCT116 viability by ~10%, this result 
was highly reproducible and this clear evidence of synergy was mirrored in BRAF 
inhibitor investigations.  Interactions were probed further using compound-
compound assays, assessing the interaction of MSC with the highly selective 
BRAF inhibitor (against both wild-type and mutant), RAF265, in HCT116 cells.  
RAF265 (at 1µM) synergised reproducibly with MSC, albeit a relatively high 
concentration of 2.5µM MSC in HCT116 cells (Figure 29; 200 times the 7df3 
TCF-reporter IC50, but lower than RAF265 inhibitor cellular IC50 of 5 and 10µM in 
HT29 and MDAMB231 cells respectively (Mordant et al., 2010)), with synergy 
also evident in Ls174T cells (Figure 30).  Interestingly, three other BRAF 
inhibitors and two MEK inhibitors (that act downstream of BRAF in the MAPK 
pathway) did not show synergy (data not shown).  The reason for this is unclear 
but may be related to the specificity of RAF265, since it is postulated to be highly 
wild-type BRAF specific with lower mutant kinase specificity.  Further studies are 
required to determine the biology of this response since RAF265 also targets 
VEGFR2 (and CRAF to a lesser extent), thus the ‘pan-inhibitory’ activity of the 
compound may be contributing to its combinatorial efficacy with MSC.  The 
observation that some RAF inhibitors show a paradoxic activation of the 
Ras/MAPK, pathway particularly when Ras is mutant (as with HCT116 and 
Ls174T cells) due the ability of the inhibitors to induce BRAF-CRAF-dimer 
formation and MEK activation (Baljuls et al., 2013), is also an interesting one.  
Further studies will be required to investigate whether RAF265 actually activates 
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Raf-MAPK signalling as part of its ability to co-operate with MSC in reducing 
tumour cell viability. 
Novel cDNA regulators of Wnt signalling 
Fourteen cDNAs were shown to super-activate TCF-dependent transcription in 
the presence of Wnt signalling co-activation, of which SezL2 (seizure related 6 
homolog (mouse)-like 2), IKZF1 (Ikaros family zinc finger 1) and TGIF1 (TGFB-
induced factor homeobox 1) currently have no known links to Wnt signalling.  
Both TGIF1 and IKZF1 act at the transcriptional level, although their potential 
function in the context of Wnt signalling is unclear as TGIF1 is a transcriptional 
co-repressor (Bertolino et al., 1995), and IKZF1 both activates and inhibits 
transcription (Kim et al., 1999).  Little is known about Sez6L2, other than it is 
likely to be expressed exclusively in the brain where it may contribute to a 
specialised endoplasmic reticulum function within neurons (by comparison with 
its murine homologue (Miyazaki et al., 2006)). One additional hit of interest was 
HMGXB4 (HMG box domain containing 4).  This non-histone chromosomal 
protein is believed to negatively regulate Wnt/!-catenin signalling during 
development (by similarity to the Xenopus laevis homologue, (Yamada et al., 
2003)), thus why its overexpression in the HEK-based context activates TCF-
dependent transcription is unclear.  Further work is required to determine the 
mechanism of action of these activators within the Wnt/!-catenin signalling 
context. 
Of the fourteen cDNAs determined to super-activate TCF-dependent 
transcription in the presence of Wnt signalling co-activation, eight induced activity 
independently of pathway stimulation by "NLRP (including the putatively labelled 
‘HMGB2*’ hit previously described).  Four of the hits were known Wnt signalling 
activators (Wnt-1, !-catenin, KRAS and HRAS) with three, including the 
transcription factor DMRTA2, having little known association with Wnt signalling.  
It had been shown that Wnt/!-catenin signalling positively regulates the 
expression of DMRTA2 during the development of the cerebral cortex (Konno et 
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al., 2012), however whether DMRTA2 has any direct effect on Wnt signalling in 
other contexts is unknown.  The work presented here would suggest that 
DMRTA2 might positively regulate TCF-dependent transcription by means of a 
feedback loop, however this would require further investigation. 
The ability of MSC to disrupt the activating ability of the cDNA hits (both with and 
without "NLRP co-activation) was determined.  As expected, all "NLRP-
dependent interactions were inhibited by MSC since MSC is able to block 
transcription induced by "NLRP alone.  Significantly, MSC was unable to disrupt 
GBX1 and HMGB2 induced "NLRP-independent TCF-dependent transcription.  
Overexpression of these transcription factors conferred resistance to the CDK8 
inhibitor, suggesting that their transcriptional regulation functions may not require 
Mediator complex co-activation.  Again, there is limited information describing the 
wider activity of these transcription factors; GBX1 has been shown to be 
essential for Wnt/!-catenin dependent regulation of neural patterning in zebrafish 
embryos (Rhinn et al., 2009), and HMGB2 enhances Wnt signalling in murine 
embryos and is essential for forelimb digit development (Itou et al., 2011).  This 
study suggests that GBX1 and HMGB2 might have important roles in MSC 
resistance via the maintenance of Wnt signalling.  For example, overexpression 
of either gene in a clinical context might be regarded as a contra-indication for 
MSC-class therapies.  Further studies of these functions may identify the 
underlying mechanisms by which they induce TCF-dependent transcription. 
 
Overall, novel Wnt pathway regulators and genes that co-operate with MSC were 
identified in two whole genome screens.  The results point to a particularly novel 
area of biology in the role of aminoacyl tRNA synthetases that will be followed up 
in future studies.  In addition, many future avenues of work have been raised that 
could be of benefit to patients in the long term.  Of highest priority may be studies 
that translate the observations here into 3D culture where stem cell function can 
be analysed. 
 165 
Bibliography 
Adler, A.S., McCleland, M.L., Truong, T., Lau, S., Modrusan, Z., Soukup, T.M., 
Roose-Girma, M., Blackwood, E.M., and Firestein, R. (2012). CDK8 Maintains 
Tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res. 72, 
2129–2139. 
Aguilera, O., Fraga, M.F., Ballestar, E., Paz, M.F., Herranz, M., Espada, J., 
García, J.M., Muñoz, A., Esteller, M., and Gonzalez-Sancho, J.M. (2006). 
Epigenetic inactivation of the Wnt antagonist Dickkopf-1 (Dkk-1) gene in human 
colorectal cancer. Oncogene 25, 4116–4121. 
Amado, N.G., Fonseca, B.F., Cerqueira, D.M., Neto, V.M., and Abreu, J.G. 
(2011). Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. 
Life. Sci. 89, 545–554. 
Amit, S. (2002). Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a 
molecular switch for the Wnt pathway. Genes Dev. 16, 1066–1076. 
Angers, S., and Moon, R.T. (2009). Proximal events in Wnt signal transduction. 
Nature Rev. Mol. Cell Biol. 10, 468–477. 
Ashton, G.H., Morton, J.P., Myant, K., Phesse, T.J., Ridgway, R.A., Marsh, V., 
Wilkins, J.A., Athineos, D., Muncan, V., Kemp, R., et al. (2010). Focal adhesion 
kinase is required for intestinal regeneration and tumorigenesis downstream of 
Wnt/c-Myc signaling. Dev. Cell 19, 259–269. 
Bafico, A., Gazit, A., Pramila, T., Finch, P.W., Yaniv, A., et al. (1999). Interaction 
of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor 
suggests alternative mechanisms for FRP inhibition of Wnt signaling. J. Biol. 
Chem. 274, 16180–16187. 
Bafico, A., Liu, G., Goldin, L., Harris, V., and Aaronson, S.A. (2004). An autocrine 
mechanism for constitutive Wnt pathway activation in human cancer cells. 
Cancer Cell 6, 497–506. 
Baljuls, A., Kholodenko, B.N., and Kolch, W. (2013). It takes two to tango - 
signalling by dimeric Raf kinases. Mol. Biosyst. 9, 551–558. 
Bao, R., Christova, T., Song, S., Angers, S., Yan, X., and Attisano, L. (2012). 
Inhibition of tankyrases induces axin stabilization and blocks Wnt signalling in 
breast cancer cells. PLoS ONE 7, e48670. 
Barker, N., Ridgway, R.A., van Es, J.H., van de Wetering, M., Begthel, H., et al. 
(2009). Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 
608–611. 
 166 
Barker, N., van Es, J.H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., 
Haegebarth, A., Korving, J., Begthel, H., Peters, P.J., et al. (2007). Identification 
of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 
1003–1007. 
Barolo, S., and Posakony, J.W. (2002). Three habits of highly effective signaling 
pathways: principles of transcriptional control by developmental cell signaling. 
Genes Dev. 16, 1167–1181. 
Basu, D., Reyes-Mugica, M., and Rebbaa, A. (2012). Role of the Beta catenin 
destruction complex in mediating chemotherapy-induced senescence-associated 
secretory phenotype. PLoS ONE 7, e52188. 
Batlle, E., Henderson, J.T., Beghtel, H., van den Born, M.M., Sancho, E., Huls, 
G., Meeldijk, J., Robertson, J., van de Wetering, M., Pawson, T., et al. (2002). 
beta-catenin and TCF mediate cell positioning in the intestinal epithelium by 
controlling the expression of EphrinB. Cell 111, 251–263. 
Bejsovec, A., and Arias, A.M. (1991). Roles of wingless in patterning the larval 
epidermis of Drosophila. Development 113, 471–485. 
Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D.S., 
Moinard, C., Vasseur-Cognet, M., Kuo, C.J., Kahn, A., Perret, C., et al. (2006). 
Apc tumor suppressor gene is the “zonation-keeper” of mouse liver. Dev. Cell 10, 
759–770. 
Bertolino, E., Reimund, B., Wildt-Perinic, D., and Clerc, R.G. (1995). A novel 
homeobox protein which recognizes a TGT core and functionally interferes with a 
retinoid-responsive motif. J. Biol. Chem. 270, 31178–31188. 
Bertrand, F.E., Angus, C.W., Partis, W.J., and Sigounas, G. (2012). 
Developmental pathways in colon cancer: Crosstalk between WNT, BMP, 
Hedgehog and Notch. Cell Cycle 11, 4344–4351. 
Bhat, R.A., Stauffer, B., Komm, B.S., and Bodine, P.V.N. (2007). Structure-
function analysis of secreted frizzled-related protein-1 for its Wnt antagonist 
function. J. Cell. Biochem. 102, 1519–1528. 
Biechele, T.L., Camp, N.D., Fass, D.M., Kulikauskas, R.M., Robin, N.C., White, 
B.D., Taraska, C.M., Moore, E.C., Muster, J., Karmacharya, R., et al. (2010). 
Chemical-genetic screen identifies riluzole as an enhancer of Wnt/"-catenin 
signaling in melanoma. Chem. Biol. 17, 1177–1182. 
Bilic, J., Huang, Y.L., Davidson, G., Zimmermann, T., Cruciat, C.M., et al. (2007). 
Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 
phosphorylation. Science 316, 1619–1622. 
 
 167 
Birmingham, A., Selfors, L.M., Forster, T., Wrobel, D., Kennedy, C.J., Shanks, E., 
Santoyo-Lopez, J., Dunican, D.J., Long, A., Kelleher, D., et al. (2009). Statistical 
methods for analysis of high-throughput RNA interference screens. Nature Meth. 
6, 569–575. 
Bishop-Bailey, D., and Warner, T.D. (2003). PPAR( ligands induce prostaglandin 
production in vascular smooth muscle cells: indomethacin acts as a peroxisome 
proliferator-activated receptor-( antagonist.  FASEB J.17, 1925–1927. 
Bjerknes, M., and Cheng, H. (1981a). The stem-cell zone of the small intestinal 
epithelium. I. Evidence from Paneth cells in the adult mouse. American J. Anat. 
160, 51–63. 
Bjerknes, M., and Cheng, H. (1981b). The stem-cell zone of the small intestinal 
epithelium. II. Evidence from paneth cells in the newborn mouse.  American J. 
Anat. 160, 65–75. 
Blumenthal, A., Ehlers, S., Lauber, J., Buer, J., Lange, C., Goldmann, T., Heine, 
H., Brandt, E., and Reiling, N. (2006). The Wingless homolog WNT5A and its 
receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells 
induced by microbial stimulation. Blood 108, 965–973. 
Bonfils, G., Jaquenoud, M., Bontron, S., Ostrowicz, C., Ungermann, C., and De 
Virgilio, C. (2012). Leucyl-tRNA synthetase controls TORC1 via the EGO 
complex. Mol. Cell 46, 105–110. 
Bourhis, E., Wang, W., Tam, C., Hwang, J., Zhang, Y., Spittler, D., Huang, O.W., 
Gong, Y., Estevez, A., Zilberleyb, I., et al. (2011). Wnt antagonists bind through a 
short peptide to the first "-propeller domain of LRP5/6. Structure 19, 1433–1442. 
Boutros, M., Brás, L.P., and Huber, W. (2006). Analysis of cell-based RNAi 
screens. Genome Biol. 7, R66. 
Brennan, K., Gonzalez-Sancho, J.M., Castelo-Soccio, L.A., Howe, L.R., and 
Brown, A.M. (2004). Truncated mutants of the putative Wnt receptor LRP6/Arrow 
can stabilize beta-catenin independently of Frizzled proteins. Oncogene 23, 
4873–4884. 
Brideau, C., Gunter, B., Pikounis, B., and Liaw, A. (2003). Improved statistical 
methods for hit selection in high-throughput screening. J. Biomol. Screen. 8, 
634–647. 
Brott, B.K., and Sokol, S.Y. (2002). Regulation of Wnt-LRP signaling by distinct 
domains. MCB 22, 6100–6110. 
 
 
 168 
Buchert, M., Athineos, D., Abud, H.E., Burke, Z.D., Faux, M.C., Samuel, M.S., 
Jarnicki, A.G., Winbanks, C.E., Newton, I.P., Meniel, V.S., et al. (2010). Genetic 
dissection of differential signaling threshold requirements for the Wnt/beta-
catenin pathway in vivo. PLoS Genet. 6, e1000816. 
Buchholz, F., Kittler, R., Slabicki, M., and Theis, M. (2006). Enzymatically 
prepared RNAi libraries. Nature Methods 3, 696–700. 
Cadigan, K.M., and Waterman, M.L. (2013). TCF/LEFs and Wnt Signaling in the 
Nucleus. Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van Amerongen, 105–
126. 
Caldwell, G.M., Jones, C., Gensberg, K., Jan, S., Hardy, R.G., et al. (2004). The 
Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 64, 883–888. 
Camargo, L.M., Collura, V., Rain, J.C., Mizuguchi, K., Hermjakob, H., Kerrien, S., 
Bonnert, T.P., Whiting, P.J., and Brandon, N.J. (2007). Disrupted in 
Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes 
and a potential synaptic basis for schizophrenia. Mol. Psychiatry 12, 74–86. 
Cancer Research UK. www.cancerresearchuk.org 
Carmona-Saez, P., Chagoyen, M., Tirado, F., Carazo, J.M., and Pascual-
Montano, A. (2007). GENECODIS: a web-based tool for finding significant 
concurrent annotations in gene lists. Genome Biol. 8, R3. 
Carrera, I., Janody, F., Leeds, N., Duveau, F., and Treisman, J.E. (2008). 
Pygopus activates Wingless target gene transcription through the mediator 
complex subunits Med12 and Med13. PNAS 105, 6644–6649. 
Carreras Puigvert, J., Stechow, von, L., Siddappa, R., Pines, A., Bahjat, M., 
Haazen, L.C.J.M., Olsen, J.V., Vrieling, H., Meerman, J.H.N., Mullenders, L.H.F., 
et al. (2013). Systems biology approach identifies the kinase csnk1a1 as a 
regulator of the DNA damage response in embryonic stem cells. Sci. Signal. 6, 
1–14. 
Casas-Selves, M., Kim, J., Zhang, Z., Helfrich, B.A., Gao, D., Porter, C.C., 
Scarborough, H.A., Bunn, P.A., Chan, D.C., Tan, A.C., et al. (2012). Tankyrase 
and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. 
Cancer Res. 72, 4154–4164. 
Castellone, M.D., Teramoto, H., Williams, B.O., Druey, K.M., and Gutkind, J.S. 
(2005). Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-
Axin-{beta}-catenin signaling axis. Science 310, 1504–1510. 
Cavallo, R.A., Cox, R.T., Moline, M.M., Roose, J., Polevoy, G.A., et al. (1998). 
Drosophila Tcf and Groucho interact to repress Wingless signalling activity. 
Nature 395, 604–608. 
 169 
Chen, G., Fernandez, J., Mische, S., and Courey, A.J. (1999). A functional 
interaction between the histone deacetylase Rpd3 and the corepressor groucho 
in Drosophila development. Genes Dev. 13, 2218–2230. 
Chen, S., Bubeck, D., MacDonald, B.T., Liang, W.X., Mao, J.H., Malinauskas, T., 
Llorca, O., Aricescu, A.R., Siebold, C., He, X., et al. (2011). Structural and 
functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Dev. 
Cell 21, 848–861. 
Chen, T., Li, M., Ding, Y., Zhang, L.S., Xi, Y., et al. (2009). Identification of zinc-
finger BED domain-containing 3 (Zbed3) as a novel axin-interacting protein that 
activates Wnt/beta-catenin signaling. J. Biol. Chem. 284, 6683–6689. 
Clarke, M.F., and Fuller, M. (2006). Stem cells and cancer: two faces of eve. Cell 
124, 1111–1115. 
Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 
127, 469–480. 
Clevers, H., and Nusse, R. (2012). Wnt/beta-catenin signaling and disease. Cell 
149, 1192–1205. 
Conaway, R.C., Sato, S., Tomomori-Sato, C., Yao, T., and Conaway, J.W. 
(2005). The mammalian Mediator complex and its role in transcriptional 
regulation. TIBS 30, 250–255. 
Cole, M.F., Johnstone, S.E., Newman, J.J., Kagey, M.H., and Young, R.A. (2008). 
Tcf3 is an integral component of the core regulatory circuitry of embryonic stem 
cells. Genes Dev. 22, 746–755. 
Collu, G.M., Meurette, O., and Brennan, K. (2009). Is there more to Wnt 
signalling in breast cancer than stabilisation of "-catenin? Breast Cancer Res. 11, 
105–106. 
Coombs, G.S., Schmitt, A.A., Canning, C.A., Alok, A., Low, I.C.C., Banerjee, N., 
Kaur, S., Utomo, V., Jones, C.M., Pervaiz, S., et al. (2012). Modulation of 
Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with 
therapeutic efficacy in genetically engineered mouse models of cancer. 
Oncogene 31, 213–225. 
Cox, L.S., and Lane, D.P. (1995). Tumour suppressors, kinases and clamps: how 
p53 regulates the cell cycle in response to DNA damage. Bioessays 17, 501–
508. 
Cruciat, C.M., and Niehrs, C. (2013). Secreted and Transmembrane Wnt 
Inhibitors and Activators. Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van 
Amerongen, 39-64. 
 170 
Cselenyi, C.S., Jernigan, K.K., Tahinci, E., Thorne, C.A., Lee, L.A., and Lee, E. 
(2008). LRP6 transduces a canonical Wnt signal independently of Axin 
degradation by inhibiting GSK3's phosphorylation of beta-catenin. PNAS 105, 
8032–8037. 
Curtin, J.C., and Lorenzi, M.V. (2010). Drug discovery approaches to target Wnt 
signaling in cancer stem cells. Oncotarget 1, 563–577. 
Dajani, R., Fraser, E., Roe, S.M., Yeo, M., Good, V.M., Thompson, V., Dale, T.C., 
and Pearl, L.H. (2003). Structural basis for recruitment of glycogen synthase 
kinase 3beta to the axin-APC scaffold complex. EMBO J. 22, 494–501. 
Daniels, D.L., and Weis, W.I. (2005). Beta-catenin directly displaces 
Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. 
Nature Struct. Mol. Biol. 12, 364–371. 
Dann, C.E., Hsieh, J.C., Rattner, A., Sharma, D., Nathans, J., and Leahy, D.J. 
(2001). Insights into Wnt binding and signalling from the structures of two 
Frizzled cysteine-rich domains. Nature 412, 86–90. 
DasGupta, R., Kaykas, A., Moon, R.T., and Perrimon, N. (2005). Functional 
genomic analysis of the Wnt-wingless signaling pathway. Science 308, 826–833. 
Davidson, G., Wu, W., Shen, J., Bilic, J., Fenger, U., Stannek, P., Glinka, A., and 
Niehrs, C. (2005). Casein kinase 1 gamma couples Wnt receptor activation to 
cytoplasmic signal transduction. Nature 438, 867–872. 
Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., 
Woffendin, H., Garnett, M.J., Bottomley, W., et al. (2002). Mutations of the BRAF 
gene in human cancer. Nature 417, 949–954. 
De Ferrari, G.V., and Moon, R.T. (2006). The ups and downs of Wnt signaling in 
prevalent neurological disorders. Oncogene 25, 7545–7553. 
de Sousa, E.M.F., Vermeulen, L., Richel, D., and Medema, J.P. (2011). 
Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res. 17, 647–
653. 
De, A. (2011). Wnt/Ca2+ signaling pathway: a brief overview. Acta Biochim. 
Biophys. Sin. 43, 745–756. 
DeAlmeida, V.I., Miao, L., Ernst, J.A., Koeppen, H., Polakis, P., and Rubinfeld, B. 
(2007). The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of 
teratocarcinomas in vivo. Cancer Res. 67, 5371–5379. 
Devenport, D., and Fuchs, E. (2008). Planar polarization in embryonic epidermis 
orchestrates global asymmetric morphogenesis of hair follicles. Nature Cell Biol. 
10, 1257–1268. 
 171 
Donner, A.J., Ebmeier, C.C., Taatjes, D.J., and Espinosa, J.M. (2010). CDK8 is a 
positive regulator of transcriptional elongation within the serum response network. 
Nature Struct. Mol. Biol. 17, 194–201. 
Dorrell, M.I., Aguilar, E., Scheppke, L., Barnett, F.H., and Friedlander, M. (2007). 
Combination angiostatic therapy completely inhibits ocular and tumor 
angiogenesis. PNAS 104, 967–972. 
Echeverri, C.J., Beachy, P.A., Baum, B., Boutros, M., Buchholz, F., Chanda, S.K., 
Downward, J., Ellenberg, J., Fraser, A.G., Hacohen, N., et al. (2006). Minimizing 
the risk of reporting false positives in large-scale RNAi screens. Nature Meth. 3, 
777–779. 
Elder, D.J., and Paraskeva, C. (1998). COX-2 inhibitors for colorectal cancer. 
Nature Medicine 4, 392–393. 
Emami, K.H., Nguyen, C., Ma, H., Kim, D.H., Jeong, K.W., Eguchi, M., Moon, 
R.T., Teo, J.L., Oh, S.W., Kim, H.Y., et al. (2004). A small molecule inhibitor of 
beta-catenin/cyclic AMP response element-binding protein transcription. PNAS 
101, 12682–12687. 
Ettarh, R., Cullen, A., and Calamai, A. (2010). NSAIDs and cell proliferation in 
colorectal cancer. Pharmaceuticals 3, 2007–2021. 
Ettenberg, S.A., Charlat, O., Daley, M.P., Liu, S., Vincent, K.J., Stuart, D.D., 
Schuller, A.G., Yuan, J., Ospina, B., and Green, J. (2010). Inhibition of 
tumorigenesis driven by different Wnt proteins requires blockade of distinct 
ligand-binding regions by LRP6 antibodies. PNAS 107, 15473–15478. 
Ewan, K.B., and Dale, T.C. (2008). The potential for targeting oncogenic 
Wnt/beta-catenin signaling in therapy. Curr. Drug Targets 9, 532–547. 
Ewan, K., Pajak, B., Stubbs, M., Todd, H., Barbeau, O., Quevedo, C., Botfield, H., 
Young, R., Ruddle, R., Samuel, L., et al. (2010). A useful approach to identify 
novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res. 70, 
5963–5973. 
Fallahi-Sichani, M., Honarnejad, S., Heiser, L.M., Gray, J.W., and Sorger, P.K. 
(2013). Metrics other than potency reveal systematic variation in responses to 
cancer drugs. Nature Chem. Biol. Advance online publication 1-9 
Fanto, M., and McNeill, H. (2004). Planar polarity from flies to vertebrates. J. of 
Cell Sci. 117, 527–533. 
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N.J., Johnson, D.A., Richardson, T.B., 
Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the 
DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 
917–921. 
 172 
Fiedler, M., Sanchez-Barrena, M.J., Nekrasov, M., Mieszczanek, J., Rybin, V., 
Muller, J., Evans, P., and Bienz, M. (2008). Decoding of methylated histone H3 
tail by the Pygo-BCL9 Wnt signaling complex. Mol. Cell 30, 507–518. 
Firestein, R., Bass, A.J., Kim, S.Y., Dunn, I.F., Silver, S.J., Guney, I., Freed, E., 
Ligon, A.H., Vena, N., Ogino, S., et al. (2008). CDK8 is a colorectal cancer 
oncogene that regulates beta-catenin activity. Nature 455, 547–551. 
Firestein, R., and Hahn, W.C. (2009). Revving the Throttle on an oncogene: 
CDK8 takes the driver seat. Cancer Res. 69, 7899–7901. 
Fodde, R., Smits, R., and Clevers, H. (2001). APC, signal transduction and 
genetic instability in colorectal cancer. Nature Rev. Cancer 1, 55–67. 
Freeman, J. (2008) Identification of a network of functional interactions regulating 
Wnt signalling. Cardiff University. 
Fujishita, T., Aoki, K., Lane, H., Aoki, M., and Taketo, M.M. (2008). Inhibition of 
the mTORC1 pathway suppresses intestinal polyp formation and reduces 
mortality in Apc716 mice. PNAS 105, 13544–13549. 
Furumoto, T., Tanaka, A., Ito, M., Malik, S., Hirose, Y., Hanaoka, F., and 
Ohkuma, Y. (2007). A kinase subunit of the human mediator complex, CDK8, 
positively regulates transcriptional activation. Genes Cells 12, 119–132. 
Galbraith, M.D., Donner, A.J., and Espinosa, J.M. (2010). CDK8: a positive 
regulator of transcription. Transcription 1, 4–12. 
Galceran, J., Farinas, I., Depew, M.J., Clevers, H., and Grosschedd, R. (1999). 
Wnt3a(-/-) - phenotype and limb deficiency in Lef1(-/-)Tcf1(-/-)mice. Genes Dev. 13, 
709–717. 
Garber, K. (2009). Drugging the Wnt pathway: problems and progress. JNCI 101, 
548–550. 
Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, 
Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012). ChEMBL: a 
large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, 
D1100–D1107. 
Gerbe, F., van Es, J.H., Makrini, L., Brulin, B., Mellitzer, G., Robine, S., 
Romagnolo, B., Shroyer, N.F., Bourgaux, J.F., Pignodel, C., et al. (2011). Distinct 
ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type 
in the intestinal epithelium. J. of Cell Biol. 192, 767–780. 
Ghogomu, S.M., van Venrooy, S., Ritthaler, M., Wedlich, D., and Gradl, D. (2006). 
HIC-5 is a novel repressor of lymphoid enhancer factor/T-cell factor-driven 
transcription. J. Biol. Chem. 281, 1755–1764. 
 173 
Gong, Y., Bourhis, E., Chiu, C., Stawicki, S., DeAlmeida, V.I., Liu, B.Y., 
Phamluong, K., Cao, T.C., Carano, R.A.D., Ernst, J.A., et al. (2010). Wnt 
isoform-specific interactions with coreceptor specify inhibition or potentiation of 
signaling by LRP6 antibodies. PLoS ONE 5, e12682. 
Gonsalves, F.C., Klein, K., Carson, B.B., Katz, S., Ekas, L.A., Evans, S., 
Nagourney, R., Cardozo, T., Brown, A.M.C., and DasGupta, R. (2011). An RNAi-
based chemical genetic screen identifies three small-molecule inhibitors of the 
Wnt/wingless signaling pathway. PNAS 108, 5954–5963. 
Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., 
Joslyn, G., Stevens, J., Spirio, L., Robertson, M., et al. (1991). Identification and 
characterization of the familial adenomatous polyposis coli gene. Cell 66, 589–600. 
Grosch, S., Tegeder, I., Niederberger, E., Bräutigam, L., and Geisslinger, G. 
(2001). COX-2 independent induction of cell cycle arrest and apoptosis in colon 
cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J. 15, 2742–2744. 
Grossmann, T.N., Yeh, J.T.H., Bowman, B.R., Chu, Q., Moellering, R.E., and 
Verdine, G.L. (2012). Inhibition of oncogenic Wnt signaling through direct 
targeting of "-catenin. PNAS 109, 17942–17947. 
Gurney, A., Axelrod, F., Bond, C.J., Cain, J., Chartier, C., Donigan, L., Fischer, 
M., Chaudhari, A., Ji, M., Kapoun, A.M., et al. (2012). Wnt pathway inhibition via 
the targeting of Frizzled receptors results in decreased growth and tumorigenicity 
of human tumors. PNAS 109, 11717–11722. 
Ha, N.C., Tonozuka, T., Stamos, J.L., Choi, H.J., and Weis, W.I. (2004). 
Mechanism of phosphorylation-dependent binding of APC to "-catenin and its 
role in "-catenin degradation. Mol. Cell 15, 511–521. 
Hagen, T., Di Daniel, E., Culbert, A.A., and Reith, A.D. (2002). Expression and 
characterization of GSK-3 mutants and their effect on beta-catenin 
phosphorylation in intact cells. J. Biol. Chem. 277, 23330–23335. 
Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B., and 
King, M.C. (1990). Linkage of early-onset familial breast cancer to chromosome 
17q21. Science 250, 1684–1689. 
Han, J.M., Jeong, S.J., Park, M.C., Kim, G., Kwon, N.H., Kim, H.K., Ha, S.H., 
Ryu, S.H., and Kim, S. (2012). Leucyl-tRNA synthetase is an intracellular leucine 
sensor for the mTORC1-signaling pathway. Cell 149, 410–424. 
Handeli, S., and Simon, J.A. (2008). A small-molecule inhibitor of Tcf/beta-
catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol. 
Cancer Ther. 7, 521–529. 
 174 
Harrison-Uy, S.J., and Pleasure, S.J. (2012). Wnt signaling and forebrain 
development. Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van Amerongen, 
297-307. 
Hart, M., Concordet, J.P., Lassot, I., Albert, I., del los Santos, R., Durand, H., 
Perret, C., Rubinfeld, B., Margottin, F., Benarous, R., et al. (1999). The F-box 
protein beta-TrCP associates with phosphorylated beta-catenin and regulates its 
activity in the cell. Curr. Biol. 9, 207–10. 
Havsteen, B.H. (2002). The biochemistry and medical significance of the 
flavonoids. Pharmacol. Ther. 96, 67–202. 
He, B., Reguart, N., You, L., Mazieres, J., Xu, Z., et al. (2005). Blockade of Wnt-1 
signaling induces apoptosis in human colorectal cancer cells containing 
downstream mutations. Oncogene 24, 3054–3058. 
He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, 
P.J., Vogelstein, B., and Kinzler, K.W. (1998). Identification of c-MYC as a target 
of the APC pathway. Science 281, 1509–1512. 
He, X., He, X., Semenov, M., Semenov, M., Tamai, K., Tamai, K., Zeng, X., and 
Zeng, X. (2004). LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin 
signaling: arrows point the way. Development 131, 1663–1677. 
He, X., Saint-Jeannet, J.P., Wang, Y., Nathans, J., Dawid, I., and Varmus, H. 
(1997). A member of the Frizzled protein family mediating axis induction by Wnt-
5A. Science 275, 1652–1654. 
He, X.C., Yin, T., Grindley, J.C., Tian, Q., Sato, T., Tao, W.A., Dirisina, R., 
Porter-Westpfahl, K.S., Hembree, M., Johnson, T., et al. (2007). PTEN-deficient 
intestinal stem cells initiate intestinal polyposis. Nature Genet. 39, 189–198. 
Henderson, W.R., Chi, E.Y., Ye, X., Nguyen, C., Tien, Y.T., Zhou, B., Borok, Z., 
Knight, D.A., and Kahn, M. (2010). Inhibition of Wnt/"-catenin/CREB binding 
protein (CBP) signaling reverses pulmonary fibrosis. PNAS 107, 14309–14314. 
Hengartner, C.J., Myer, V.E., Liao, S.M., Wilson, C.J., Koh, S.S., and Young, R.A. 
(1998). Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-
dependent kinases. Mol. Cell 2, 43–53. 
Hernando, E., Nahle, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., et al. 
(2004). Rb inactivation promotes genomic instability by uncoupling cell cycle 
progression from mitotic control. Nature 430, 797–802. 
Hirata, A., Utikal, J., Yamashita, S., Aoki, H., Watanabe, A., Yamamoto, T., 
Okano, H., Bardeesy, N., Kunisada, T., Ushijima, T., et al. (2013). Dose-
dependent roles for canonical Wnt signalling in de novo crypt formation and cell 
cycle properties of the colonic epithelium. Development 140, 66–75. 
 175 
Hoeppner, L.H., Secreto, F.J., and Westendorf, J.J. (2009). Wnt signaling as a 
therapeutic target for bone diseases. Expert Opin. Ther. Targets 13, 485–496. 
Hsieh, J.C., Kodjabachian, L., Rebbert, M.L., Rattner, A., Smallwood, P.M., 
Samos, C.H., Nusse, R., Dawid, I.B., and Nathans, J. (1999). A new secreted 
protein that binds to Wnt proteins and inhibits their activities. Nature 398, 431–
436. 
Hu, T., and Li, C. (2010). Convergence between Wnt-"-catenin and EGFR 
signaling in cancer. Mol. Cancer 9, 236. 
Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009a). Systematic and 
integrative analysis of large gene lists using DAVID bioinformatics resources. 
Nature Protoc. 4, 44–57. 
Huang, S.M.A., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A., 
Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009b). Tankyrase 
inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620. 
Ibb, M. (2004). Aminoacyl-tRNAs: setting the limits of the genetic code. Genes 
Dev. 18, 731–738. 
Ingenuity Pathway Analysis. www.ingenuity.com 
Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Waterman, M., 
Shibuya, H., Moon, R.T., Ninomiya-Tsuji, J., and Matsumoto, K. (2003). The 
TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-
5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol. Cell. Biol. 23, 
131–139. 
Itasaki, N., and Hoppler, S. (2009). Crosstalk between Wnt and bone 
morphogenic protein signaling: A turbulent relationship. Dev. Dyn. 239, 16–33. 
Itou, J., Taniguchi, N., Oishi, I., Kawakami, H., Lotz, M., and Kawakami, Y. 
(2011). HMGB factors are required for posterior digit development through 
integrating signaling pathway activities. Dev. Dyn. 240, 1151–1162. 
Janda, C.Y., Waghray, D., Levin, A.M., Thomas, C., and Garcia, K.C. (2012). 
Structural basis of Wnt recognition by Frizzled. Science. 337, 259–263. 
Janssen, K.P., Alberici, P., Fsihi, H., Gaspar, C., Breukel, C., Franken, P., Rosty, 
C., Abal, M., Marjou, El, F., Smits, R., et al. (2006). APC and oncogenic KRAS 
are synergistic in enhancing Wnt signaling in intestinal tumor formation and 
progression. Gastroent. 131, 1096–1109. 
 
 
 176 
Jarde, T., Evans, R.J., McQuillan, K.L., Parry, L., Feng, G.J., Alvares, B., Clarke, 
A.R., and Dale, T.C. (2013). In vivo and in vitro models for the therapeutic 
targeting of Wnt signaling using a Tet-O%N89"-catenin system. Oncogene 32, 
883–893. 
Johnson, E.B., Hammer, R.E., and Herz, J. (2005). Abnormal development of the 
apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. Hum. Mol. 
Genet. 14, 3523–3538. 
Joslyn, G., Carlson, M., Thliveris, A., Albertsen, H., Gelbert, L., Samowitz, W., 
Groden, J., Stevens, J., Spirio, L., and Robertson, M. (1991). Identification of 
deletion mutations and three new genes at the familial polyposis locus. Cell 66, 
601–613. 
Kapoor, A., Goldberg, M.S., Cumberland, L.K., Ratnakumar, K., Segura, M.F., 
Emanuel, P.O., Menendez, S., Vardabasso, C., Leroy, G., Vidal, C.I., et al. 
(2010). The histone variant macroH2A suppresses melanoma progression 
through regulation of CDK8. Nature 468, 1105–1109. 
Kawamoto, S.A., Coleska, A., Ran, X., Yi, H., Yang, C.Y., and Wang, S. (2012). 
Design of triazole-stapled BCL9 #-helical peptides to target the "-catenin/B-cell 
CLL/lymphoma 9 (BCL9) protein–protein interaction. J. Med. Chem. 55, 1137–
1146. 
Kestler, H.A., and Kuhl, M. (2008). From individual Wnt pathways towards a Wnt 
signalling network. PTRSL 363, 1333–1347. 
Kikuchi, A., Yamamoto, H., and Sato, A. (2009). Selective activation mechanisms 
of Wnt signaling pathways. TICB 19, 119–129. 
Kim, C.H., Oda, T., Itoh, M., Jiang, D., Artinger, K.B., Chandrasekharappa, S.C., 
Driever, W., and Chitnis, A.B. (2000). Repressor activity of Headless/Tcf3 is 
essential for vertebrate head formation. Nature 407, 913–6. 
Kim, D., Kim, D., Rath, O., Rath, O., Kolch, W., Kolch, W., Cho, K.H., and Cho, 
K.H. (2007). A hidden oncogenic positive feedback loop caused by crosstalk 
between Wnt and ERK pathways. Oncogene 26, 4571–4579. 
Kim, J., Sif, S., Jones, B., Jackson, A., Koipally, J., Heller, E., Winandy, S., Viel, 
A., Sawyer, A., Ikeda, T., et al. (1999). Ikaros DNA-binding proteins direct 
formation of chromatin remodeling complexes in lymphocytes. Immunity 10, 345–
355. 
Kim, S., Xu, X., Hecht, A., and Boyer, T.G. (2006). Mediator is a transducer of 
Wnt/beta-catenin signaling. J. Biol. Chem. 281, 14066–14075. 
Kimelman, D., and Xu, W. (2006). beta-catenin destruction complex: insights and 
questions from a structural perspective. Oncogene 25, 7482–7491. 
 177 
Kinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary colorectal 
cancer. Cell 87, 159–170. 
Kinzler, K.W., Nilbert, M.C., Su, L.K., Vogelstein, B., Bryan, T.M., Levy, D.B., 
Smith, K.J., Preisinger, A.C., Hedge, P., McKechnie, D., et al. (1991). 
Identification of FAP locus genes from chromosome 5q21. Science 253, 661–665. 
Kittler, R., Putz, G., Pelletier, L., Poser, I., Heninger, A.K., Drechsel, D., Fischer, 
S., Konstantinova, I., Habermann, B., Grabner, H., et al. (2004). An 
endoribonuclease-prepared siRNA screen in human cells identifies genes 
essential for cell division. Nature 432, 1036–1040. 
Klampfer, L. (2008). The role of signal transducers and activators of transcription 
in colon cancer. Front. Biosci. 13, 2888–2899. 
Klein, P.S. (2012). GSK-3 and Wnt signaling in neurogenesis and bipolar 
disorder. Front. Mol. Neurosci. 5, 1–13. 
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., 
Mak, C., Neveu, V., et al. (2011). DrugBank 3.0: a comprehensive resource for 
“omics” research on drugs. Nucleic Acids Res. 39, D1035–D1041. 
Knuesel, M.T., Meyer, K.D., Donner, A.J., Espinosa, J.M., and Taatjes, D.J. 
(2009). The human CDK8 subcomplex is a histone kinase that requires Med12 
for activity and can function independently of mediator. Mol. Cell. Biol. 29, 650–
661. 
Knuesel, M.T., Meyer, K.D., Bernecky, C., and Taatjes, D.J. (2009). The human 
CDK8 subcomplex is a molecular switch that controls Mediator coactivator 
function. Genes Dev. 23, 439–451. 
Koles, K., and Budnik, V. (2012). Wnt Signaling in neuromuscular junction 
development. Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van Amerongen, 
373-394. 
Kongkanuntn, R., Bubb, V.J., Sansom, O.J., Wyllie, A.H., Harrison, D.J., and 
Clarke, A.R. (1999). Dysregulated expression of beta-catenin marks early 
neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 
deficient mice. Oncogene 18, 7219–7225. 
Konno, D., Iwashita, M., Satoh, Y., Momiyama, A., Abe, T., Kiyonari, H., and 
Matsuzaki, F. (2012). The mammalian DM domain transcription factor Dmrta2 is 
required for early embryonic development of the cerebral cortex. PLoS ONE 7, 
e46577. 
Korinek, V., Barker, N., Moerer, P., van Donselaar, E., Huls, G., Peters, P.J., and 
Clevers, H. (1998). Depletion of epithelial stem-cell compartments in the small 
intestine of mice lacking Tcf-4. Nature Genet. 19, 379–383. 
 178 
Kosinski, C., Li, V.S.W., Chan, A.S.Y., Zhang, J., Ho, C., Tsui, W.Y., Chan, T.L., 
Mifflin, R.C., Powell, D.W., Yuen, S.T., et al. (2007). Gene expression patterns of 
human colon tops and basal crypts and BMP antagonists as intestinal stem cell 
niche factors. PNAS 104, 15418–15423. 
Kramps, T., Peter, O., Brunner, E., Nellen, D. and Froesch, B. (2002). 
Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus 
to the nuclear "-catenin-TCF complex. Cell. 109, 47–60. 
Kratochwil, K., Galceran, J., Tontsch, S., Roth, W., and Grosschedl, R. (2002). 
FGF4, a direct target of LEF1 and Wnt signaling, can rescue the arrest of tooth 
organogenesis in Lef1(-/-) mice. Genes Dev. 16, 3173–3185. 
Kuhl, M., Sheldahl, L.C., Malbon, C.C., and Moon, R.T. (2000). 
Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled 
homologs and promotes ventral cell fates in Xenopus. JBC 275, 12701–12711. 
Kühl, S.J., and Kühl, M. (2012). On the role of Wnt/"-catenin signaling in stem 
cells. BBA 1830, 2297–2306. 
la Roche, de, M., Rutherford, T.J., Gupta, D., Veprintsev, D.B., Saxty, B., et al. 
(2012). An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-
catenin is required for its inhibition by carnosic acid. Nature Comms. 3, 680–10. 
Lee, H.J., Wang, N.X., Shi, D.L., and Zheng, J.J. (2009). Sulindac inhibits 
canonical Wnt signaling by blocking the PDZ domain of the protein dishevelled. 
Angew. Chem. Int. Ed. 48, 6448–6452. 
Lee, S.B., Gong, Y.D., Park, Y.I., and Dong, M.S. (2013). 2,3,6-Trisubstituted 
quinoxaline derivative, a small molecule inhibitor of the Wnt/beta-catenin 
signaling pathway, suppresses cell proliferation and enhances radiosensitivity in 
A549/Wnt2 cells. Biochem. Biophys. Res. Commun. 431 746–752. 
Lepourcelet, M., Chen, Y.N., France, D.S., Wang, H., Crews, P., Petersen, F., 
Bruseo, C., Wood, A.W., and Shivdasani, R.A. (2004). Small-molecule 
antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5, 
91–102. 
Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L.B., Azarin, S.M., Raval, K.K., 
Zhang, J., Kamp, T.J., and Palecek, S.P. (2012). Robust cardiomyocyte 
differentiation from human pluripotent stem cells via temporal modulation of 
canonical Wnt signaling. PNAS 109, 10759–10760. 
Lickert, H., Takeuchi, J.K., Both, Von, I., Walls, J.R., McAuliffe, F., Adamson, 
S.L., Henkelman, R.M., Wrana, J.L., Rossant, J., and Bruneau, B.G. (2004). 
Baf60c is essential for function of BAF chromatin remodelling complexes in heart 
development. Nature 432, 107–112. 
 179 
Lim, S., and Kaldis, P. (2013). Cdks, cyclins and CKIs: roles beyond cell cycle 
regulation. Development 140, 3079–3093. 
Lin, J., Wang, X., and Dorsky, R.I. (2011). Progenitor expansion in APC mutants 
is mediated by Jak/Stat signaling. BMC Dev. Biol. 11, 73-81. 
Lin, K., Wang, S., Julius, M.A., Kitajewski, J., Moos, M., and Luyten, F.P. (1997). 
The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for 
modulation of Wnt signaling. PNAS 94, 11196–11200. 
Lin, X., and Perrimon, N. (1999). Dally cooperates with Drosophila Frizzled 2 to 
transduce Wingless signalling. Nature 400, 281–284. 
Liu, B.Y., Soloviev, I., Huang, X., Chang, P., Ernst, J.A., Polakis, P., and 
Sakanaka, C. (2012). Mammary Tumor Regression Elicited by Wnt Signaling 
Inhibitor Requires IGFBP5. Cancer Res. 72, 1568–1578. 
Liu, G., Bafico, A., and Aaronson, S.A. (2005). The mechanism of endogenous 
receptor activation functionally distinguishes prototype canonical and 
noncanonical Wnts. Mol. Cell. Biol. 25, 3475–3482. 
Liu, H., Fergusson, M.M., Wu, J.J., Rovira, I.I., Liu, J., Gavrilova, O., Lu, T., Bao, 
J., Han, D., Sack, M.N., et al. (2011). Wnt Signaling Regulates Hepatic 
Metabolism. Sci. Signal. 4, ra6–ra6. 
Liu, J., Xing, Y., Hinds, T.R., Zheng, J., and Xu, W. (2006). The Third 20 Amino 
Acid Repeat Is the Tightest Binding Site of APC for "-Catenin. JMB 360, 133–
144. 
Liu, T., Lee, Y.N., Malbon, C.C., and Wang, H.Y. (2002). Activation of the beta-
catenin/Lef-Tcf pathway is obligate for formation of primitive endoderm by mouse 
F9 totipotent teratocarcinoma cells in response to retinoic acid. J. Biol. Chem. 
277, 30887–30891. 
Liu, W., Dong, X., Mai, M., Seelan, R.S., and Taniguchi, K. (2000). Mutations in 
AXIN2 cause colorectal cancer with defective mismatch repair by activating "-
catenin/TCF signalling. Nature. 26, 146–147. 
Lloyd-Lewis, B. (2011) High-throughput screening for novel regulators of beta-
catenin in Wnt signalling. Cardiff University. 
Logan, C.Y., and Nusse, R. (2004). The Wnt signaling pathway in development 
and disease. Ann. Rev. Cell Dev. Biol. 20, 781–810. 
Lopez-Rios, J., Esteve, P., Ruiz, J.M., and Bovolenta, P. (2008). The Netrin-
related domain of Sfrp1 interacts with Wnt ligands and antagonizes their activity 
in the anterior neural plate. Neural Dev. 3, 19-37. 
 180 
Lu, W., Lu, W., Yamamoto, V., Yamamoto, V., Ortega, B., Ortega, B., Baltimore, 
D., and Baltimore, D. (2004). Mammalian Ryk is a Wnt coreceptor required for 
stimulation of neurite outgrowth. Cell 119, 97–108. 
Lu, W., Lin, C., Roberts, M.J., Waud, W.R., Piazza, G.A., and Li, Y. (2011). 
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 
degradation and inhibiting the Wnt/"-catenin pathway. PLoS ONE 6, e29290. 
Lucero, O.M., Dawson, D.W., Moon, R.T., and Chien, A.J. (2010). A re-
evaluation of the “oncogenic” nature of Wnt/beta-catenin signaling in melanoma 
and other cancers. Curr. Oncol. Rep. 12, 314–318. 
Luis, T.C., Naber, B., Roozen, P., and Brugman, M.H. (2011). Canonical Wnt 
signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell 
9, 345–356. 
Lundholt, B.K., Scudder, K.M., and Pagliaro, L. (2003). A simple technique for 
reducing edge effect in cell-based assays. J. Biomol. Screen 8, 566–570. 
Macdonald, B.T., and He, X. (2012). Frizzled and LRP5/6 receptors for Wnt/!-
catenin signaling. Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van 
Amerongen, 65-87. 
MacDonald, B.T., Yokota, C., Tamai, K., Zeng, X., and He, X. (2008). Wnt signal 
amplification via activity, cooperativity, and regulation of multiple intracellular 
PPPSP motifs in the Wnt co-receptor LRP6. J. Bio. Chem. 283, 16115–16123. 
Mahmoudi, T., .Li, V.S., Li, .Ng, S.S., .Taouatas, N., .Vries, R.G., et al. (2009). 
The kinase TNIK is an essential activator of Wnt target genes. EMBO J. 28, 
3329–3340. 
Major, M.B., Roberts, B.S., Berndt, J.D., Marine, S., Anastas, J., Chung, N., 
Ferrer, M., Yi, X., Stoick-Cooper, C.L., Haller, von, P.D., et al. (2008). New 
regulators of Wnt/beta-catenin signaling revealed by integrative molecular 
screening. Sci. Signal. 1, ra12. 
Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.A. et al. 
(2011). Interactions between cancer stem cells and their niche govern metastatic 
colonization. Nature 481, 85–89. 
Malik, S., and Roeder, R.G. (2005). Dynamic regulation of pol II transcription by 
the mammalian Mediator complex. TIBS 30, 256–263. 
Malik, S., and Roeder, R.G. (2010). The metazoan Mediator co-activator complex 
as an integrative hub for transcriptional regulation. Nature 11, 761–772. 
Malumbres, M., and Barbacid, M. (2005). Mammalian cyclin-dependent kinases. 
TIBS 30, 630–641. 
 181 
Malumbres, M., and Barbacid, M. (2009). Cell cycle, CDKs and cancer: a 
changing paradigm. Nature Rev. Cancer 9, 153–166. 
Malumbres, M., Harlow, E., Hunt, T., Hunter, T., Lahti, J.M., Manning, G., 
Morgan, D.O., Tsai, L.H., and Wolgemuth, D.J. (2009). Cyclin-dependent 
kinases: a family portrait. Nature Cell Biol. 11, 1275–1276. 
Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B.M., Delius, H., 
Hoppe, D., Stannek, P., Walter, C., et al. (2002). Kremen proteins are Dickkopf 
receptors that regulate Wnt/beta-catenin signalling. Nature 417, 664–667. 
Mao, B., Wu, W., Li, Y., Hoppe, D., Stannek, P., Glinka, A., and Niehrs, C. 
(2001a). LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. 
Nature 411, 321–325. 
Mao, B., and Niehrs, C. (2003). Kremen2 modulates Dickkopf2 activity during 
Wnt/LRP6 signaling. Gene 302, 179–183. 
Mao, J., Wang, J., Liu, B., Pan, W., Farr, G.H. et al. (2001b). Low-density 
lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical 
Wnt signaling pathway. Mol. Cell 7, 801–9. 
Mao, Y., Lin, N., Tian, W., Han, X., Han, X., Huang, Z., and An, J. (2012). Design, 
synthesis, and biological evaluation of new diaminoquinazolines as "-
catenin/Tcf4 pathway inhibitors. J. Med. Chem. 55, 1346–1359. 
von Marschall, Z., and Fisher, L.W. (2010). Secreted Frizzled-related protein-2 
(sFRP2) augments canonical Wnt3a-induced signaling. Biochem. Biophys. Res. 
400, 299–304. 
Marsh, V., Winton, D.J., Williams, G.T., Dubois, N., Trumpp, A., Sansom, O.J., 
and Clarke, A.R. (2008). Epithelial Pten is dispensable for intestinal homeostasis 
but suppresses adenoma development and progression after Apc mutation. 
Nature Genet. 40, 1436–1444. 
McMahon, A.P., and Moon, R.T. (1989). Ectopic expression of the proto-
oncogene int-1 in Xenopus embryos leads to duplication of the embryonic axis. 
Cell 58, 1075–1084. 
Merrill, B.J. (2012). Wnt pathway regulation of embryonic stem cell self-renewal. 
Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van Amerongen, 233-249. 
Merrill, B.J., Pasolli, H.A., Polak, L., and Rendl, M. (2004). Tcf3: a transcriptional 
regulator of axis induction in the early embryo. Development 131, 263–274. 
 
 
 182 
Miki, T., Bottaro, D.P., Fleming, T.P., Smith, C.L., Burgess, W.H., Chan, A.M., 
and Aaronson, S.A. (1992). Determination of ligand-binding specificity by 
alternative splicing: two distinct growth factor receptors encoded by a single gene. 
PNAS 89, 246–250. 
Minami, I., Yamada, K., Otsuji, T.G., Yamamoto, T., Shen, Y., Otsuka, S., Kadota, 
S., Morone, N., Barve, M., Asai, Y., et al. (2012). A small molecule that promotes 
cardiac differentiation of human pluripotent stem cells under defined, cytokine- 
and xeno-free conditions. Cell Rep. 2, 1448–1460. 
Miyazaki, T., Hashimoto, K., Uda, A., Sakagami, H., Nakamura, Y., Saito, S.Y., 
Nishi, M., Kume, H., Tohgo, A., Kaneko, I., et al. (2006). Disturbance of 
cerebellar synaptic maturation in mutant mice lacking BSRPs, a novel brain-
specific receptor-like protein family. FEBS Lett. 580, 4057–4064. 
Mologni, L., Brussolo, S., Ceccon, M., and Gambacorti-Passerini, C. (2012). 
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. 
PLoS ONE 7, e51449. 
Moore, A.C., Amann, J.M., Williams, C.S., Tahinci, E., Farmer, T.E., Martinez, 
J.A., Yang, G., Luce, K.S., Lee, E., and Hiebert, S.W. (2008). Myeloid 
translocation gene family members associate with T-cell factors (TCFs) and 
influence TCF-dependent transcription. Mol. Cell. Biol. 28, 977–987. 
Mordant, P., Loriot, Y., Leteur, C., Calderaro, J., Bourhis, J., Wislez, M., Soria, 
J.C. and Deutsch, E. (2010). Dependence on phosphoinositide 3-kinase and 
RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, 
and RAD001 (Everolimus) in combination. Mol. Cancer Ther. 9, 358–368. 
Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and 
Kinzler, K.W. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by 
mutations in beta-catenin or APC. Science 275, 1787–1790. 
Morris, E.J., Ji, J.Y., Yang, F., Di Stefano, L., Herr, A., Moon, N.S., Kwon, E.J., 
Haigis, K.M., Naar, A.M., and Dyson, N.J. (2008). E2F1 represses beta-catenin 
transcription and is antagonized by both pRB and CDK8. Nature 455, 552–556. 
Moser, A.R., Pitot, H.C., and Dove, W.F. (1990). A dominant mutation that 
predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322–324. 
Naito, A.T., Sumida, T., Nomura, S., Liu, M.L., Higo, T. et al. (2012). 
Complement C1q activates canonical Wnt signaling and promotes aging-related 
phenotypes. Cell 149, 1298–1313. 
Neumann, C.J., and Cohen, S.M. (1996). Distinct mitogenic and cell fate 
specification functions of wingless in different regions of the wing. Development 
122, 1781–1789. 
 183 
Niehrs, C. (2012). The complex world of WNT receptor signalling. Nature Rev. 
Mol. Cell Biol. 13, 767–779. 
Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y. and Ando, H. (1991). Mutations 
of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 251, 
1366–1370. 
Nishita, M., Enomoto, M., Yamagata, K., and Minami, Y. (2010). Cell/tissue-tropic 
functions of Wnt5a signaling in normal and cancer cells. Trends in Cell Biology 
20, 346–354. 
Nogales-Cadenas, R., Carmona-Saez, P., Vazquez, M., Vicente, C., Yang, X., 
Tirado, F., Carazo, J.M., and Pascual-Montano, A. (2009). GeneCodis: 
interpreting gene lists through enrichment analysis and integration of diverse 
biological information. Nucleic Acids Res. 37, W317–W322. 
Orford, K., Crockett, C., Jensen, J.P., Weissman, A.M. and Byers, S.W. (1997). 
Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. 
J. Biol. Chem. 272, 24735–24738. 
Osada, T., Chen, M., Yang, X.Y., Spasojevic, I., Vandeusen, J.B., Hsu, D., Clary, 
B.M., Clay, T.M., Chen, W., Morse, M.A., et al. (2011). Antihelminth compound 
niclosamide downregulates Wnt signaling and elicits antitumor responses in 
tumors with activating APC mutations. Cancer Res. 71, 4172–4182. 
Paganoni, S., Bernstein, J., and Ferreira, A. (2010). Ror1-Ror2 complexes 
modulate synapse formation in hippocampal neurons. Neuroscience 165, 1261–
1274. 
Papkoff, J., Brown, A.M., and Varmus, H.E. (1987). The  int-1  proto-oncogene  
products are glycoproteins that appear to enter the secretory pathway. Mol. Cell. 
Biol. 7, 3978–3984. 
Park, M.C., Kang, T., Han, J.M., Kim, S.B., Park, Y.J., Cho, K., Park, Y.W., Guo, 
M., Yang, X.L., Schimmel, P., et al. (2012). Secreted human glycyl-tRNA 
synthetase implicated in defense against ERK-activated tumorigenesis. PNAS 
e640–e647. 
Park, S., Gwak, J., Cho, M., Song, T., Won, J., Kim, D.E., Shin, J.G., and Oh, S. 
(2006). Hexachlorophene inhibits Wnt/beta-catenin pathway by promoting Siah-
mediated beta-catenin degradation. Mol. Pharmacol. 70, 960–966. 
Perrimon, N., and Bernfield, M. (2000). Specificities of heparan sulphate 
proteoglycans in developmental processes. Nature 404, 725–728. 
 
 
 184 
Phelps, R.A., Chidester, S., Dehghanizadeh, S., Phelps, J., Sandoval, I.T., Rai, 
K., Broadbent, T., Sarkar, S., Burt, R.W., and Jones, D.A. (2009). A two-step 
model for colon adenoma initiation and progression caused by APC loss. Cell 
137, 623–634. 
Pierce, S.B., Chisholm, K.M., Lynch, E.D., Lee, M.K., Walsh, T., Opitz, J.M., Li, 
W., Klevit, R.E., and King, M.C. (2011). Mutations in mitochondrial histidyl tRNA 
synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of 
Perrault syndrome. PNAS 108, 6543–6548. 
Pinto, D., and Clevers, H. (2005a). Wnt control of stem cells and differentiation in 
the intestinal epithelium. Exp. Cell Res. 306, 357–363. 
Pinto, D., and Clevers, H. (2005b). Wnt, stem cells and cancer in the intestine. 
Biol. Cell 97, 185–196. 
Pires-daSilva, A., and Sommer, R.J. (2003). The evolution of signalling pathways 
in animal development. Nature Rev. Genet. 4, 39–49. 
Pitts, T.M., Davis, S.L., Eckhardt, S.G., and Bradshaw-Pierce, E.L. (2013). 
Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. 
Pharmacol. Ther. (In press) 
Porter, D.C., Farmaki, E., and Altilia, S. (2012). Cyclin-dependent kinase 8 
mediates chemotherapy-induced tumor-promoting paracrine activities. PNAS 109, 
13799–13804. 
Puffenberger, E.G., Jinks, R.N., Sougnez, C., Cibulskis, K., Willert, R.A., Achilly, 
N.P., Cassidy, R.P., Fiorentini, C.J., Heiken, K.F., Lawrence, J.J., et al. (2012). 
Genetic mapping and exome sequencing identify variants associated with five 
novel diseases. PLoS ONE 7, e28936. 
Radtke, F., and Clevers, H. (2005). Self-renewal and cancer of the gut: two sides 
of a coin. Science 307, 1904–1909. 
Radulescu, S., Brookes, M.J., Salgueiro, P., Ridgway, R.A., McGhee, E., 
Anderson, K., Ford, S.J., Stones, D.H., Iqbal, T.H., Tselepis, C., et al. (2012). 
Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell 
Rep. 2, 270–282. 
Ramanathan, Y., Rajpara, S.M., Reza, S.M., Lees, E., Shuman, S., Mathews, 
M.B., and Pe'ery, T. (2001). Three RNA polymerase II carboxyl-terminal domain 
kinases display distinct substrate preferences. J. Biol. Chem. 276, 10913–10920. 
Reya, T., O'Riordan, M., Okamura, R., Devaney, E., Willert, K., Nusse, R., and 
Grosschedl, R. (2000). Wnt signaling regulates B lymphocyte proliferation 
through a LEF-1 dependent mechanism. Immunity 13, 15–24. 
 185 
Rhinn, M., Lun, K., Ahrendt, R., Geffarth, M., and Brand, M. (2009). Zebrafish 
gbx1 refines the midbrain-hindbrain boundary border and mediates the Wnt8 
posteriorization signal. Neural Dev. 4, 12. 
Riffell, J.L., Lord, C.J., and Ashworth, A. (2012). Tankyrase-targeted 
therapeutics: expanding opportunities in the PARP family. Nature Rev. Drug 
Discov. 11, 923–936. 
Rodriguez, J., Esteve, P., Weinl, C., Ruiz, J.M., Fermin, Y., Trousse, F., Dwivedy, 
A., Holt, C., and Bovolenta, P. (2005). SFRP1 regulates the growth of retinal 
ganglion cell axons through the Fz2 receptor. Nature Neurosci. 8, 1301–1309. 
Roose, J., Huls, G., van Beest, M., Moerer, P., van der Horn, K., Goldschmeding, 
R., Logtenberg, T., and Clevers, H. (1999). Synergy between tumor suppressor 
APC and the beta-catenin-tcf4 target tcf1. Science 285, 1923–1926. 
Roose, J., Molenaar, M., Peterson, J., Hurenkamp, J., Brantjes, H., Moerer, P., 
van de Wetering, M., Destree, O., and Clevers, H. (1998). The Xenopus Wnt 
effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 
395, 608–612. 
Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S.H., Masiarz, F.R., 
Munemitsu, S., and Polakis, P. (1993). Association of the APC gene product with 
ß-catenin. Science 262, 1731–1733. 
Rudloff, S., and Kemler, R. (2012). Differential requirements for "-catenin during 
mouse development. Development 139, 3711–3721. 
Saneyoshi, T., Kume, S., Amasaki, Y., and Mikoshiba, K. (2002). The 
Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus 
embryos. Nature 417, 295–299. 
Sansom, O.J., Reed, K.R., Hayes, A.J., and Ireland, H. (2004). Loss of Apc in 
vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes & 
Dev. 18, 1385–1390.  
Sansom, O.J., Meniel, V., Wilkins, J.A., Cole, A.M., Oien, K.A. et al. (2006). Loss 
of Apc allows phenotypic manifestation of the transforming properties of an 
endogenous K-ras oncogene in vivo. PNAS 103, 14122–14127. 
Sansom, O.J., Meniel, V.S., Muncan, V., Phesse, T.J., Wilkins, J.A., Reed, K.R., 
Vass, J.K., Athineos, D., Clevers, H., and Clarke, A.R. (2007). Myc deletion 
rescues Apc deficiency in the small intestine. Nature 446, 676–679. 
Saraswati, S., Alfaro, M.P., Thorne, C.A., Atkinson, J., Lee, E., and Young, P.P. 
(2010). Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair 
and post-MI cardiac remodeling. PLoS ONE 5, e15521. 
 186 
Sato, A., Yamamoto, H., Sakane, H., Koyama, H., and Kikuchi, A. (2010). Wnt5a 
regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 29, 41–
54. 
Schepers, A., and Clevers, H. (2012). Wnt Signaling, Stem Cells, and Cancer of 
the Gastrointestinal Tract. Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van 
Amerongen, 251-264. 
Schuijers, J., and Clevers, H. (2012). Adult mammalian stem cells: the role of 
Wnt, Lgr5 and R-spondins. EMBO J. 31, 2685–2696. 
Schwarz-Romond, T., Metcalfe, C., and Bienz, M. (2007). Dynamic recruitment of 
axin by Dishevelled protein assemblies. J. Cell Sci. 120, 2402–2412. 
Shibata, H., Toyama, K., Shioya, H., Ito, M., and Hirota, M. (1997). Rapid 
colorectal adenoma formation initiated by conditional targeting of the Apc gene. 
Science 278, 120–123. 
Shimizu, H., Julius, M.A., Giarre, M., Zheng, Z., Brown, A.M., and Kitajewski, J. 
(1997). Transformation by Wnt family proteins correlates with regulation of beta-
catenin. Cell Growth Differ. 8, 1349–1358. 
Simons, M., Gault, W.J., Gotthardt, D., Rohatgi, R., Klein, T.J. et al. (2009). 
Electrochemical cues regulate assembly of the Frizzled/Dishevelled complex at 
the plasma membrane during planar epithelial polarization. Nature Cell Biol. 11, 
286–294. 
Sinnberg, T., Menzel, M., Ewerth, D., Sauer, B., Schwarz, M., Schaller, M., 
Garbe, C., and Schittek, B. (2011). "-Catenin signaling increases during 
melanoma progression and promotes tumor cell survival and chemoresistance. 
PLoS ONE 6, e23429. 
Smalley, W.E., and DuBois, R.N. (1997). Colorectal cancer and nonsteroidal anti-
inflammatory drugs. Advances in Pharmacology 39, 1–20. 
Spemann, H., and Mangold, H. (1924). über Induktion von Embryonalanlagen 
durch Implantation artfremder Organisatoren. Roux' Arch. Entw. Mech. 100, 599–
638. 
Spemann, H., and Mangold, H. (2001). Induction of embryonic primordia by 
implantation of organizers from a different species. Translation of original text, Int. 
J. Dev. Biol. 45, 13–38. 
Stamos, J.L., and Weis, W.I. (2013). The  beta-catenin destruction complex. Cold 
Spring Harb. Perspect. Biol. Ed. Nusse, He, van Amerongen, 89-104. 
Su, L.K., Vogelstein, B., and Kinzler, K.W. (1993). Association of the APC tumor 
suppressor protein with catenins. Science 262, 1734–1737. 
 187 
Su, Y.Y., Fu, C., Ishikawa, S., Stella, A., Kojima, M., and Shitoh, K. (2008). APC 
is essential for targeting phosphorylated "-catenin to the SCF "-TrCP ubiquitin 
ligase. Mol. Cell 32, 652–661. 
Sun, Y., Campisi, J., Higano, C., Beer, T.M., Porter, P., Coleman, I., True, L., and 
Nelson, P.S. (2012). Treatment-induced damage to the tumor microenvironment 
promotes prostate cancer therapy resistance through WNT16B. Nature Medicine 
18, 1359–1368. 
Swiatek, W., Kang, H., Garcia, B.A., Shabanowitz, J., Coombs, G.S., Hunt, D.F., 
and Virshup, D.M. (2006). Negative regulation of LRP6 function by casein kinase 
I epsilon phosphorylation. J. Biol. Chem. 281, 12233–12241. 
Taatjes, D.J. (2010). The human Mediator complex: a versatile, genome-wide 
regulator of transcription. TIBS 35, 315–322. 
Tabas-Madrid, D., Nogales-Cadenas, R., and Pascual-Montano, A. (2012). 
GeneCodis3: a non-redundant and modular enrichment analysis tool for 
functional genomics. Nucleic Acids Res. 40, W478–W483. 
Takagi, Y., Calero, G., Komori, H., Brown, J.A., Ehrensberger, A.H., Hudmon, A., 
Asturias, F., and Kornberg, R.D. (2006). Head module control of mediator 
interactions. Mol. Cell 23, 355–364. 
Takahashi-Yanaga, F., Yoshihara, T., Jingushi, K., Miwa, Y., Morimoto, S., Hirata, 
M., and Sasaguri, T. (2008). Celecoxib-induced degradation of T-cell factors-1 
and -4 in human colon cancer cells. Biochem. Biophys. Res. Commun. 377, 
1185–1190. 
Tamai, K., Semenov, M., Kato, Y., Spokony, R., Liu, C., Katsuyama, Y., Hess, F., 
Saint-Jeannet, J. P., and He, X. (2000). LDL-receptor-related proteins in Wnt 
signal transduction. Nature 407, 530–535. 
Tamai, K., Zeng, X., Liu, C., Zhang, X., Harada, Y., Chang, Z., and He, X. (2004). 
A mechanism for Wnt coreceptor activation. Mol. Cell 13, 149–156. 
Tang, W., Dodge, M., Gundapaneni, D., Michnoff, C., Roth, M., and Lum, L. 
(2008). A genome-wide RNAi screen for Wnt/beta-catenin pathway components 
identifies unexpected roles for TCF transcription factors in cancer. PNAS 105, 
9697–9702. 
Tauriello, D.V.F., Jordens, I., Kirchner, K., Slootstra, J.W., Kruitwagen, T., et al. 
(2012). Wnt/"-catenin signaling requires interaction of the Dishevelled DEP 
domain and C terminus with a discontinuous motif in Frizzled. PNAS 109, e812–
e820. 
 
 188 
Tenbaum, S.P., Puig, I., Chicote, I., Landolfi, S., Herance, J. Gispert, J.D., 
Mendizabal, L., et al. (2012). Beta-catenin confers resistance to PI3K and AKT 
inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature 
Med. 18, 892–901. 
Theis, M., and Buchholz, F. (2011). High-throughput RNAi screening in 
mammalian cells with esiRNAs. Methods 53, 424–429. 
Thorne, C.A., Hanson, A.J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C.S., 
Jernigan, K.K., Meyers, K.C., Hang, B.I., Waterson, A.G., et al. (2010). Small-
molecule inhibition of Wnt signaling through activation of casein kinase 1#. 
Nature Chem. Biol. 6, 829–836. 
Tian, W., Han, X., Yan, M., Xu, Y., Duggineni, S., Lin, N., Luo, G., Li, Y.M., Han, 
X., Huang, Z., et al. (2012). Structure-based discovery of a novel inhibitor 
targeting the "-Catenin/Tcf4 interaction. Biochemistry 51, 724–731. 
Tol, J., Nagtegaal, I.D., and Punt, C.J.A. (2009). BRAF mutation in metastatic 
colorectal cancer. N. Engl. J. Med. 361, 98–99. 
Tolwinski, N.S., Wehrli, M., Rives, A., Erdeniz, N., DiNardo, S., et al. (2003). 
Wg/Wnt signal can be transmitted through Arrow/LRP5,6 and Axin independently 
of Zw3/Gsk3beta Activity. Dev. Cell 4, 407–418. 
Trosset, J.Y., Dalvit, C., Knapp, S., Fasolini, M., Veronesi, M., Mantegani, S., 
Gianellini, L.M., Catana, C., Sundström, M., Stouten, P.F.W., et al. (2006). 
Inhibition of protein-protein interactions: The discovery of druglike "-catenin 
inhibitors by combining virtual and biophysical screening. Proteins 64, 60–67. 
Tsutsui, T., Umemura, H., Tanaka, A., Mizuki, F., Hirose, Y., and Ohkuma, Y. 
(2008). Human mediator kinase subunit CDK11 plays a negative role in viral 
activator VP16-dependent transcriptional regulation. Genes Cells 13, 817–826. 
Valvezan, A.J., Zhang, F., Diehl, J.A., and Klein, P.S. (2012). Adenomatous 
Polyposis Coli (APC) Regulates Multiple Signaling Pathways by Enhancing 
Glycogen Synthase Kinase-3 (GSK-3) Activity. J. Bio. Chem. 287, 3823–3832. 
van Amerongen, R. (2012). Alternative Wnt Pathways and Receptors. Cold 
Spring Harb. Perspect. Biol. Ed. Nusse, He, van Amerongen, 127-145. 
van Amerongen, R., and Nusse, R. (2009). Towards an integrated view of Wnt 
signaling in development. Development 136, 3205–3214. 
van Amerongen, R., Mikels, A., and Nusse, R. (2008). Alternative wnt signaling is 
initiated by distinct receptors. Sci. Signal. 1, re9–re9. 
 
 189 
van Beest, M., Dooijes, D., and van de Wetering, M. (2000). Sequence-specific 
high mobility group box factors recognize 10–12-base pair minor groove motifs. 
JBC 275, 27266–27273. 
van de Wetering, M., and Clevers, H. (1992). Sequence-specific interaction of the 
HMG box proteins TCF-1 and SRY occurs within the minor groove of a Watson-
Crick double helix. EMBO J. 11, 3039–3044. 
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., et al. (2002). 
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on 
colorectal cancer cells. Cell 111, 241–250. 
Veeman, M.T., Slusarski, D.C., Kaykas, A., Louie, S.H., and Moon, R.T. (2003). 
Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates 
gastrulation movements. Curr. Biology 13, 680–685. 
Venerando, A., Girardi, C., Ruzzene, M., and Pinna, L.A. (2013). Pyrvinium 
pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-
regulation and GSK3 activation. Biochem. J. 452, 131–137. 
Voronkov, A., and Krauss, S. (2012). Wnt/beta-catenin signaling and small 
molecule inhibitors. Curr. Pharm. Des. 19, 634–664. 
Wang, J., Sinha, T., and Wynshaw-Boris, A. (2012). Wnt signaling in mammalian 
development: lessons from mouse genetics. Cold Spring Harb. Perspect. Biol. Ed. 
Nusse, He, van Amerongen, 217-232. 
Wang, W., Liu, H., Wang, S., Hao, X., and Li, L. (2011). A diterpenoid derivative 
15-oxospiramilactone inhibits Wnt/"-catenin signaling and colon cancer cell 
tumorigenesis. Cell Res. 21, 730–740. 
Wend, P., Holland, J.D., Ziebold, U., and Birchmeier, W. (2010). Wnt signaling in 
stem and cancer stem cells. Semin. Cell Dev. Biol. 21, 855–863. 
Westerling, T., Kuuluvainen, E., and Mäkelä, T.P. (2007). Cdk8 is essential for 
preimplantation mouse development. Mol. Cell. Biol. 27, 6177–6182. 
Willert, K., Shibamoto, S., and Nusse, R. (1999). Wnt-induced dephosphorylation 
of axin releases beta-catenin from the axin complex. Genes Dev. 13, 1768–73. 
Wong, G.T., Gavin, B.J., and McMahon, A.P. (1994). Differential transformation 
of mammary epithelial cells by Wnt genes. Mol. Cell. Biol. 14, 6278–6286. 
Wong, H.C., Bourdelas, A., Krauss, A., Lee, H.J., Shao, Y., Wu, D., Mlodzik, M., 
Shi, D.L., and Zheng, J. (2003). Direct binding of the PDZ domain of Dishevelled 
to a conserved internal sequence in the C-terminal region of Frizzled. Mol. Cell. 
12, 1251–1260. 
 190 
Wright, K.J., and Tjian, R. (2009). Wnt signaling targets ETO coactivation domain 
of TAF4/TFIID in vivo. PNAS 106, 55–60. 
Wu, G., Huang, H., Garcia Abreu, J., and He, X. (2009). Inhibition of GSK3 
phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt 
coreceptor LRP6. PLoS ONE 4, e4926. 
Wu, W., Glinka, A., Delius, H., and Niehrs, C. (2000). Mutual antagonism 
between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr. 
Biology 10, 1611–1614. 
Xavier, C.P.R., Lima, C.F., Rohde, M., and Pereira-Wilson, C. (2011). Quercetin 
enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through 
p53 modulation. Cancer Chemother. Pharmacol. 68, 1449–1457. 
Xu, W., and Ji, J.Y. (2011). Dysregulation of CDK8 and Cyclin C in tumorigenesis. 
J. Genetics and Genomics 38, 439–452. 
Xu, Z., Wei, Z., Zhou, J.J., Ye, F., Lo, W.S., Wang, F., Lau, C.F., Wu, J., Nangle, 
L.A., Chiang, K.P., et al. (2012). Internally Deleted Human tRNA Synthetase 
Suggests Evolutionary Pressure for Repurposing. Structure/Folding and Design 
20, 1470–1477. 
Yamada, M., Ohkawara, B., Ichimura, N., Hyodo-Miura, J., Urushiyama, S., 
Shirakabe, K., and Shibuya, H. (2003). Negative regulation of Wnt signalling by 
HMG2L1, a novel NLK-binding protein. Genes Cells 8, 677–684. 
Yamamoto, H. (1999). Phosphorylation of Axin, a Wnt signal negative regulator, 
by Glycogen Synthase Kinase-3beta regulates its stability. J. Bio. Chem. 274, 
10681–10684. 
Yamamoto, H., Komekado, H., and Kikuchi, A. (2006). Caveolin is necessary for 
Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev. 
Cell 11, 213–223. 
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., 
and Lu, Z. (2011). Nuclear PKM2 regulates "-catenin transactivation upon EGFR 
activation. Nature 480, 118–122. 
Yang, X.L. (2013). Structural disorder in expanding the functionome of 
Aminoacyl-tRNA synthetases. Chem. Biol. 20, 1093–1099. 
Yang, Y., Mallampati, S., Sun, B., Zhang, J., Kim, S., Lee, J.S., Gong, Y., Cai, Z., 
and Sun, X. (2013). Wnt pathway contributes to the protection by bone marrow 
stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic 
target. Cancer Lett. 333, 9–17. 
Yashiroda, Y., Okamoto, R., Hatsugai, K., Takemoto, Y., Goshima, N., Saito, T., 
 191 
Hamamoto, M., Sugimoto, Y., Osada, H., Seimiya, H., et al. (2010). A novel 
yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochem. 
Biophys. Res. Commun. 394, 569–573. 
Ying, Y., and Tao, Q. (2009). Epigenetic disruption of the Wnt/beta-catenin 
signaling pathway in human cancers. Epigenetics 4, 307–312. 
Yo, Y.T., Lin, Y. W., Wang, Y.C., Balch, C., Huang, R.L., Chan, M., Sytwu, H.K., 
Chen, C.K., Chang, C.C., Nephew, K.P., et al. (2012). Growth inhibition of 
ovarian tumor-initiating cells by niclosamide. Mol. Cancer Ther. 11, 1703–1712. 
Yu, D.H., Macdonald, J., Liu, G., Lee, A.S., Ly, M., et al. (2008). Pyrvinium 
targets the unfolded protein response to hypoglycemia and its anti-tumor activity 
is enhanced by combination therapy. PLoS ONE 3, e3951. 
Zarnescu, D.C., and Zinsmaier, K.E. (2009). Ferrying Wingless across the 
Synaptic Cleft. Cell 139, 229–231. 
Zecca, M., Basler, K., and Struhl, G. (1996). Direct and long-range action of a 
Wingless morphogen gradient. Cell 87, 833–844. 
Zeng, X., Tamai, K., Doble, B., Li, S., Huang, H., Habas, R., Okamura, H., 
Woodgett, J., and He, X. (2005). A dual-kinase mechanism for Wnt co-receptor 
phosphorylation and activation. Nature 438, 873–877. 
Zeng, X., Huang, H., Tamai, K., Zhang, X., Harada, Y., Yokota, C., Almeida, K., 
Wang, J., Doble, B., Woodgett, J., et al. (2008). Initiation of Wnt signaling: control 
of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and 
axin functions. Development 135, 367–375. 
Zhang, G. N., Liang, Y., Zhou, L. J., Chen, S. P., Chen, G., Zhang, T. P., Kang, 
T., and Zhao, Y. P. (2011). Combination of salinomycin and gemcitabine 
eliminates pancreatic cancer cells. Cancer Lett. 313, 137–144. 
Zhang, J., Chung, T., and Oldenburg, K. (1999). A Simple Statistical Parameter 
for Use in Evaluation and Validation of High Throughput Screening Assays. J. 
Biomol. Screen 4, 67–73. 
Zhao, J., Ramos, R., and Demma, M. (2012). CDK8 regulates E2F1 
transcriptional activity through S375 phosphorylation. Oncogene 32, 3520–3530. 
Zimmerman, Z.F., Moon, R.T., and Chien, A.J. (2012). Targeting Wnt Pathways 
in Disease. Cold Spring Harb. Perspect. Biol. Ed. Nusse, He, van Amerongen, 
423-446. 
 192 
 
Appendices 
 
Appendix 1:  Wnt ‘canonical pathway’ therapeutics 
 
 
     Appendix 2:  Colorectal cancer cell line mutation status 
 
     Appendix 3:  cDNA library IDs (on CD) 
 
Appendix 4:  esiRNA primary screen well identities (on CD) 
 
Appendix 5:  esiRNA primary screen sequences (on CD) 
 
Appendix 6:  Non-overlapping esiRNA sequences (on CD) 
 
Appendix 7:  esiRNA primary screen master results (on CD) 
 
Appendix 8:  Small molecule:MSC chequerboard compound combination 
studies in HCT116 cells 
 
 
 
 
! !
 193 
!"#$% &'()*+% &,*('-*.+/#% 011*#+%% &2-*% 3/4*'4*% 5+')*% 5.--6/*(% 7*1*(*$#*%
"#! $%&'(! !89:;<=%%>?@<A% )! *+! +,-./01.2!34,.562!!7./84,.698!8./8,4! $!)! +9-6,/:-2!(0;.46952!',--.<,/2=90;9590/!
>$40??966!,6!.-@2!ABCAD!('EBCFGCCBF!
"#! $%&'(! F!)H$!5,49,5!)2!))2!)))! )! *+! I,;,-071,/6.-!5:56,1!6,565! $!)! >I0J<,!,6!.-@2!ABCAD! >I0J<,!,6!.-@2!ABCAD!
"#! $%&'(! )H$KA! )! *+! I,;,-071,/6.-!5:56,1!6,565! $!)! +L-697-,! >'M,/!,6!.-@2!ABBN.D!
"#! H/6KC! B$+:C%DEF% )! =! OL/<2!34,.56!8./8,4! I! >P,!,6!.-@2!ABBQD! >P,!,6!.-@2!ABBQR!H,9!,6!.-@2!ABBND!
"#! H/6KC! H)SKC! )! =! =-.JJ,42!056,05.4801.2!74056.6,! E! >E./<!,6!.-@2!ABBND! >E./<!,6!.-@2!ABBND!
"#! H/6KA! B$+:G%DE@! )! =! +,-./01.! I! >T0L!,6!.-@2!ABBQD! >T0L!,6!.-@2!ABBQD!
"#! *0-L3-,!H/6KFU! U/6C@Q=42!U/6C@Q'-! )! *+! (06!6,56,J! E! >+044,--!,6!.-@2!ABBVD! >+044,--!,6!.-@2!ABBVD!
"#! H/6KF! 4HI3<% )! =! P''! I! >H,9!,6!.-@2!ABCCD! >H,9!,6!.-@2!ABCCD!
! !
 194 
"#! $%&! !"#$%&' '! (! )*%+,!-./012.2! 30*! 4560*%70+%!*&!+,89!:;;<=! 4560*%70+%!*&!+,89!:;;<=!
"#! 2>)3?@! $AB?C@DD;D! A! 5E! F2&*1G1012.2! H! E6,&.G,*!
4(17.%*!*&!+,89!:;;IJ!E110*!*&!+,89!:;;I=!
"#! 2>)3?@! 'K.%11#1&L.+M1,.7.%*2!N18<! A! 5E! F2&*1G1012.2! O! $P*&L!)*2*+0QL! 45L.!*&!+,89!:;;I=!
"#! >M7?@9:!?!"#$%&'! ()*'+,+*-.,'/0123' '! 3! EP1Q+07.+,!.%-+0Q&.1%! O! 4R+*0*K+%2!*&!+,89!:;@@=! 4R+*0*K+%2!*&!+,89!:;@@=!
"#! >M7?<!?! "#&'! ()*'+,+*-.,'"456%7' '! 3! 3012&+&*!Q+%Q*0! 30*! $%&)*2*+0QL! 45S-L1,K!*&!+,89!:;;T=!
"#! >M7U! >M7U!A/8! '! (! $.,KV2!&6K160! O! 4317*?5L+WW*7!*&!+,89!:;@@=! 4317*?5L+WW*7!*&!+,89!:;@@=!
"#! >M7?@9:9<9U9T! "8.'9:';0$%<=#7'>?)*-@*AB?:' '! (! (0*+2&9!G+%Q0*+&.Q9!Q1,1%9!!,6%X!Q+%Q*0! 3!'! F%Q1E*7!! 4Y60%*P!*&!+,89!:;@:=!
"#! $%&?@! "=C#DE"@';0$%7&"1=' '! (! H*0+&1Q+0Q.%1K+9!/0*+2&9!21,.7!&6K1602! 3!'! F%Q1E*7!!
4O*A,K*.7+!*&!+,89!:;;UJ!R.6!*&!+,89!:;@:=!
"#! >M7?@;! "8.<2'9:F'GH2IJ%09:'H1%<K' '! (! 5P%1Z.+,!2+0Q1K+! O! 4>6W6W+[+!*&!+,89! 4>6W6W+[+!*&!+,89!
! !
 195 
"##$%! "##$%!
&'! ()(*! !"#$%&'()*+,-.+,/01234+ +! ,! )-./01020-3-! 4!555! +67/8! 94:;<3!/.!:=>?!"#@#%!
&'! ()(*! !"#$%&'()*+,-.+ +! ,! )-./01020-3-! 42/! A0B:2.3-! C(!4:./8.!D$DEF""!
&'! ()(*! !"#$%&'()*+,-.+ +! ,! )-./01020-3-?!0-./01/83:?!0-./0:2.<23.3-! 42/! &=3!G3==H! C(!4:./8.!"#@##""@"IF!
&'! JKK@! 5667+,-.+89:33;<+=9>173?@;7+ +! ,! LL! 4!55! A0B:2.3-?!L/2MK!
9NO=M383.3!/.!:=>?!"##EP!Q=:8.-M<837!/.!:=>?!"#@#%!
&'! GR4STI! AAA@B+ +! (L! J3:U/./-! J! &8V0!G3W/!(M3/8M/-! 9G3!/.!:=>?!"#@"%!
&'! XANRF!Y!G72S! =1'C&*D)*7+EF>;G+ +! ,! 58W=:66:.02H!M0=3.3-! 4!5! AOB/=0! 9X<:0!/.!:=>?!"##D%!
&'! GR4I!Z!!""#! /$'D+C$C()D$+ 5! 4! ,2/:-.!M:8M/2! 42/! +U7/8.! 9G3O!/.!:=>?!"#@#%!
&'! GR4IZ!$%&'(')! ?=HG+,-<+I,-.+,21AJ0+ 5! ,! ,2/:-.![:8M/2! 42/! A0B:2.3-! 9&../8U/27!/.!:=>?!"#@#%!
&'! GR4I!Z$%&#*+*,*-.*-/*0.*#1.*#1/! ?=HG+,-<+I,-.+8>+1AJ0+ 5! ,! ,2/:-.![:8M/2! 42/! A0B:2.3-! 9&../8U/27!/.!:=>?!"#@#%!
! !
 196 
"#! $%&'!(!"#$%$&! !"#$%&'(%)*+,,(-,%% )! *! +,-./01.-12304.! &-,! 5,3,3/,16! 75038!,/!.9:;!<=>=?!
"#! $%&'!(!"#'()*()*+(),()-.()/.()/+()'0+! !"#$%&'(%)*+,.(./%% @! *! *-,.A/!1.31,-! &-,! 5,3,3/,16! 75038!,/!.9:;!<=>=?!
"#! $%&'!(122'! $%&'!@B:!C@B>DE! @! *! FA/,09GA2A!23!CC! H! IJK,90! 7*233,-/A!,/!.9:;!<==L?!
MG! $%&'NOPQ>! 01234567189% )! RC! M0903;!0K.-2.3!1.31,-! &-,! CJ9/2S9,!
7M6,3!,/!.9:;!<==LBT!FA.Q.!,/!.9:;!<=>>T!$J!,/!.9:;!<=>>BT!O03A,1.!,/!.9:;!<=><T!U0!,/!.9:;!<=><?!
MG! $%&'! :631;47<21;% )! RC! M$$;!B-,.A/;!CC;!S-0A/./,!1.31,-! &-,! CJ9/2S9,!
75JS/.!,/!.9:;!<==LT!$J!,/!.9:;!<=>>.?!
MG! HK9!3456! =>8%#9?@189%"A#B% )! &! VMM! H! 7I.4B0/23!,/!.9:;!<=>>?! 7I.4B0/23!,/!.9:;!<=>>?!
!"# 5!$# *)C(W'>XW! )! %&# '()*#+,$-./.0#1/)10,# H! 7&-,K0A/;!<=='?! 7&-,K0A/;!<=='?!
MG! @%O5@&>! YR>>! @! RC! *-,.A/!1.31,-!1,99!428-./203!! +! CJ9/2S9,! 7Z6.38!,/!.9:;!
! !
 197 
"##$%!
&'! ()*!+!"#! ,"-.+-/"0! 1! 23! 4567898:!;9<;:5! =! 3>*8?@*:! AB59<C'!:8!9*DE!"##.%!
&'! ()*!+!"#$! !"#$ 1! 23! !"#$%&'#&()*%+(,'#-+'% (! FG>H??I"##$JKL! AG>H??!:8!9*DE!"##$%!&'! ()*!+!"#! M2&//-#,/E!N#O+#O$9! 1! 23! &9<;:5! =E!(! 3>*8?@*:! A2P9<!:8!9*DE!"#O"%!
&'! &QO!R"! 4G/$#S/"! 1! 23! T5:978!;9<;:5E!U?V56795;6W9!;:**7! =! 3>*8?@*:! A&P:6<X!:8!9*DE!"#OO%!
&'! &QO#!9;8?)9865! %&'()*)+,$ 1! 23! &6*6<!;9<;:5E!;95C?6W'6X:<:7?7! 45:! 3>*8?@*:!
A29597J98?!:8!9*DE!"#O#Y!=P65<:!:8!9*DE!"#O#Y!T97>!:8!9*DE!"#O"Y!29597J98?!:8!9*DE!"#O"%!
&'! 4Q&#!9;8?)9865! -./012$$ 1! 23! 4567898:!8>W6>57! 45:! B*?ZZ![9V7! ABJ9\!:8!9*DE!"#O"%!
&'! =MQ2OR"! 3456#7#$ 1! 23!
&6*6<!;9<;:5E!U?V567?7E!;95C?W'6X:<:7?7E!W>*8?@*:!7;*:567?7! =! M6)958?7E!3>*8?@*:!
A]>9<X!:8!9*DE!"##.Y!G9<;'!:8!9*DE!"#OOY!^9<X!:8!9*DE!"#OO9Y!(?78*:5!:8!
! !
 198 
"#$%!&'(&)!*#+",-.!-/!"#$%!&'(&0!
12! 3456(7&! 89:;(! 8! 6<! 1=#=>%!?.=+/"/-!@">@-.! 3! <A#/B?#-! C1D->!-/!"#$%!&''E"0!
12! 3456(7&! F9GH%!!"#$!I!!"%%! 8! 6<! 1=#=>!@">@-.! J.-! 1D-,KB=4-/!
C9""#-.!-/!"#$%!&'(()!6DA#/L!-/!"#$%!&'(&)!9""#-.!-/!"#$%!&'(&0!
12! 3456&! 9858M! 8! 6<! 1=#=>!@">@-.!! N! 1D-,O.BPQ-! CF",-+!-/!"#$%!&'(&0!
12! R65;S! &'()*%*++ T! 6<! U+/-=?=.=+B+! 3! T+/."!V->-@"! C<".+-##!-/!"#$%!&'(&0!
12! R65;S! ,-.)/0#01+ T! 6<! 32?-!&!PB"O-/-+%!@=#=>!@">@-.! 3! <A#/B?#-! C1=QD#">!-/!"#$%!&'''0!
12! R65;S! 234567893:+;<=>1///)?+ T! 6<! T#LD-B,-.W+%!?.=Q.-++BX-!+A?.">A@#-".!?"#+2! J!88! <A#/B?#-!
CYA>";<-PB>"!-/!"#$%!&''H0%!413'('MESEE%!413'(SZ'SG&!
! !
 199 
"#! $%&'(!)*+,-'&'! ./01223! $! .4! 56,-787976&6! :! 4-9*;(4&<<&879-! =>?+;!-,!+<@A!1233B!
"#! (!)*+,-'&'B! !"#$%& C! .4! 44! D! =E+7!-,!+<@A!1233B! =E+7!-,!+<@A!1233B!
"#! (!)*+,-'&'B! "":2F3FGH! C! .4! "7<7'!*+'*-9! :! 4I<,&8<-! =J?+'!-,!+<@A!1232B!
"#! (!)*+,-'&'B! K-%+*L<7978L-'-! C! .4! "7<7'!*+'*-9! :! 4I<,&8<-! =M+9;!-,!+<@A!122NB!
"#! (!)*+,-'&'B! D"$!O&<-!$*&P! $! .4! "7<7'!*+'*-9!=P&-,!Q-*L+'&6QB! :! 4I<,&8<-! =M+&!-,!+<@A!122HB!
R! !)*+,-'&'!)!"#$! &"S:FA)TA)3H! C! .4! O9-+6,A!*7<7'!*+'*-9A!44! D! .&UQ+!$<P9&*L!
=>7'6+<V-6!-,!+<@A!1233W!R+9+#+'+'!-,!+<@A!1231B!
R! !)*+,-'&'!)!"#$! O"13! C! .4! "7<7'!*+'*-9! D! "+<X&7*L-Q! =:&+'!-,!+<@A!1231B!
R! !)*+,-'&'!)!"#$! MRY)GHNTH! C! .4! R7'-!,-6,-P! :! 4I<,&8<-! =:9766-,!-,!+<@A!122NB!
R! !)*+,-'&'!)!"#$! Z.,$%)FT! C! M! "7<7'!*+'*-9! D! =>9766Q+''!+'P!E-LA!1231B! =>9766Q+''!+'P!E-LA!1231B!
R! !)*+,-'&'!)!"#$! .,+8<-P!O*<[!8-8,&P-! C! M! R7'-!,-6,-P! D! =/+?+Q7,7!-,!+<@A! =/+?+Q7,7!-,!+<@A!
! !
 200 
"#$"%! "#$"%!
&! '()*!+!!+,-./010!!
!"#$$%&%'()*+,-./0123456)
+7!8(98986)!"#$$'&:$86)
!"#$$'&;;()*/,-0<=3404>5) 2! 34! (5650!,-0,/7!!8((9!!(::9!;/6-05;-! '! 4<6.1=6/!
>(?/0!/.!-6@9!"###A!:/=5<7,/6/.!/.!-6@9!"##*A!410B/!/.!-6@9!"##CA!D-0E?17-F-0!/.!-6@9!"#$#A!G/1!/.!-6@9!"#$#A!3100H/7I!/.!-6@9!"#$$A!8-6H/E6!/.!-6@9!"#$J%!
&! >'()*!+!!+,-./010%! ?+8(:) 2! 34! (5650!,-0,/7! K7/! >G-0I!/.!-6@9!"#$$H%! >G-0I!/.!-6@9!"#$$H%!
&! >'()*!+!!+,-./010%! @ABC) 2! 34! (5650!,-0,/7! K7/! >(55;HL!/.!-6@9!"#$$%! >(55;HL!/.!-6@9!"#$$%!
&! KK"M! DA&$) 2! 34! 20N6-;;-.57O!6<0I!E1L/-L/! '! (-6H15,?/;!
>41O-H-O-L?1!/.!-6@9!"##PA!Q/;-0L!/.!-6@9!"#$$%!
&! (RK!+!!"#$%&'&! D+7&88$) 2! 34! (5650!,-0,/79!=<6;50-7O!N1H75L1L! '! 4<6.1=6/!
>S;-;1!/.!-6@9!"##*A!8/0E/7L50!/.!-6@9!"#$#%!
! !
 201 
"! #$%!&!!"#$%&'&! !"#$%&'( '! ()! *+,-./0+!1234+!5672681! %!'! %8417!%9-87-!#2:! ;<-8=08>!?@@AB!
"! #$%!&!!"#$%&'&! )*!&+&&,-( '! ()! *)C! %!'! DE!%9-87-:! ;<-8=08>!?@@AB!
"! !&/-50.4.!&(")*! #-8.214/!-/4+! '! ()! #232.!/-./08! F! )6354G30!
;$-8.4!05!-3:>!?@H?I!3-!J2/90!05!-3:>!?@H?B!
"! CKL&H! ./01234562(1267( '! ()! #CC>!))!! %80! )6354G30! ;C6!05!-3:>!?@@AI!M47!05!-3:>!?@H?=B!
"! #FMN! 8959:65(;( '! ()! C6.O!/-./08!15827-! F! (0.0P!$4250/9:! ;%28508!05!-3:>!?@H?B!
)Q!
( ! ! ! ! ! ! !)Q! Q.R.2S.! MT@?HHH! '! ()! #-8+427U2/U50!+4VV080.54-542.! W! <34PP!C-=1! ;)4.-74!05!-3:>!?@H?B!
)Q! Q.R.2S.! <FM&H@@@HX!! '! ()! "(#C#>!#232.! F! ;C00!05!-3:>!?@HYB! ;C00!05!-3:>!?@HYB!
)Q! Q.R.2S.! E*T&?Z?ZHH!! *! ()! [1502G282141! F! EU059>!#-3=42/907! ;%03305408!05!-3:>!?@@AB!
)Q! Q.R.2S.! Y>Y\&$414.+2301!! '! ()! "25!50150+! F! ;*8-4!05!-3:>!?@HYB! ;*8-4!05!-3:>!?@HYB!
)Q! Q.R.2S.! #G+H>!#G+?! *! ()! "25!50150+! W! )08/R! ;]08R--8!05!-3:>!
! !
 202 
"#$$%!
&'! '()(*+(!
",-./(*,0,1230,4.567895(5:/*;8%<5(=89,!-./(*>,?,42,.567*;8@75(89%@8A/./:/(5!! B! C&! D*6!65E65:! F! 4G/H!56!-9I3!"##J%! 4G/H!56!-9I3!"##J%!
&'! '()(*+(!
FA/K9HA/:/(53!L-5.@K5A*93!MNO$0"3!PE5A*9/(53!P6789!QR,@8A/:*1230,<>/(:*95,2,S-A<*;89-65! B! C&! D*6!65E65:! T! &H96/@95!
4U7-*!56!-9I3!"#$"<%!
&'! '()(*+(! VH/(*;-9/(5!:5A/W-6/W5E!! X! C&! DCGY! T! 4N*(Z!56!-9I3!"#$$%! 4N*(Z!56!-9I3!"#$$%!
&'! '()(*+(! :/-./(*VH/(-=*9/(5E! X! C&! Y*9*A5S6-9!S-(S5A! T! [K/=5A!
4Y75(!56!-9I3!"##QS\!T57(7-A:6!56!-9I3!"#$#\!&-*!56!-9I3!"#$"%!
&'! ]-A/*HE! !"#$%"&'()&"*+,-./01&02+2034,5& X!
!
Y*9*(! D^B! D^B!
4G55!56!-9I3!"##Q\!F-)-7-E7/,_-(-Z-!56!-9I3!"##`\!NA*ES7!56!-9I3!"##$%!
! !
 203 
"#! $%&'()*!
+,%-(.('/*!012!3)4&546'.7!5)&5)8'.7!9,%-(.47!/':;/&(<;!9,%-(.4! =!
!
$%&'()*! >?@! >?@!
A@8%/(!46!%,27!BCDDE!F:(&.4!46!%,27!BCDDG!
"#! H@H7!HIH7!JJ@H!7!@H7!KH7!$LH! >MH*!012!+MNON! =!
!
$%&'()*! >?@! >?@!
AP4',/45Q!46!%,27!BCDCE!M%./4,'!%./!R'8(.7!BCCSE!T%.1!46!%,27!BCCUG!
"#! $%&'()*! "#$%!&'()*+,-&),&'()*+,+.!/'.!$0(1&2*)3! @!
!
012!R5:'V(W:&4.'%! >?@! >?@! AX%.1!46!%,27!BCCYE!H(:!46!%,27!BCCZG!
 
Appendix 1. Wnt ‘canonical pathway’ therapeutics 
Wnt therapeutics are listed according to their approximate order of action from the extracellular space (Ex) via the cytoplasm (Cy) 
to the nucleus (N).  MU; molecules with multi-level or undefined action.  Targets are indicated together with specific interactions, in 
italics, that are blocked if known.  Therapeutics in bold have been demonstrated to have action in mammalian systems in vivo.  
Inhibitory (I) or activating (A) effects are noted by Small Molecule (SM), Peptide (P) or Biological agents (B).  Stage of development 
of the therapeutic is noted or estimated (Preclinical, Pre; Phase I, P I; Tool compound, T; Discovery phase, D). 
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Appendix 2. Colorectal cancer cell line mutation status 
The mutation status of each of the cell lines used for further compound combination studies. 
Cell Line Type
Wnt/!-
catenin 
pathway 
alteration
Fold Reporter 
Induction: 
Topflash/Fopflash
Reference Biomarkers Minus Confirmed mutations Notes Sanger CGP cell line DB
HCT116 colon 
carcinoma
oncogenic !-
catenin, ! 
Wnt1, ! 
Wnt7b 
6 fold PNAS 2002: 99, 
8265-70
Biomarkers 
available: 
Axin2, 
Bmp4, 
Emp1, FGF9 
(CE)
Relatively 
low reporter 
induction
CDKN2A p.R24fs*20; 
CTNNB1 p.S45del; KRAS 
p.G13D; MLH1 p.S252*; 
PIK3CA p.H1047R 
c.3140A>G Reported in 
another cancer sample as 
somatic Heterozygous 
Verified
http://www.sanger.ac.uk/perl/geneti
cs/CGP/core_line_viewer?action=sa
mple&id=905936
SW480
colon 
carcinoma
APC 
inactivation, 
(C terminal 
trunc.) ! 
Wnt1 
4-6 fold
Oncogene 2008: 
27, 966-75. Axin2, cMyc
905962 APC p.Q1338*; 
KRAS p.G12V; MAP2K4 
p.? ; SMAD4 p.? ; TP53 
p.R273H; TP53 p.P309S
check if same applies to 
SW620 (APC mutant, same 
patient, better xenograft
SW620
colon 
carcinoma
APC 
inactivation, 
(C terminal 
trunc.) ! 
Wnt2
good in Merck 
Serono model
also PNAS 2004: 
101, 12682-87
905962 APC p.Q1338*; 
KRAS p.G12V; MAP2K4 
p.? ; SMAD4 p.? ; TP53 
p.R273H; TP53 p.P309S
Isolated from lymph node 
metastases 1 year after 
SW480 isolated from primary.  
In house SNP profiling 
confirmed SW480 and SW620 
from same patient
http://www.sanger.ac.uk/perl/geneti
cs/CGP/core_line_viewer?action=sa
mple&id=905962
Ls174T colon 
carcinoma
oncogenic b-
catenin
10 fold Cell 2002: 111, 
241-50
Lots of 
biomarkers 
available, 
Cell 2002: 
111, 241-50
Relatively 
low reporter 
induction
 CTNNB1 p.S45F; KDM6A 
p.E1316fs*17; KRAS 
p.G12D; PIK3CA p.H1047R
Beta-catenin shRNA reporter 
line available
http://www.sanger.ac.uk/perl/geneti
cs/CGP/core_line_viewer?action=sa
mple&id=907793
DLD-1 colon 
carcinoma
APC 
inactivation
4 fold Cell 2002: 111, 
241-50
Lots of 
biomarkers 
available, 
Cell 2002: 
111, 241-50
Relatively 
low reporter 
induction
KRAS G13D; PIK3CA 
E545K; also APC, BRCA2, 
p53
COLO 205 
colon 
carcinoma APC mutant
APC p.T1556fs*3; BRAF 
p.V600E; SMAD4 p.?; 
TP53 p.Y103_L111>L
highly amplified CDK8; 
shCDK8 and CDK19 
underway
http://www.sanger.ac.uk/perl/geneti
cs/CGP/core_line_viewer?action=sa
mple&id=905961
COLO320
colon 
carcinoma APC mutant
APC  p.S811*;  TP53  
p.R248W
Amplified CDK8 - line is 
distinct from colo205
http://www.sanger.ac.uk/perl/geneti
cs/CGP/core_line_viewer?action=sa
mple&id=910569
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Appendix 8. Small molecule:MSC chequerboard compound combination studies in HCT116 cells 
The dose response curves for RAF265, BIO, BX-795 (labelled as MSC2119074A), Senexin A (labelled as MSC2501503A) and 
Salinomycin (labelled as MSC1913177A) are shown with and without MSC titration (labelled as MSC2316900).  
 
 
 
 
 
 
 
 
 
 
 
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
 R
AF
26
5 
in
co
m
bi
na
tio
n 
w
ith
 d
iff
er
en
t c
on
ce
nt
ra
tio
ns
 o
f
M
SC
23
16
90
0 
fo
r 2
4h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
R
A
F
26
5
M
S
C
23
16
90
0
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,0
4!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[2
,5
!M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[1
0!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,1
6!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,6
3!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[2
5!
M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
 R
AF
26
5 
in
co
m
bi
na
tio
n 
w
ith
 d
iff
er
en
t c
on
ce
nt
ra
tio
ns
 o
f
M
SC
23
16
90
0 
fo
r 4
8h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
R
A
F
26
5
M
S
C
23
16
90
0
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,0
4!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[2
,5
!M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[1
0!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,1
6!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,6
3!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[2
5!
M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
 R
AF
26
5 
in
co
m
bi
na
tio
n 
w
ith
 d
iff
er
en
t c
on
ce
nt
ra
tio
ns
 o
f
M
SC
23
16
90
0 
fo
r 7
2h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
R
A
F
26
5
M
S
C
23
16
90
0
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,0
4!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[2
,5
!M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[1
0!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,1
6!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[0
,6
3!
M
]
R
A
F
26
5/
M
S
C
23
16
90
0 
[2
5!
M
]
RA
F2
65
205
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
 B
IO
in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 2
4h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
B
IO
M
S
C
23
16
90
0
B
IO
/M
S
C
23
16
90
0[
0,
04
!M
]
B
IO
/M
S
C
23
16
90
0[
2,
5!
M
]
B
IO
/M
S
C
23
16
90
0[
10
!M
]
B
IO
/M
S
C
23
16
90
0[
0,
16
!M
]
B
IO
/M
S
C
23
16
90
0[
0,
63
!M
]
B
IO
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
 B
IO
in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 4
8h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
B
IO
M
S
C
23
16
90
0
B
IO
/M
S
C
23
16
90
0[
0,
04
!M
]
B
IO
/M
S
C
23
16
90
0[
2,
5!
M
]
B
IO
/M
S
C
23
16
90
0[
10
!M
]
B
IO
/M
S
C
23
16
90
0[
0,
16
!M
]
B
IO
/M
S
C
23
16
90
0[
0,
63
!M
]
B
IO
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
 B
IO
in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 7
2h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
B
IO
M
S
C
23
16
90
0
B
IO
/M
S
C
23
16
90
0[
0,
04
!M
]
B
IO
/M
S
C
23
16
90
0[
2,
5!
M
]
B
IO
/M
S
C
23
16
90
0[
10
!M
]
B
IO
/M
S
C
23
16
90
0[
0,
16
!M
]
B
IO
/M
S
C
23
16
90
0[
0,
63
!M
]
B
IO
/M
S
C
23
16
90
0[
25
!M
]
BI
O
206
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
21
19
07
4A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 2
4h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
21
19
07
4A
M
S
C
23
16
90
0
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
21
19
07
4A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 4
8h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
21
19
07
4A
M
S
C
23
16
90
0
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
21
19
07
4A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 7
2h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
21
19
07
4A
M
S
C
23
16
90
0
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
21
19
07
4A
/M
S
C
23
16
90
0[
25
!M
]
BX
-7
95
207
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
25
01
50
3A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 2
4h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
25
01
50
3A
M
S
C
23
16
90
0
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
25
01
50
3A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 4
8h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
25
01
50
3A
M
S
C
23
16
90
0
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
25
01
50
3A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 7
2h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
25
01
50
3A
M
S
C
23
16
90
0
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
25
01
50
3A
/M
S
C
23
16
90
0[
25
!M
]
Se
ne
xi
n 
A
208
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
19
13
17
7A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 2
4h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
19
13
17
7A
M
S
C
23
16
90
0
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
19
13
17
7A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 4
8h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
19
13
17
7A
M
S
C
23
16
90
0
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
25
!M
]
Vi
ab
ili
ty
 o
f H
C
T1
16
 a
fte
r t
re
at
m
en
t w
ith
M
SC
19
13
17
7A
 in
 c
om
bi
na
tio
n 
w
ith
 d
iff
er
en
t
co
nc
en
tr
at
io
ns
 o
f M
SC
23
16
90
0 
fo
r 7
2h
by
 A
TP
lit
e,
 9
6w
el
l
02040608010
0
12
0 DM
SO
co
m
po
un
d 
[!
M
]
% of control
0.0
1
0.1
1
10
si
ng
le
 tr
ea
tm
en
t
co
m
bi
na
tio
n 
tr
ea
tm
en
t
co
nt
ro
l
M
S
C
19
13
17
7A
M
S
C
23
16
90
0
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
04
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
2,
5!
M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
10
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
16
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
0,
63
!M
]
M
S
C
19
13
17
7A
/M
S
C
23
16
90
0[
25
!M
]
Sa
lin
om
yc
in
209
! !
 210 
Appendix 1 Bibliography "#$%&'!()*)'!+&,-./$'!0)+)'!1.234.52$'!6)7)'!(.8&'!9)7)'!$,%!":2.4'!;)*)!<=>??@)!+A$B&,&5%-C!D&8.,85$A!E,8F:.8$G/$8.,5,!-5H,$A5,H!#&%4A$8&2-!5,!/$,/.2)!I5J.!K/5)!
!"'!LMLNLLM)!"2$5'!O)'!P$#$#&8&'!P)'!"Q$8$'!")'!R$#5S$'!R)'!T-U5:$-U5'!7)'!$,%!"2$5'!7)")!<=>?V@)!1$8$AS85/!$-S##.825/!-S,8U.-5-!&J!#5W.%!V'VXG:5-5,%&A.-!$,%!8U.52!.B$A4$85&,!$-!E,8!-5H,$A5,H!5,U5:58&2-)!",H.Q)!1U.#)!T,8)!Y%)!52, 2486–`VN?__=)!05,,.28-'!7)Y)'!O&#$-.B5/'!()'!025HU8'!;)7)'!I.4,H'!;)'!"U,'!9)Y)'!R5#'!R)")'!aU$,'!b)'!I54'!K)'!P&,^&B5/U'!K)'!E5AA5$#-'!;)'!.8!$A)!<=>>c@)!OU.!J52-8!D2&D.AA.2!%&#$5,!&J!I\Z`!2.H4A$8.-!-.,-585B58S!8&!6RR?)!7&A)!05&A)!1.AA!#('!VLL=NVL`>)!0&%5,.'!Z)9)()'!K8$4JJ.2'!0)'!Z&,/.G%.GI.&,'!d)'!0U$8'!\)")'!7$,H5,.'!")'!K..-8$AA.2GE.U2'!I)7)'!7&2$,'!\)")'!05AA5$2%'!;)'!+4^$S$#$'!K)'!R&##'!0)K)'!.8!$A)!<=>>c@)!"!-#$AA!#&A./4A.!5,U5:58&2!&J!8U.!E,8!$,8$H&,5-8!-./2.8.%!J25eeA.%G2.A$8.%!D2&8.5,G?!-85#4A$8.-!:&,.!J&2#$85&,)!0&,.!))'!?>`VN?>`])!1U.,'!0)'!6&%H.'!7)Y)'!O$,H'!E)'!I4'!;)'!7$'!a)'!+$,'!1)E)'!E.5'!K)'!d$&'!E)'!R5AH&2.'!;)'!E5AA5$#-'!()K)'!.8!$A)!<=>>c$@)!K#$AA!#&A./4A.G#.%5$8.%!%5-24D85&,!&J!E,8G%.D.,%.,8!-5H,$A5,H!5,!85--4.!2.H.,.2$85&,!$,%!/$,/.2)!($8)!1U.#)!05&A)!*!?>>G?>_)!!
! !
 211 
"#$%&!'(&!)*%+&!,(&!-.&!,(&!/0%1&!'("(&!2$%&!3(2(&!-4$564&!7(8(&!/*5*9&!-(:(&!*%1!"#$%&!)(!;<==>?@(!A#$!*%BCD#$6EC%B#CF!%CF60G*EC1$!C%#C?CBG!)%BHI5CJJ6$1K!GC+%*6C%+(!/C0F#$ECGB54!!"&!K=<LMNK=<MO(!!"#$%&!2(7(&!PC%+&!)(Q(&!*%1!'F"05ECF9&!I(!;<===@(!)%B!GC+%*6C%+!B0!RD"*B$%C%!C%S06S$G!BT0!C%B$5*FBCS$!F0EU0%$%BG(!,(!/C06(!"#$E(!275, 17894–17899. "#$%&!V(&!Q$%9*B$G*%&!W('(&!P$#%#*51B&!"('(&!:*%B0G&!X(P(&!:*%B0G&!Y(P(&!W45*6D8*60.GBC*%&!:(&!"#$%&!-(&!Z$%+&![(&!W5%1B&!8(A(&!-.F*G&!,(&!$B!*6(!;<==>F@(!<&ODPC*EC%0D\.C%*J06C%$G!*G!C%#C?CB05G!0]!RDF*B$%C%HAF]DO!U*B#T*4^!_0B$%BC*6!B5$*BE$%B!]05!F0605$FB*6!F*%F$5(!/C005+(!'$1(!"#$E(!-$BB(!#$&!O>`=NO>`a(!"#$0%+&!,(8(&!7.%+&!b(A(&!)*%+&!7(&!A*%&!_(&!Q005#0$S$&!_('(&!-$$&!:(7(&!*%1!QC5G#.U&!P('(!;<=KK@(!c"<LK!C%1.F$G!F$66!F4F6$!*55$GB!*%1!*U0UB0GCG!0]!#.E*%!F*%F$5!F$66G!SC*!"8KdHe!*%1!)%BHRDF*B$%C%!C%1$U$%1$%B!C%#C?CBC0%!0]!ECB0BCF!GUC%16$!]05E*BC0%(!X%F0+$%$!%&&!<ff`N<fL>(!"0+#6*%&!'(_(&!".6?$5B&!W(W(&!"50GG&!P(W(&!"05F05*%&!:(-(&![*B$G&!,()(&!_$*5F$&!b(,(&!2*.GF#&!X(-(&!'.5U#4&!Z(,(&!"*5B$5&!_(:(&!20g?$$!"0g&!-(&!$B!*6(!;<===@(!:$6$FBCS$!GE*66!E06$F.6$!C%#C?CB05G!0]!+64F0+$%!G4%B#*G$!9C%*G$Da!E01.6*B$!+64F0+$%!E$B*?06CGE!*%1!+$%$!B5*%GF5CUBC0%(!"#$E(!/C06(!'&!M>aN`=a(!"00E?G&!Z(:(&!:F#ECBB&!W(W(&!"*%%C%+&!"(W(&!W609&!W(&!-0T&!c("("(&!/*%$5h$$&!b(&!8*.5&!:(&!iB0E0&!Q(&!,0%$G&!"('(&!_$5S*CJ&!:(&!$B!*6(!;<=KK@(!'01.6*BC0%!0]!)%B!*%1!?$B*DF*B$%C%!GC+%*6C%+!*%1!U506C]$5*BC0%!?4!*!]$550.G!C50%!F#$6*B05!TCB#!B#$5*U$.BCF!$]]CF*F4!C%!+$%$BCF*664!$%+C%$$5$1!E0.G$!E01$6G!0]!F*%F$5(!X%F0+$%$!%#&!<KaN<<f(!P$W6E$C1*&!Q(c(&!'C*0&!-(&!Y5%GB&!,(W(&!80$UU$%&!7(&!_06*9CG&!_(&!*%1!2.?C%]$61&!/(!;<==M@(!A#$!G06.?6$!T%B!5$F$UB05!I5CJJ6$1`"2PD#IF!C%#C?CBG!B#$!+50TB#!0]!B$5*B0F*5FC%0E*G!()*+(+,(!"*%F$5!2$G(!-'&!faMKNfaM>(!P$#%#*51B&!"('(&!Q$%9*B$G*%&!W('(&!"#$%&!V(&!W45*6D8*60.GBC*%&!:(&!:*%B0G&!P0G&!X(&!P$60G!:*%B0G&!Y(&!".55*%&!8(&!I066$BBC$&!'(A(&!PC$G6&!Q(&!-.F*G&!,(&!$B!*6(!;<=K=@(!P$GC+%!*%1!G4%B#$GCG!0]!%0S$6!1C*EC%0\.C%*J06C%$G!TCB#!()*+(+,!$]]CF*F4!]05!RDF*B$%C%HADF$66!B5*%GF5CUBC0%*6!]*FB05!O!U*B#T*4!C%#C?CBC0%(!,(!'$1(!"#$E(!.%&!`>MN>K=(!
! !
 212 

`23)!>+)!92a2N)!?+)!D%1;;$)!S+)!U,BB)!0+)!?2(;'21)!C+)!b1'L'B,)!6+)!?,%M#'&B)!0+)!8,134)!Q+)!Q1BB&')!Q+)!D2:1'&)!/+)!'%!2&+!FGHIHJ+!*!1$'M1&!2PP(,2-.!%,!#B'3%#M@!3,L'&!$:2&&<:,&'-1&'!#3.#;#%,($!,M!A3%<B'P'3B'3%!%(23$-(#P%#,3+!623-'(!Q'$+!$!)!ZcRWYZc]W+!d23-@)!D+9+5+)!02((#34%,3)!T+9+)!81'3)!U+5+)!D#&;'('#$)!5+6+)!=.2,)!6+)!?2(23e#3#)!D+T+)!?(1-')!6+6+)!C%'(,)!5+5+)!01234)!T+5+)!71$$')!Q+)!'%!2&+!FGHIIJ+!*O#3G!2$!('41&2%,(@!23B!%.'(2P'1%#-!%2(4'%!#3!3'`;,(3!;(2#3!#3a1(@!23B!(':@'&#32%#,3+!72%+!7'1(,$-#+!%&)!IHHcYIHIR+!d,3$'-2)!?+"+)!"#'(#34)!E+0+)!?#B#3,$%#)!S+*+)!"2&2&)!>+)!*&2#3)!U+)!?2&4#)!*+"+)!d,('$%#'(#)!Q+)!7,B`'&&)!S+)!Q2a2B1(2#)!6+^+)!E132(2%32:)!6+)!'%!2&+!FGHIGJ+!D%(1-%1('<2-%#L#%@!232&@$#$!,M!3#-&,$2:#B'!('L'2&$!P,%'3%#2&!(,&'!M,(!-@%,P&2$:#-!P0!#3!-,3%(,&!,M!:2::2&#23!%2(4'%!,M!(2P2:@-#3!-,:P&'O!I!F:UCQ6IJ!$#432&#34+!5+!?#,&+!6.':+!"#$)!I]ZWHYI]ZXZ+!
! !
 213 
"#$%%&!'(&!)*#&!+(&!,#&!-(&!./0123#&!4(&!5617&!8(&!9/&!:(&!;%<10%&!=(&!>?0*7?3*7&!+(@(&!'/1A/&!B(&!-6/7C&!8(&!/2!1A(!DEFFGH(!I7!1721C*7%32!*J!?%36/K/AA/?!LM*2/%7NLM*2/%7!%72/M1O2%*7!3#LLM/33/3!P/21NO12/7%7N?/L/7?/72!2#0*M!O/AA!CM*Q26(!R17O/M!@/3(!
`/M&!4(I(!DEF[FH(!501AA!0*A/O#A/!%76%P%2*M3!*J!a72bP/21NO12/7%7bA/JN[!3%C71A%7C!%7?#O/3!1L*L2*3%3!%7!O6M*7%O!AW0L6*OW2%O!A/#</0%1!O/AA3&'(&)'*+,!17?!'(&)'),(!'/*LA13%1!$-&!TEcUTTS(!B1MP/M&!4(!DEFFVH(!ZM#CC%7C!26/!a72!L126Q1Wd!LM*PA/03!17?!LM*CM/33(!8(!'12A(!R17O/M!=732(!$.$&!S\YUSSF(!BA1723O67%C&!9(&!910L2*7&!@(I(&!+#&!](&!-61*&!8(-(&!^%2/AA%&!5(&!9#17C&!+(&!91W2<*&!](&!R#3%O<&!X(&!=M/A17?&!R(&!81M172*Q&!5(a(&!/2!1A(!DEF[FH(!B/7/M12%*7!17?!3/A/O2%*7!*J!7*K/A!J#AAW!6#017!0*7*OA*71A!172%P*?%/3!2612!7/#2M1A%`/!Z%O<<*LJN[!DZ44[H!%76%P%2*MW!J#7O2%*7!%7!K%2M*!17?!%7OM/13/!P*7/!0133!%7!K%K*(!8(!:%*A(!R6/0(!-/0&!\F[TSU\F[\G(!B*7C&!)(&!:*#M6%3&!>(&!R6%#&!R(&!521Q%O<%&!5(&!Z/IA0/%?1&!^(=(&!+%#&!:()(&!]610A#*7C&!4(&!R1*&!X(R(&!R1M17*&!@(I(Z(&!>M732&!8(I(&!/2!1A(!DEF[FH(!a72!%3*J*M0N3L/O%J%O!%72/M1O2%*73!Q%26!O*M/O/L2*M!3L/O%JW!%76%P%2%*7!*M!L*2/72%12%*7!*J!3%C71A%7C!PW!+@]c!172%P*?%/3(!]+*5!e'>!0&!/[EcYE(!B*7C&!)(Z(&!Z*7C&!;(5(&!+//&!5(:(&!4%0&!'(&!:1/&!;(5(&!17?!417C&!'(5(!DEF[[H(!I!7*K/A!TN1MWA/26W7WAN3#P32%2#2/?!LWM%?*fE&T&NPgLWM1`%7/!?/M%K12%K/3!17?!L61M01O*L6*M/!0*?/A!13!a72Eb!NO12/7%7!L126Q1W!%76%P%2*M3!%7!7*7N301AANO/AA!A#7C!O17O/M!O/AA!A%7/3(!:%**MC(!;/?(!R6/0(!$#&!ScTVUSc\G(!
! !
 214 
`/J,!+8451!X,!!&*!EaTEUEaTT,!"0#%%M&$$*!?,9,*!&$>!\)L*!X,!DEFGEH,!]$L/J/2/#$!#N!#$K#:)$/K!O$2!%/:$&'/$:!2L0#;:L!>/0)K2!2&0:)2/$:!#N!bIK&2)$/$,!Q984!!"'*!GaSTEIGaSTa,!";C2&*!Q,1,*!_$>)0*!?,?,*!X/&$:*!",*!?&#*!.,*!.;C)0@&%%)0*!-,*!O)/$J)0:*!=,8,*!&$>!7&$>)0*!5,4,!DEFFSH,!]>)$2/N/K&2/#$!#N!%)')K2/()!/$L/J/2#0%!#N!K&$K)0!%2)M!K)''%!J<!L/:LI2L0#;:LC;2!%K0))$/$:,!-)''!!(#*!VTRUVRS,!";0$)<*!8,*!8`)'0#>*!+,*!1#$>*!-,X,*!-&/$*!X,*!-L&02/)0*!-,*!B#$/:&$*!7,*!+/%KL)0*!A,*!-L&;>L&0/*!8,*!X/*!A,*!.&C#;$*!8,A,*!)2!&',!DEFGEH,!O$2!C&2L@&<!/$L/J/2/#$!(/&!2L)!2&0:)2/$:!#N!+0/33')>!0)K)C2#0%!0)%;'2%!/$!>)K0)&%)>!:0#@2L!&$>!2;M#0/:)$/K/2<!#N!L;M&$!2;M#0%,!Q984!!"'*!GGaGaIGGaEE,!!"@&6*!X,*![@&$:*!4,",*!Q&06*![,4,*!-L#/*!4,=,*!Q&06*!4,[,*!./M*![,*![&*!9,-,*!1&)*!4,X,*![&$*!X,.,*!./M*!B,5,*!)2!&',!DEFGGH,!4M&''!M#')K;')IJ&%)>!>/%0;C2/#$!#N!2L)!8`/$PbIK&2)$/$!C0#2)/$!K#MC')`!0):;'&2)%!M)%)$KL<M&'!%2)M!K)''!>/NN)0)$2/&2/#$,!-)''!=)%,!$$*!EWaUETa,!"@&6*!X,*!7))*!X,[,*!-L;$:*!\,[,*!4#$:*!",\,*!&$>!_L*!4,!DEFGEH,!4M&''!M#')K;')IJ&%)>!C0#M#2/#$!#N!Q.-cIM)>/&2)>!bI-&2)$/$!>):0&>&2/#$!%;CC0)%%)%!2L)!C0#'/N)0&2/#$!#N!-=?IC#%/2/()!K&$K)0!K)''%,!Q7#4!_95!)*!)TVVSa,!!
! !
 215 
`=28%8-84=!4G!L=-YaNI#-&=8=Y01P;!%8='8=K!9,4-&8=!@0;ZE!58K=#$8=K!,&H&,5&5!9W$34=#,F!G8%,4585*!Z6U)!%&$(!C_DB[NC_DC_*!"W#=K(!)*/*(!/8528=#(!\*/*(!Q8W(!)*(!02&W=K(!U*(!)-&K3&8&,(!O*(!/8I2#W'(!>*U*(!02#,$#-(!b*(!L8&$$&--&(!P*(!72#=K(!\*(!L8&55=&,(!)*(!&-!#$*!@ABB[E*!X#=JF,#5&!8=28%8-84=!5-#%8$8.&5!#c8=!#='!#=-#K4=8.&5!L=-!58K=#$$8=K*!6#-W,&!'#%(!dC_NdAB*!:#3&5(!1*>*(!?#H8'54=(!+*0*(!;45I2(!+*U*(!;8&I2&$&(!X*Q*(!14%8=(!6*0*(!X#F$4,(!1*:*(!/#e4,(!/*;*(!0#39(!6*?*(!O4M$&,(!+*(!/#,-8=5(!X*:*(!&-!#$*!@ABCAE*!L`+`_(!#!=4H&$!8=28%8-4,!4G!-#=JF,#5&!#='!L=-YfNI#-&=8=!58K=#$8=K*!ZQ4)!b6P!$(!&RB_RT*!+#=K(!]*>*(!)&4(!/*)*(!142(!/*)*(!+83(!\*(!\44=(!)*0*(!#='!+83(!\*)*!@ABB_E*!X2&!&GG&I-5!4G!I$4.#98=&!4=!-2&!>)+NDN3&'8#-&'!58K=#$8=K!9#-2M#F*!OP;)!Q&--*!!#&(!CCRSCC[*!+#M#34-4(!)*U*(!04$&5J#(!U*(!1#=(!^*(!\8(!"*(!\#=K(!0*\*(!#='!L#=K(!)*!@ABCAE*!?&58K=!4G!-,8#.4$&N5-#9$&'!;0Q[!gN2&$8I#$!9&9-8'&5!-4!-#,K&-!-2&!aN0#-&=8=Y;NI&$$!0QQY$F39243#![!@;0Q[E!9,4-&8=S9,4-&8=!8=-&,#I-84=*!:*!/&'*!02&3*!!!(!CCDTSCC_d*!+83(!\*(!>#5-(!)*/*(!P='4(!X*(!QW(!?*(!0#,54=(!?*(!#='!)I238'-NL4$G(!`*>*"*!@ABCA%E*!`=!H8H4!&GG8I#IF!4G!-2&!'8W,&-8I!#K&=-!&-2#I,F=8I!#I8'!#K#8=5-!3W$-89$&!3F&$43#*!Q&WJ*!1&5*!(#(!R[VSdBB*!
! !
 216 
`*,!`8I",!$%)!PaaQRPa\B,!K(()!<,;,)!3%8I)!b,5,)!^#/T)!b,_,)!#8*!5%8I)!+,<,!ABCDZE,!B)Z)PH1/79-G9.7.-.(*!M-78%=#"78(!*(/7:#.7:()!#!9O#""!O%"(&-"(!78'7G7.%/!%0!.'(!X8.[G(.#H&#.(878!97I8#"78I!4#.'Y#>)!9-44/(99(9!&(""!4/%"70(/#.7%8!#8*!(8'#8&(9!/#*7%9(897.7:7.>!78!F\aL[X8.B!&(""9,!;7%&'(O,!;7%4'>9,!$(9,!J%OO-8,!$!")!caPHc\B,!K(4%-/&("(.)!+,)!J'(8)!b,N,)!?/#8&()!5,<,)!X#8I)!S,)!J/(Y9)!^,)!^(.(/9(8)!?,)!;/-9(%)!J,)!X%%*)!F,X,)!#8*!<'7:*#9#87)!$,F,!ABCCaE,!<O#""HO%"(&-"(!#8.#I%879.9!%0!.'(!%8&%I(87&!1&0[G(.#H&#.(878!4/%.(78!&%O4"(=,!J#8&(/!J(""!&)!LDRDCB,!K7)!],)!<'#8)!2,)!J'#8I)!X,)!d7O)!_,)!;#%)!2,)!K(()!S,2,)!U'#8I)!],)!<#O-(")!6,1,)!<'-"O#8)!3,_,)!#8*!K7-)!5,!ABCDBE,!J'(O7&#"!#8*!I(8(.7&!(:7*(8&(!0%/!.'(!78:%":(O(8.!%0!X8.!#8.#I%879.!57&TT%40B!78!/(I-"#.7%8!%0!I"-&%9(!O(.#G%"79O,!^NF<!"'()!DDaCBRDDaCc,!K7-)!;,b,)!<%"%:7(:)!_,)!S-#8I)!],)!J'#8I)!^,)!`/89.)!2,F,)!^%"#T79)!^,)!#8*!<#T#8#T#)!J,!ABCDBE,!+#OO#/>!.-O%/!/(I/(997%8!("7&7.(*!G>!X8.!97I8#"78I!78'7G7.%/!/(M-7/(9!_3?;^\,!J#8&(/!$(9,!)#)!D\PQRD\cQ,!K7-)!J,J,)!^/7%/)!2,)!^7Y87&#HX%/O9)!5,)!#8*!;-)!3,!ABCDCE,!K$^P!%:(/(=4/(997%8!*(078(9!#!&"#99!%0!G/(#9.!&#8&(/!9-G.>4(!#8*!79!#!.#/I(.!0%/!.'(/#4>,!^NF<!"'))!\DZPR\DaD,!
! !
 217 
`FT.3+C%!*'&'%!(8$9%!('`'%!;#8::8%!<'B'%!829!"#%!R'!=>?MMTA'!W#,/FC8D#9.!C$HH3.CC.C!,82,.3!,.//!63FI+-!TJ!#29$,#26!(2+!,FE3.,.H+F3!"`;a!9.63898+#F2!829!#2-#T#+#26!+-.!(2+\]E,8+.2#2!H8+-I8J'!;"F7!^WL!%%!.>N>N?'!"$28E*.9#28%!`'%!4F3+.CE482+./#%!*'%!782,-.:E<8/#82F%!7'%!*F38/.CE<83,#8%!&'B'%!*83+#2.:%!B'%!782+FC%!B'%!829!;.3.:E48C+#//F%!B'!=>??PA'!W;?XMMM>%!8!+-#89#8:F/#9#2F2.!,FDHF$29%!H3.U.2+C!#2G/8DD8+#F2!829!2.$3F9.6.2.38+#F2!$29.3!.[,#+F+F[#,!,F29#+#F2Cb!HF+.2+#8/!+-.38H.$+#,!3F/.!#2!T38#2!9#CF39.3C'!&'!W.$3FC,#'!&'%!@PaaQ@PPa'!*8F%!R'%!"#2%!W'%!S#82%!('%!Z82%!)'%!Z82%!)'%!Z$826%!Y'%!829!B2%!&'!=>?M>A'!5.C#62%!CJ2+-.C#C%!829!T#F/F6#,8/!.U8/$8+#F2!FG!2.I!9#8D#2Fc$#28:F/#2.C!8C!]E,8+.2#2\S,G_!H8+-I8J!#2-#T#+F3C'!&'!*.9'!4-.D'!((%!MX_aQMX@N'!*83C.//%!`'%!7#C8CV%!<'%!W#/CCF2%!R'%!7$2963.2EB29.3CCF2%!B'1'%!B29.3CCF2%!d'%!"83CCF2%!7'%!W#/CCF2%!^'%!"e$2663.2%!f'%!829!&F2CCF2%!1'0'!=>?M>A'!<71EX!#2-#T#+#F2!TJ!82!F38//J!8,+#U.!CD8//!DF/.,$/.!#2,3.8C.C!TF2.!D8CC!#2!38+C'!0F2.!(#%!aMNQa>P'!*#28D#%!K'%!R8D898%!1'%!^+C$e#%!S'<'%!R8D8DF+F%!S'%!7-.2%!R'%!^+C$V8%!7'%!189F+8%!7'%!*F3F2.%!W'%!083U.%!*'%!BC8#%!R'%!.+!8/'!=>?M>A'!B!CD8//!DF/.,$/.!+-8+!H3FDF+.C!,839#8,!9#GG.3.2+#8+#F2!FG!-$D82!H/$3#HF+.2+!C+.D!,.//C!$29.3!9.G#2.9%!,J+FV#2.E!829![.2FEG3..!,F29#+#F2C'!4.//!`.HF3+C!&%!M__OQM_a?'!!
! !
 218 
`)'!X&0+3#99:$'!.)'!(#<'!")'!F,$5;'!M)7)'!U3&J,99#&0'!")'!M,9#$:+'!.)'!*8:,?&8'!M)T)'!H0&L:'!U)'!&+!,9)!@ABNND)!.3,0<,8:9:I#8,9!#$3#-#+#:$!:E![0#??9&5WR!5#;L9,K;!,$+#W+/<:0!L0:L&0+#&;!#$!3&L,+:8&99/9,0!8,08#$:<,)!M)!>&L,+)&%'!AYYQACC)!G,0,K,$,$'!X)1)'!^:/5#8,$'!G)1)'!.,0%'!M)'!`/'!^)'!G,0,K,$,$'!G)()'!^,;2/L+,'!7)'!,$5!",?/<5&0'!1)!@ABNAD)!1$+,I:$#;+#8!&EE&8+!:E!;<,99W<:9&8/9&!#$3#-#+:0;!:E!F$+VaW8,+&$#$!#$!</9+#L9&!<K&9:<,)!1$+#8,$8&0!7&;)!,"'!bOCRQbRBR)!_;,5,'!H)'!U3&$'!")'!T,$I'!`)T)'!*L,;:6&J#8'!4)'!c,$5&/;&$'!M)X)'!>;/'!^)'!U9,0K'!X)")'!U9,K'!H)")'!U3&$'!F)'!":0;&'!")1)'!&+!,9)!@ABNND)!1$+#3&9<#$+3!8:<L:/$5!$#89:;,<#5&!5:\$0&I/9,+&;!F$+!;#I$,9#$I!,$5!&9#8#+;!,$+#+/<:0!0&;L:$;&;!#$!+/<:0;!\#+3!,8+#J,+#$I!1.U!</+,+#:$;)!U,$8&0!7&;)!-#'!bNRAQbNYA)!!
! !
 219 
`)9)'!4@?&U'!5)H)'!-8@@+'!()I)'!@/!#?)!:;<<N>)!:=A:TA:_#B%/%#?@+A;AF?>BF8&D&$&+A;AF?>B&B@8&$&+ATAF?>D@/%#+#D&+@a!#!R&+,?@66!C@/#A2#/@+&+!#,0+&6/!/%#/!&+28@#6@6!C0+@!G08D#/&0+!8#/@)!*)!I@$)!W%@D)!$!'!PNP;OPNPL)!"0$@A.%#SS@$'!_)'!\#8#8&A./@&+C@8,'![)'!\#C@8D#+Ab&7'!c)'!M0DA-8066'!9)'!3#%#8'!.)'![D@8'!()'!I@/61F#+&D'!.)'!31E%08'!9)'!*#20CA\&862%'!*)'!-0?$6/@&+'!M).)'!@/!#?)!:;<==>)!M@6&6/#+2@!08!6@+6&/&7&/F!0G!Y&?D6d!/1D08!/0!#+/&A4b(J!#+/&C0$F!%&,%?&,%/6!/%@!Y+/!B#/%R#F!#6!#!B066&C?@!/%@8#B@1/&2!/#8,@/)![+20,@+@!'&'!=PPTO=PK<)!"08/@8'!()W)'!4#8D#S&'!9)'!#+$!H?/&?&#'!.)!:;<=;>)!WF2?&+A$@B@+$@+/!S&+#6@!K!D@$&#/@6!2%@D0/%@8#BFA!&+$12@$!/1D08AB80D0/&+,!B#8#28&+@!#2/&7&/&@6)!"_H.!=<N'!=XJNNA=XK<T)!"8@706/'!-)")!:;<<P>)!H+/&2#+2@8!#2/&7&/F!0G!3eIATP=JT'!#!+@R!&+%&C&/08!0G!/%@!%@/@80/8&D@8&2!-!]-"!B80/@&+!20DB?@U)!W#+2@8)!M@6)!""'!N;;JON;XT)!"80GG&//'!Z)()'!I#$#+'!3)'!Z@'!b)'!"@+$%#8S#8'!`)'!(&+,'!5)'!5@@'!I)H)'!\#++016%'!M)_)'!#+$!`&86%1B'!()I)!:;<=;>)!"%#8D#20?0,&2#?!&+%&C&/&0+!0G!/%@!Y+/!#2F?/8#+6G@8#6@!"[MW_!B8@7@+/6!,80R/%!0G!Y+/A$8&7@+!D#DD#8F!2#+2@8)!W#+2@8!M@6)!%''!L<;OL<J)!!!
! !
 220 
"#$%!&'('%!()#%!&'('%!*+,%!-'%!*+,%!('.'%!/)#0%!1'/'%!2$0%!-'&'%!*304%!5'6'%!/7$00%!-'('%!308!*+,%!-'('!9:;;<='!.3>#?)@+8#>!308!A>#B3?+0)!8+CC)@)0D+3>>E!@)47>3D)!F+403>F!7?FD@)3,!#C!4>EA#4)0!FE0D$3F)!G+03F)!H!+0!D$)!@3D!C@#0D3>!A#@D)I'!JI?'!&#>'!&)8'!
`H'!($30%!/'%!a$304%!b'%!c3#%!/'%!Y3FF)>>%!"'%!308!a$)04%!/'/'!9:;\:='!(E0D$)F+F!#C!?#D)0D!8+F$)P)>>)8!TQa!8#,3+0!+0$+X+D#@F!47+8)8!XE!P+@D73>!FA@))0+04!308!_&"!FD78+)F'!Y$),+A3>!c+#>#4E!d!Q@74!Q)F+40!("%!H<MLHUH'!($+%!&'%!(D37CC)@%!c'%!c$3D%!"'%!308!c+>>+3@8%!/'!9:;;`='!]8)0D+C+A3D+#0!#C!+,+0##I#D$+3B#>+8+0)F!3F!F)A@)D)8!C@+BB>)8!@)>3D)8!?@#D)+0V\!+0$+X+D#@F'!c+##@4'!&)8%!Y$),'![)DD'!#"%!MHH<VMHH`'!($7>DB%!&'Q'%!*+@XE%!Y'2'%!(D3,F%!O'%!Y$+0%!Q'_'%!c>30G%!/'%!Y$3@>3D%!^'%!Y$)04%!.'%!Y$)704%!2'%!Y#04%!W'%!W)04%!-'%!)D!3>'!9:;\:='!e\%:%fgO@+3B#>VHVE>F7>C30E>,)D$E>=VHV?$)0E>Ve\%:%fg#I38+3B#>)Fh!20D34#0+FDF!#C!D$)!10D!?3D$Z3E!D$3D!+0$+X+D!D30GE@3F)F!\!308!:!P+3!0#P)>!38)0#F+0)!?#AG)D!X+08+04'!/'!&)8'!Y$),'!%%%!\\:<L\\HM'!(+00X)@4%!O'%!&)0B)>%!&'%!JZ)@D$%!Q'%!(37)@%!c'%!(A$Z3@B%!&'%!(A$3>>)@%!&'%!63@X)%!Y'%!308!(A$+DD)G%!c'!9:;\\='!iVA3D)0+0!F+403>+04!+0A@)3F)F!87@+04!,)>30#,3!?@#4@)FF+#0!308!?@#,#D)F!D7,#@!A)>>!F7@P+P3>!308!A$),#@)F+FD30A)'!T[#(!^_J!)%!):Hf:`'!
! !
 221 
`+!F(:+!N-%B+!Q.A?+!")!J5TIJG\+!K-A$&%)!N+3+)!U(@?%#$)!Q+)!U%Y.1)![+)!0(&1A&)!3+E+)!E%$&.>(&)!*+*+)!9%(/%$)!_+N+)!0#<<%$:)!*+3+)!N-%&)!K+9+)!9.,-(.'.:)!N+)!N1%?%&R.)!N+"+)!%:!(?+!456PP8+!3!=.A,-%B.,(?!1,$%%&!@A$!.'%&:.@.,(:.A&!A@!1B(??;BA?%,#?%!$%>#?(:A$1!A@!:-%!9&:!<(:-Y(R!#1.&>!V%&A<#1!%>>!%O:$(,:1+!E+!Q.ABA?+!",$%%&+!!")!TT7IP66\+!K.(&)!9+)!0(&)!V+)!L(&)![+)!V#)!L+)!_#>>.&%&.)!"+)!U.&)!F+)!U#A)!W+)!U.)!L+[+)!0(&)!V+)!0#(&>)!a+)!%:!(?+!456P58+!":$#,:#$%;=(1%'!'.1,A/%$R!A@!(!&A/%?!.&-.=.:A$!:($>%:.&>!:-%!b;,(:%&.&cK,@D!.&:%$(,:.A&+!Q.A,-%B.1:$R!&!)!H5DIHGP+!K$A11%:)!E+L+)!_(?/.:)!N+)!*&(<<)!"+)!M(1A?.&.)![+)!d%$A&%1.)![+)![(&:%>(&.)!"+)!W.(&%??.&.)!U+[+)!N(:(&()!N+)!"#&'1:$eB)![+)!":A#:%&)!Z+M+9+)!%:!(?+!4566\8+!X&-.=.:.A&!A@!<$A:%.&;<$A:%.&!.&:%$(,:.A&1f!K-%!'.1,A/%$R!A@!'$#>?.2%!b;,(:%&.&!.&-.=.:A$1!=R!,AB=.&.&>!/.$:#(?!(&'!=.A<-R1.,(?!1,$%%&.&>+!Z$A:%.&1!"')!\6I\H+!g?1(B%$)!3+)!9%.)!L+)!*.B)!*+*+)!K(&)!*+)!9-%%?%$)!"+)!V.)!L+)!K-.%1)!S+"+)!(&'!N-(<B(&)!0+3+!456P58+!3O.&!<(:-Y(R!(,:./.:R!$%>#?(:%1!()*+(+,!<L\7D;!;,(:%&.&!(,,#B#?(:.A&!(&'!<#?BA&($R!@.=$A1.1+!E+!Q.A?+!N-%B+!-%$)!7P\DI7PH5+!
! !
 222 
`)!5&+I'!5)'!K3F'!Z)'!5&+I'!-)'!Z&7'!a)'!&+,!K3'!K)!>?@AATB)!8!,3.#$^#+73,!,#$3*&.3*#!AQH7b72^3$&:3/&C.7+#!3+R3T3.2!5+.]GHC&.#+3+!23I+&/3+I!&+,!C7/7+!C&+C#$!C#//!.F:7$3I#+#232)!V#//!=#2)!$#'!W[@XWc@)!5#3'!5)'!VRF&'!0)-)'!;$#^^#$'!-)'!&+,!-7'!-)S)!>?@@OB)!1/7C%&,#!7E!5+.HA!23I+&/3+I!/#&,2!.7!&+.3H.F:7$!#EE#C.2!3+!R#^&.7C#//F/&$!C&$C3+7:&!C#//2)!07/)!V&+C#$!''!W`)!5#3'!5)'!VRF&'!0)-)'!;$#^^#$'!-)'!&+,!-7'!-)!>?@A@B)!-:&//!:7/#CF/#!&+.&I7+32.2!7E!YCEc]!HC&.#+3+!C7:^/#b!3+R3T3.!.R#!I$7U.R!7E!ZVV!C#//2!()*+(,-.!&+,!()*+(+.)!\+.)!<)!V&+C#$!#$!'!?c?`H?c[`)!!!
! !
 223 
`$$%!L&%!+$M*C$%!a&%!N#B)*.@%!L&%!+?a0@2A(%!K&3&%!3*A(*0$=,*:#@%!+&%!#@!*9&!4566X8&!H0!*0@$="0@=5!C202?920*9!*0@$:21P!$01)?#A!*/2/@2A$A!$0!C*9$B0*0@!C#9*02C*!?#99A!*01!$0($:$@A!@)C2.!B.2D@(&!'*0?#.!N#A&!#$%!SYbS\SYbc&!^#C*0A%!N&Z&%!W.$20#A%!L&%!'*C/:#99%!+&%!+?'9#0120%!K&%!F2)0B%!,&3&%!,)<)M$%!O&%!F*0B%!a&Q&%!d#!Z*0B(#%!,&%!N#P0291A%!,&d&%!*01!+*A20%!N&K&!456778&!L#)@.2/($9!@.*0AC$B.*@$20!@.$BB#.A!.#/*$.!2V!@(#!9)0B!#/$@(#9$)C!J$*!U=?*@#0$0!A$B0*9$0B&![LH,!!"%%!7Scc6\7SccS&!^(*0B%!e&%!+*`2.%!+&W&%!O*M*0*A($%!,&%!'*C/%!L&d&%!L$A($P*%!L&%![#@#.A%!I&'&%!-$0A:#.B%!+&G&%!K$*0%!]&%!N*01*<<2%![&H&%!,?()9@<%![&-&%!#@!*9&!4566>8&!,C*99=C29#?)9#!AP0#.B$A@!2V!@(#!"0@T:#@*=?*@#0$0!A$B0*9$0B!/*@(D*P&![LH,!"$%!>XXX\>XXb&!^(*2%!K&%!1#!Q#.*%!K&%!L*.)A($C*%!,&%!W#?M%!I&]&%![*9#0?$*%!,&%!,($0M*D*%![&%!3$C%!3&H&%!Z$)%!F&%!Z#JP%!+&d&%!W#.B%!d&K&%!#@!*9&!4566>8&!N=A/201$07%!*!02J#9!$0@#A@$02@.2/($?!C$@2B#0%!*C#9$2.*@#A!#E/#.$C#0@*9!?29$@$A!$0!C$?#&!-*A@.2#0@#.292BP!!&'%!7YY7\7YXY&!^(*2%!"&L&%!'(#0B%!'&%!O(#.$*)9@%!3&+&%!,(#.$1*0%!,&d&%!OA*$%!Z&G&%!*01!G*BB*.@P%!,&K&!45675:8&!H!($B(=@(.2)B(/)@!A?.##0!V2.!"0@T!=?*@#0$0!A$B0*9$0B!/*@(D*P!C21)9*@2.A!$0!()C*0!$[,'=1#.$J#1!0#).*9!/.2B#0$@2.A&!K&!W$2C29&!,?.##0&!!(%!75S5\75RY&!
